<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="2.3" xml:lang="EN"><front><journal-meta><journal-id journal-id-type="publisher-id">TPX</journal-id><journal-id journal-id-type="hwp">sptpx</journal-id><journal-id journal-id-type="nlm-ta">Toxicol Pathol</journal-id><journal-title>Toxicologic Pathology</journal-title><issn pub-type="ppub">0192-6233</issn><issn pub-type="epub">1533-1601</issn><publisher><publisher-name>SAGE Publications</publisher-name><publisher-loc>Sage CA: Los Angeles, CA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.1177/0192623311430695</article-id><article-id pub-id-type="publisher-id">10.1177_0192623311430695</article-id><article-categories><subj-group subj-group-type="heading"><subject>Continuing Education CE3 - Histopathology of the Rodent Lymphoid and Hematopoietic Systems</subject></subj-group></article-categories><title-group><article-title>The Utility of Immunohistochemistry for the Identification of Hematopoietic and Lymphoid Cells in Normal Tissues and Interpretation of Proliferative and Inflammatory Lesions of Mice and Rats</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" xlink:type="simple"><name name-style="western"><surname>Rehg</surname><given-names>Jerold E.</given-names></name><xref ref-type="aff" rid="aff1-0192623311430695">1</xref><xref ref-type="corresp" rid="corresp1-0192623311430695"/></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Bush</surname><given-names>Dorothy</given-names></name><xref ref-type="aff" rid="aff1-0192623311430695">1</xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Ward</surname><given-names>Jerrold M.</given-names></name><xref ref-type="aff" rid="aff2-0192623311430695">2</xref></contrib></contrib-group><aff id="aff1-0192623311430695"><label>1</label>Department of Pathology, St. Jude Children’s Research Hospital, Memphis, Tennessee, USA</aff><aff id="aff2-0192623311430695"><label>2</label>Global Vet Pathology, Montgomery Village, Maryland, USA</aff><author-notes><corresp id="corresp1-0192623311430695">Jerold E. Rehg, DVM., St. Jude Children’s Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105; phone: (901) 595-2293; fax: (901) 595-3100; e-mail: <email xlink:type="simple">jerold.rehg@stjude.org</email>.</corresp></author-notes><pub-date pub-type="epub-ppub"><month>2</month><year>2012</year></pub-date><volume>40</volume><issue>2</issue><fpage>345</fpage><lpage>374</lpage><permissions><copyright-statement>© Society of Toxicologic Pathology 2012</copyright-statement><copyright-year>2012</copyright-year><copyright-holder content-type="society">Society of Toxicologic Pathology</copyright-holder></permissions><abstract><p>Expression of antigens in cells and tissues can be readily studied immunohistochemically with the use of antibodies. A panel of antibodies to cell-specific markers can be used to diagnose lesions, including tumors, in the hematopoietic and lymphoid systems. This review discusses the use of readily available antibodies and procedures to identify antigens expressed in normal tissues and in proliferative and inflammatory lesions in formalin-fixed, paraffin-embedded (FFPE) murine specimens.</p></abstract><kwd-group><kwd>immunohistochemistry; erythrocytes; lymphocytes; macrophages; myeloid; mice; rats.</kwd></kwd-group></article-meta></front><body><sec id="section1-0192623311430695"><title>Introduction</title><p>For a long time, the only effective method of phenotyping hematopoietic and lymphoid cells in tissue sections was immunoperoxidase staining of acetone-fixed frozen sections. Now, with the advances in monoclonal antibody development and epitope retrieval methods, many hematopoietic- and lymphoid-associated antigens can be studied in formalin-fixed, paraffin-embedded tissue sections. Immunohistochemistry (IHC) studies of formalin-fixed, paraffin-embedded (FFPE) tissue provide two main advantages over other immunologic methods: (1) the tissue does not require special handling; and (2) cytologic and architectural features are well perceived, allowing for improved histopathologic interpretation. Modern immunohistochemistry studies of paraffin tissue sections make it possible to</p><list list-type="order"><list-item><p>assess the normal expression pattern of tissue antigens in cells and tissues;</p></list-item><list-item><p>diagnose hematopoietic disorders;</p></list-item><list-item><p>determine whether cellular antigens are lost;</p></list-item><list-item><p>identify changes in the expression of antigens associated with a cell; and</p></list-item><list-item><p>identify the cell types associated with an inflammatory lesion.</p></list-item></list><p>However, it is important to recognize that the majority of hematolymphoid antigen markers are cell lineage–associated and only a few are cell lineage–specific. Consequently, panels of antibodies are needed to confirm a cell’s lineage, and the makeup of a panel depends on the cellular lineage to be determined.</p><p>Here we review the use of readily available antibodies to cellular antigens of the myeloid and lymphoid lineages and provide examples of how they can be used immunohistochemically for the five purposes described above. Our sources of antibodies are listed in <xref ref-type="table" rid="table1-0192623311430695">Tables 1</xref> and <xref ref-type="table" rid="table2-0192623311430695">2</xref>, but other commercially available antibodies may work equally well.</p><table-wrap id="table1-0192623311430695" position="float"><label>Table 1.</label><caption><p>Commonly used antibodies and sources for mouse hematolymphoid antigens detectable in formalin-fixed, paraffin-embedded tissues.</p></caption><graphic alt-version="no" alternate-form-of="table1-0192623311430695" position="float" xlink:href="10.1177_0192623311430695-table1.tif" xlink:type="simple"/><table><thead><tr><th colspan="1" rowspan="1">Antigen</th><th colspan="1" rowspan="1">Major cells expressing antigen</th><th colspan="1" rowspan="1">Antibody</th><th colspan="1" rowspan="1">Clone</th><th align="center" colspan="1" rowspan="1">Dilution</th><th colspan="1" rowspan="1">Source</th><th colspan="1" rowspan="1">Epitope retrieval</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">BCL2</td><td colspan="1" rowspan="1">Non-germinal center B-cells; T-cells; many lymphomas except mouse follicular lymphoma</td><td colspan="1" rowspan="1">Rabbit anti-mouse</td><td colspan="1" rowspan="1">n/a</td><td colspan="1" rowspan="1">1,000</td><td colspan="1" rowspan="1">BD Biosciences</td><td colspan="1" rowspan="1">HIER<sup><xref ref-type="table-fn" rid="table-fn1-0192623311430695">a</xref></sup>, Target Retrieval (DAKO pH 9)</td></tr><tr><td colspan="1" rowspan="1">BCL6</td><td colspan="1" rowspan="1">Germinal center (GC) B-cells (centroblasts and centrocytes), GC or post GC B-cell lymphomas</td><td colspan="1" rowspan="1">Rabbit anti-human</td><td colspan="1" rowspan="1">n/a</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">Santa Cruz</td><td colspan="1" rowspan="1">HIER, Target Retrieval (DAKO pH 6)</td></tr><tr><td colspan="1" rowspan="1">CD3</td><td colspan="1" rowspan="1">T-cells and many T-cell lymphomas</td><td colspan="1" rowspan="1">Goat anti-human</td><td colspan="1" rowspan="1">n/a</td><td colspan="1" rowspan="1">350</td><td colspan="1" rowspan="1">Santa Cruz</td><td colspan="1" rowspan="1">HIER, Target Retrieval (DAKO pH 6)</td></tr><tr><td colspan="1" rowspan="1">CD5</td><td colspan="1" rowspan="1">T-cells and many T-cell lymphomas</td><td colspan="1" rowspan="1">Rat anti-mouse</td><td colspan="1" rowspan="1">53-7.3</td><td colspan="1" rowspan="1">200</td><td colspan="1" rowspan="1">BD Biosciences</td><td colspan="1" rowspan="1">HIER, Target Retrieval (DAKO pH 6)</td></tr><tr><td colspan="1" rowspan="1">CD21/35</td><td colspan="1" rowspan="1">B-cells, Follicular dendritic cells</td><td colspan="1" rowspan="1">Rat anti-mouse</td><td colspan="1" rowspan="1">7G6</td><td colspan="1" rowspan="1">50</td><td colspan="1" rowspan="1">BD Biosciences</td><td colspan="1" rowspan="1">HIER, Target Retrieval (DAKO pH 6)</td></tr><tr><td colspan="1" rowspan="1">CD34</td><td colspan="1" rowspan="1">Progenitor cells, some myeloid and lymphoblastic neoplasms</td><td colspan="1" rowspan="1">Rat anti-mouse</td><td colspan="1" rowspan="1">RAM34</td><td colspan="1" rowspan="1">50</td><td colspan="1" rowspan="1">BD Biosciences</td><td colspan="1" rowspan="1">HIER, Target Retrieval (DAKO pH 6)</td></tr><tr><td colspan="1" rowspan="1">CD40</td><td colspan="1" rowspan="1">Activated T-cells, interdigitating dendritic cells and some B-cells</td><td colspan="1" rowspan="1">Goat anti-mouse</td><td colspan="1" rowspan="1">n/a</td><td colspan="1" rowspan="1">200</td><td colspan="1" rowspan="1">Santa Cruz</td><td colspan="1" rowspan="1">HIER, Citrate pH 6</td></tr><tr><td colspan="1" rowspan="1">CD43</td><td colspan="1" rowspan="1">Early B-progenitors, T-cells, myeloid cells, plasma cells, pro B-lymphoblastic lymphoma, T-cell lymphomas, myeloid leukemia, plasmacytomas</td><td colspan="1" rowspan="1">Rat anti-mouse</td><td colspan="1" rowspan="1">S7</td><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">BD Biosciences</td><td colspan="1" rowspan="1">HIER, Target Retrieval (DAKO pH 6)</td></tr><tr><td colspan="1" rowspan="1">CD45</td><td colspan="1" rowspan="1">All hematolymphoid cells; low to no expression on plasma cell neoplasms</td><td colspan="1" rowspan="1">Rat anti-mouse</td><td colspan="1" rowspan="1">30-F11</td><td colspan="1" rowspan="1">150</td><td colspan="1" rowspan="1">BD Biosciences</td><td colspan="1" rowspan="1">HIER, Target Retrieval (DAKO pH 6)</td></tr><tr><td colspan="1" rowspan="1">CD45R/B220</td><td colspan="1" rowspan="1">B-cells, subsets of T-cells, dendritic cells and NK cells</td><td colspan="1" rowspan="1">Rat anti-mouse</td><td colspan="1" rowspan="1">RA3-6B2</td><td colspan="1" rowspan="1">4,000</td><td colspan="1" rowspan="1">BD Biosciences</td><td colspan="1" rowspan="1">HIER, Citrate pH 6</td></tr><tr><td colspan="1" rowspan="1">CD68</td><td colspan="1" rowspan="1">Histiocytes, myeloid cells, mast cells and their neoplasms</td><td colspan="1" rowspan="1">Rat anti-mouse</td><td colspan="1" rowspan="1">FA-11</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">AbD Serotec</td><td colspan="1" rowspan="1">HIER, Target Retrieval (DAKO pH 6)</td></tr><tr><td colspan="1" rowspan="1">CD79acy</td><td colspan="1" rowspan="1">Immature and mature B-cells, plasma cells; B-cell lymphoma</td><td colspan="1" rowspan="1">Mouse anti-human</td><td colspan="1" rowspan="1">HM57</td><td colspan="1" rowspan="1">50</td><td colspan="1" rowspan="1">DAKO</td><td colspan="1" rowspan="1">HIER, Target Retrieval (DAKO pH 9)</td></tr><tr><td colspan="1" rowspan="1">CD117 (KIT)</td><td colspan="1" rowspan="1">Immature myeloid cells, T-, B-cells, and mast cells</td><td colspan="1" rowspan="1">Rabbit anti-human</td><td colspan="1" rowspan="1">n/a</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">DAKO</td><td colspan="1" rowspan="1">HIER, Target Retrieval (DAKO pH 6)</td></tr><tr><td colspan="1" rowspan="1">CD138</td><td colspan="1" rowspan="1">Plasma cells</td><td colspan="1" rowspan="1">Rat anti-mouse</td><td colspan="1" rowspan="1">281-2</td><td colspan="1" rowspan="1">1,000</td><td colspan="1" rowspan="1">BD Biosciences</td><td colspan="1" rowspan="1">HIER, ER1 (Leica, pH 6)</td></tr><tr><td colspan="1" rowspan="1">CD163</td><td colspan="1" rowspan="1">Normal macrophages, and histiocytes, histiocytic sarcomas Rabbit anti-mouse</td><td colspan="1" rowspan="1">n/a</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">Santa Cruz</td><td colspan="1" rowspan="1">HIER, Target Retrieval (DAKO pH 6)</td></tr><tr><td colspan="1" rowspan="1">F4/80</td><td colspan="1" rowspan="1">Histiocytes/macrophages and histiocytic sarcoma</td><td colspan="1" rowspan="1">Rat anti-mouse</td><td colspan="1" rowspan="1">BM8</td><td colspan="1" rowspan="1">1,000</td><td colspan="1" rowspan="1">Caltag</td><td colspan="1" rowspan="1">HIER, Target Retrieval (DAKO pH 6)</td></tr><tr><td colspan="1" rowspan="1">FOXP3</td><td colspan="1" rowspan="1">CD4+CD25+regulatory T-cells</td><td colspan="1" rowspan="1">Rat anti-mouse</td><td colspan="1" rowspan="1">FJK-16s</td><td colspan="1" rowspan="1">50</td><td colspan="1" rowspan="1">eBioscience</td><td colspan="1" rowspan="1">HIER, Target Retrieval (DAKO pH 6)</td></tr><tr><td colspan="1" rowspan="1">GATA1</td><td colspan="1" rowspan="1">Erythroid cells, megakaryocytes, eosinophils, basophils and mast cells</td><td colspan="1" rowspan="1">Goat anti-mouse</td><td colspan="1" rowspan="1">n/a</td><td colspan="1" rowspan="1">500</td><td colspan="1" rowspan="1">Santa Cruz</td><td colspan="1" rowspan="1">HIER, Target Retrieval (DAKO pH 6)</td></tr><tr><td colspan="1" rowspan="1">Glycophorin A</td><td colspan="1" rowspan="1">Immature, mature and leukemic erythroid cells</td><td colspan="1" rowspan="1">Goat anti-mouse</td><td colspan="1" rowspan="1">n/a</td><td colspan="1" rowspan="1">40</td><td colspan="1" rowspan="1">Santa Cruz</td><td colspan="1" rowspan="1">HIER, EDTA pH 8</td></tr><tr><td colspan="1" rowspan="1">Granzyme B</td><td colspan="1" rowspan="1">Natural killer cells and cytotoxic T-cells</td><td colspan="1" rowspan="1">Rabbit anti-human</td><td colspan="1" rowspan="1">n/a</td><td colspan="1" rowspan="1">50</td><td colspan="1" rowspan="1">Abcam</td><td colspan="1" rowspan="1">HIER, ER2 (Leica, pH 9)</td></tr><tr><td colspan="1" rowspan="1">Histamine</td><td colspan="1" rowspan="1">Normal and neoplastic mast cells</td><td colspan="1" rowspan="1">Rabbit anti-human</td><td colspan="1" rowspan="1">n/a</td><td colspan="1" rowspan="1">6,000</td><td colspan="1" rowspan="1">Fitzgerald</td><td colspan="1" rowspan="1">HIER, Target Retrieval (DAKO pH 9)</td></tr><tr><td colspan="1" rowspan="1">IBA-1</td><td colspan="1" rowspan="1">Histiocytes/Macrophages</td><td colspan="1" rowspan="1">Rabbit anti-human</td><td colspan="1" rowspan="1">n/a</td><td colspan="1" rowspan="1">500</td><td colspan="1" rowspan="1">Biocare Medical</td><td colspan="1" rowspan="1">HIER, Citrate pH 6</td></tr><tr><td colspan="1" rowspan="1">IRF4/MUM1</td><td colspan="1" rowspan="1">Normal and neoplastic plasma cells; B-cell lymphomas</td><td colspan="1" rowspan="1">Goat anti-mouse</td><td colspan="1" rowspan="1">n/a</td><td colspan="1" rowspan="1">6,000</td><td colspan="1" rowspan="1">Santa Cruz</td><td colspan="1" rowspan="1">HIER, Target Retrieval (DAKO pH 6)</td></tr><tr><td colspan="1" rowspan="1">IgM</td><td colspan="1" rowspan="1">Immunoglobulin heavy chains, some immature B-cells; mature B-cells; plasma cells</td><td colspan="1" rowspan="1">Rat anti-mouse</td><td colspan="1" rowspan="1">II/41</td><td colspan="1" rowspan="1">60</td><td colspan="1" rowspan="1">BD Biosciences</td><td colspan="1" rowspan="1">HIER, Target Retrieval (DAKO pH 6)</td></tr><tr><td colspan="1" rowspan="1">iNOS2</td><td colspan="1" rowspan="1">Activated neutrophils; Th1 activated macrophages</td><td colspan="1" rowspan="1">Rabbit anti-human</td><td colspan="1" rowspan="1">n/a</td><td colspan="1" rowspan="1">400</td><td colspan="1" rowspan="1">Santa Cruz</td><td colspan="1" rowspan="1">HIER, Citrate pH 6</td></tr><tr><td colspan="1" rowspan="1">KLC</td><td colspan="1" rowspan="1">Immunoglobulin light chains, some immature B-cells; mature B-cells; plasma cells</td><td colspan="1" rowspan="1">Goat anti-mouse</td><td colspan="1" rowspan="1">n/a</td><td colspan="1" rowspan="1">2,000</td><td colspan="1" rowspan="1">Southern Biotechnology</td><td colspan="1" rowspan="1">HIER, Target Retrieval (DAKO pH 6)</td></tr><tr><td colspan="1" rowspan="1">Lysozyme</td><td colspan="1" rowspan="1">Histiocytes/monocytes and myeloid cells (normal and neoplastic)</td><td colspan="1" rowspan="1">Rabbit anti-human</td><td colspan="1" rowspan="1">n/a</td><td colspan="1" rowspan="1">4,000</td><td colspan="1" rowspan="1">DAKO</td><td colspan="1" rowspan="1">HIER, Citrate pH 6</td></tr><tr><td colspan="1" rowspan="1">MAC2</td><td colspan="1" rowspan="1">Histiocytes/macrophages</td><td colspan="1" rowspan="1">Rat anti-mouse</td><td colspan="1" rowspan="1">M3/38</td><td colspan="1" rowspan="1">20,000</td><td colspan="1" rowspan="1">Accurate</td><td colspan="1" rowspan="1">HIER, Citrate pH 6</td></tr><tr><td colspan="1" rowspan="1">MAC3</td><td colspan="1" rowspan="1">Histiocytes/macrophages</td><td colspan="1" rowspan="1">Rat anti-mouse</td><td colspan="1" rowspan="1">M3/84</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">BD Biosciences</td><td colspan="1" rowspan="1">HIER, Citrate pH 6</td></tr><tr><td colspan="1" rowspan="1">MBP eosinophil</td><td colspan="1" rowspan="1">Eosinophils</td><td colspan="1" rowspan="1">Rat anti-mouse</td><td colspan="1" rowspan="1">MT-14.7</td><td colspan="1" rowspan="1">1,000</td><td colspan="1" rowspan="1">Mayo</td><td colspan="1" rowspan="1">EIER<sup>a</sup>, Proteinase K</td></tr><tr><td colspan="1" rowspan="1">MPO</td><td colspan="1" rowspan="1">Myeloid cells, normal and neoplastic</td><td colspan="1" rowspan="1">Rabbit anti-human</td><td colspan="1" rowspan="1">n/a</td><td colspan="1" rowspan="1">1,500</td><td colspan="1" rowspan="1">DAKO</td><td colspan="1" rowspan="1">No retrieval</td></tr><tr><td colspan="1" rowspan="1">PAX5</td><td colspan="1" rowspan="1">B-cells; B lymphomas; not expressed in plasma cells</td><td colspan="1" rowspan="1">Goat anti-human</td><td colspan="1" rowspan="1">n/a</td><td colspan="1" rowspan="1">300</td><td colspan="1" rowspan="1">Santa Cruz</td><td colspan="1" rowspan="1">HIER, Citrate pH 6</td></tr><tr><td colspan="1" rowspan="1">Perforin</td><td colspan="1" rowspan="1">Natural killer cells and cytotoxic T-cells</td><td colspan="1" rowspan="1">Rat anti-mouse</td><td colspan="1" rowspan="1">CB5.4</td><td colspan="1" rowspan="1">4,000</td><td colspan="1" rowspan="1">Abcam</td><td colspan="1" rowspan="1">HIER, ER2 (Leica, pH 9)</td></tr><tr><td colspan="1" rowspan="1">PNA Lectin</td><td colspan="1" rowspan="1">GC cells &amp; follicular dendritic cells</td><td colspan="1" rowspan="1">n/a</td><td colspan="1" rowspan="1">n/a</td><td colspan="1" rowspan="1">200</td><td colspan="1" rowspan="1">Vector</td><td colspan="1" rowspan="1">HIER, Citrate pH 6</td></tr><tr><td colspan="1" rowspan="1">RUNX1/AML</td><td colspan="1" rowspan="1">Myeloid cells, megakaryocytes and lymphoid cells</td><td colspan="1" rowspan="1">Rabbit anti-human</td><td colspan="1" rowspan="1">n/a</td><td colspan="1" rowspan="1">600</td><td colspan="1" rowspan="1">Active Motif</td><td colspan="1" rowspan="1">HIER, ER1 (Leica, pH 6)</td></tr><tr><td colspan="1" rowspan="1">S100P</td><td colspan="1" rowspan="1">Interdigitating dendritic cells, Langerhans cells, some histiocytes</td><td colspan="1" rowspan="1">Rabbit anti-cow</td><td colspan="1" rowspan="1">n/a</td><td colspan="1" rowspan="1">1,000</td><td colspan="1" rowspan="1">DAKO</td><td colspan="1" rowspan="1">HIER, Citrate pH 6</td></tr><tr><td colspan="1" rowspan="1">TdT</td><td colspan="1" rowspan="1">Immature thymic lymphoid cells, lymphoblastic neoplasms</td><td colspan="1" rowspan="1">Rabbit anti-human</td><td colspan="1" rowspan="1">n/a</td><td colspan="1" rowspan="1">50</td><td colspan="1" rowspan="1">Supertechs</td><td colspan="1" rowspan="1">HIER, Citrate pH 6</td></tr><tr><td colspan="1" rowspan="1">TER 119</td><td colspan="1" rowspan="1">Immature, mature erythroid cells; late stage erythroid leukemia cells</td><td colspan="1" rowspan="1">Rat anti-mouse</td><td colspan="1" rowspan="1">TER-119</td><td colspan="1" rowspan="1">500</td><td colspan="1" rowspan="1">BD Biosciences</td><td colspan="1" rowspan="1">No retrieval</td></tr><tr><td colspan="1" rowspan="1">von Willebrand factor</td><td colspan="1" rowspan="1">Normal and neoplastic megakaryocytes and endothelial cells</td><td colspan="1" rowspan="1">Rabbit anti-human</td><td colspan="1" rowspan="1">Polyclonal</td><td colspan="1" rowspan="1">1:500</td><td colspan="1" rowspan="1">DAKO</td><td colspan="1" rowspan="1">HIER, citrate buffer, pH 6 </td></tr><tr><td colspan="1" rowspan="1">YM1 (CHI3l3)</td><td colspan="1" rowspan="1">Immature neutrophils; Th2 activated macrophages</td><td colspan="1" rowspan="1">Goat anti-mouse</td><td colspan="1" rowspan="1">n/a</td><td colspan="1" rowspan="1">3,000</td><td colspan="1" rowspan="1">R&amp;D</td><td colspan="1" rowspan="1">HIER, Target Retrieval (DAKO pH 6)</td></tr></tbody></table><table-wrap-foot><fn id="table-fn1-0192623311430695"><p><sup>a</sup>HIER (heat induced epitope retrieval); EIER (enzyme induced epitope retrieval)</p></fn></table-wrap-foot></table-wrap><table-wrap id="table2-0192623311430695" position="float"><label>Table 2.</label><caption><p>Commonly used antibodies and sources for rat hematolymphoid antigens detectable in formalin-fixed, paraffin-embedded tissues. </p></caption><graphic alt-version="no" alternate-form-of="table2-0192623311430695" position="float" xlink:href="10.1177_0192623311430695-table2.tif" xlink:type="simple"/><table><thead><tr><th colspan="1" rowspan="1">Antigen</th><th colspan="1" rowspan="1">Major cells expressing Antigen</th><th align="center" colspan="1" rowspan="1">Source</th><th align="center" colspan="1" rowspan="1">Product number</th><th align="center" colspan="1" rowspan="1">Clone</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">CD3</td><td colspan="1" rowspan="1">All T-cells</td><td colspan="1" rowspan="1">Dako</td><td colspan="1" rowspan="1">A0452</td><td colspan="1" rowspan="1">n/a</td></tr><tr><td colspan="1" rowspan="1">CD4</td><td colspan="1" rowspan="1">T-helper cells</td><td colspan="1" rowspan="1">AbD Serotec</td><td colspan="1" rowspan="1">MCA55G</td><td colspan="1" rowspan="1">W3/25</td></tr><tr><td colspan="1" rowspan="1">CD5</td><td colspan="1" rowspan="1">Subset of T-lymphocytes, most thymocytes and NK cells</td><td colspan="1" rowspan="1">AbD Serotec</td><td colspan="1" rowspan="1">MCA52G</td><td colspan="1" rowspan="1">OX-19</td></tr><tr><td colspan="1" rowspan="1">CD8</td><td colspan="1" rowspan="1">Subset of T-lymphocytes, most thymocytes and NK cells</td><td colspan="1" rowspan="1">AbD Serotec</td><td colspan="1" rowspan="1">MCA48R</td><td colspan="1" rowspan="1">OX-8</td></tr><tr><td colspan="1" rowspan="1">CD11b<sup><xref ref-type="table-fn" rid="table-fn2-0192623311430695">a</xref></sup></td><td colspan="1" rowspan="1">Most macrophages, Kupffer cells, also dendritic cells, granulocytes</td><td colspan="1" rowspan="1">AbD Serotec</td><td colspan="1" rowspan="1">MCA275GA</td><td colspan="1" rowspan="1">OX-42</td></tr><tr><td colspan="1" rowspan="1">CD25</td><td colspan="1" rowspan="1">Activated rat T-cells</td><td colspan="1" rowspan="1">AbD Serotec</td><td colspan="1" rowspan="1">MCA273R</td><td colspan="1" rowspan="1">OX-39</td></tr><tr><td colspan="1" rowspan="1">CD43</td><td colspan="1" rowspan="1">All leukocytes with the exception of B-lymphocytes</td><td colspan="1" rowspan="1">AbD Serotec</td><td colspan="1" rowspan="1">MCA54G</td><td colspan="1" rowspan="1">W3/13</td></tr><tr><td colspan="1" rowspan="1">CD45RA</td><td colspan="1" rowspan="1">B-cells among thoracic duct lymphocytes with little labeling in bone marrow and none on thymocytes</td><td colspan="1" rowspan="1">AbD Serotec</td><td colspan="1" rowspan="1">MCA340GA</td><td colspan="1" rowspan="1">OX-33</td></tr><tr><td colspan="1" rowspan="1">CD45RC</td><td colspan="1" rowspan="1">B-cells among thoracic duct lymphocytes with little labeling in bone marrow and none on thymocytes</td><td colspan="1" rowspan="1">AbD Serotec</td><td colspan="1" rowspan="1">MCA53R</td><td colspan="1" rowspan="1">OX-22</td></tr><tr><td colspan="1" rowspan="1">CD68</td><td colspan="1" rowspan="1">Myeloid cells</td><td colspan="1" rowspan="1">AbD Serotec</td><td colspan="1" rowspan="1">MCA341R</td><td colspan="1" rowspan="1">ED1</td></tr><tr><td colspan="1" rowspan="1">CD163</td><td colspan="1" rowspan="1">50% peritoneal macrophages, splenic and most other macrophages</td><td colspan="1" rowspan="1">AbD Serotec</td><td colspan="1" rowspan="1">MCA342GA</td><td colspan="1" rowspan="1">ED2</td></tr><tr><td colspan="1" rowspan="1">CD169<sup>a</sup></td><td colspan="1" rowspan="1">Macrophages</td><td colspan="1" rowspan="1">AbD Serotec</td><td colspan="1" rowspan="1">MCA343R</td><td colspan="1" rowspan="1">ED3</td></tr><tr><td colspan="1" rowspan="1">IgM</td><td colspan="1" rowspan="1">B-cells</td><td colspan="1" rowspan="1">Vector</td><td colspan="1" rowspan="1">BA-2020</td><td colspan="1" rowspan="1">n/a</td></tr><tr><td colspan="1" rowspan="1">MHC Class II</td><td colspan="1" rowspan="1">B-cells</td><td colspan="1" rowspan="1">AbD Serotec</td><td colspan="1" rowspan="1">MCA46G</td><td colspan="1" rowspan="1">OX-6</td></tr><tr><td colspan="1" rowspan="1">Immunoglobulin human kappa light chains</td><td colspan="1" rowspan="1">Immunoglobulin-producing B-cells</td><td colspan="1" rowspan="1">Dako</td><td colspan="1" rowspan="1">A0191</td><td colspan="1" rowspan="1">n/a</td></tr></tbody></table><table-wrap-foot><fn id="table-fn2-0192623311430695"><p><sup>a</sup>Works only with frozen sections.</p></fn></table-wrap-foot></table-wrap></sec><sec id="section2-0192623311430695"><title>Technical Considerations</title><p>The specific fixative, antibodies, antibody sources, and IHC methods used play an important role in the effectiveness of IHC. Because many aspects of these important factors have been well reviewed (<xref ref-type="bibr" rid="bibr102-0192623311430695">Ramos-Vara et al. 2005</xref>; <xref ref-type="bibr" rid="bibr119-0192623311430695">Swerdlow et al. 2008</xref>; <xref ref-type="bibr" rid="bibr21-0192623311430695">Chu and Weiss 2009</xref>; <xref ref-type="bibr" rid="bibr26-0192623311430695">Dabbs 2010</xref>), we will focus only on some that affect studies in rodents.</p><p>There are many commercial sources of antibodies against specific rodent antigens; the largest include AbD Serotec, BD Biosciences, Biotechnology, Dako, and Santa Cruz. When antigens are well conserved across species (e.g., CD3 and immunoglobulin kappa light chains), anti-human antibodies work well in mice. Frozen sections are the optimal material to use for IHC; hundreds of antibodies against rodent antigens work well with frozen sections (BD Biosciences Mouse CD Chart, BD Biosciences Rat CD Chart), but tissue cytologic morphology is often not optimal. A significant subset of antigens work well with formalin-fixed, paraffin-embedded (FFPE) tissues and they can be found in several reports (<xref ref-type="bibr" rid="bibr81-0192623311430695">Mikaelian et al. 2004</xref>; <xref ref-type="bibr" rid="bibr130-0192623311430695">Ward et al. 2006</xref>, <xref ref-type="bibr" rid="bibr67-0192623311430695">Kunder et al. 2007</xref>) and the following Web sites http://tumor.informatics.jax.org/html/antibodies.html; http://www.niehs.nih.gov/research/atniehs/labs.lep/path-support/immuno/protocols.cfm; http://icg.cpmc.columbia.edu/cattoretti/Protocol/Mouse_IHC/Antibodies_for_mouse_IHC.html; and http://web.ncifcrf.gov/rtp/lasp/phl/immuno/.</p><p><xref ref-type="table" rid="table1-0192623311430695">Tables 1</xref> and <xref ref-type="table" rid="table2-0192623311430695">2</xref> list the more common antibodies for hematolymphoid antigens detectable in mouse and rat paraffin sections. Some fixatives, such as Bouin’s, ethanol, and B-5, may eliminate the need for retrieval of selected antigens in paraffin sections, and in some circumstances, they can inhibit antigen retrieval.</p></sec><sec id="section3-0192623311430695"><title>Myeloid Antigens</title><p>The most useful myeloid markers depend on the differentiation and maturation stage of the myeloid cell population studied, as depicted in <xref ref-type="table" rid="table3-0192623311430695">Table 3</xref>.</p><table-wrap id="table3-0192623311430695" position="float"><label>Table 3.</label><caption><p>Antigens in myeloid cells detected by IHC in formalin-fixed, paraffin-embedded tissues.</p></caption><graphic alt-version="no" alternate-form-of="table3-0192623311430695" position="float" xlink:href="10.1177_0192623311430695-table3.tif" xlink:type="simple"/><table><thead><tr><th colspan="1" rowspan="1">Antigen</th><th colspan="1" rowspan="1">Undifferentiated</th><th colspan="1" rowspan="1">Granulocyte</th><th colspan="1" rowspan="1">Monocyte</th><th colspan="1" rowspan="1">Erythrocyte</th><th colspan="1" rowspan="1">Megakaryocyte</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">CD34</td><td align="center" colspan="1" rowspan="1">+<sup><xref ref-type="table-fn" rid="table-fn3-0192623311430695">a</xref></sup></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">CD117 (cKit)</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">CD43</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">CD45</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">MPO</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">+</td><td align="center" colspan="1" rowspan="1">–/+</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Lysozyme</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">CD68</td><td colspan="1" rowspan="1"/><td align="center" colspan="1" rowspan="1"/><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">GATA1</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+</td></tr><tr><td colspan="1" rowspan="1">Glycophorin A (CD235a)</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">+</td><td align="center" colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">TER 119</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">+</td><td align="center" colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">von Willebrand factor (Factor VIII related antigen)</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">+</td></tr></tbody></table><table-wrap-foot><fn id="table-fn3-0192623311430695"><p><sup>a</sup>+, expressed; −/+, sometimes expressed.</p></fn></table-wrap-foot></table-wrap><sec id="section4-0192623311430695"><title>Undifferentiated Myeloid Antigens: CD34, CD43, CD45, and CD117</title><p>CD34 is a surface glycophosphoprotein developmentally expressed in the early hematolymphoid stem cell stage (<xref ref-type="fig" rid="fig1-0192623311430695">Figure 1</xref>). During normal development, a very small percentage of myeloid bone marrow cells, including granulocytic, monocytic, erythroid, and megakaryocytic precursors, are CD34-positive. In mice, CD34 is also present on progenitor and mature mast cells and basophils (<xref ref-type="bibr" rid="bibr8-0192623311430695">Arinobu 2005</xref>) and consequently should not be used to identify mouse stem cells for bone marrow transplantation. CD34 antigen is also expressed on some blood vessel endothelial cells. Immunohistochemically, CD34 antigen shows a cell membrane expression pattern (<xref ref-type="fig" rid="fig1-0192623311430695">Figure 1</xref>) and is an excellent marker of undifferentiated myeloid leukemia. Unlike most other CD antigens, CD34 is expressed on many malignant and benign nonhematopoietic tumors (<xref ref-type="bibr" rid="bibr21-0192623311430695">Chu and Weiss 2009</xref>).</p><fig id="fig1-0192623311430695" position="float"><label>Figure 1.</label><caption><p>Bone marrow of an adult FVB mouse showing cell membrane expression of CD34 on a few progenitor bone marrow cells.</p> <p>Figure 2.`—Bone marrow of an adult FVB mouse showing cell membrane expression of CD43 on several bone marrow cells.</p> <p>Figure 3.`—Bone marrow of an adult FVB mouse showing cell membrane expression of CD117 (cKit) on a few progenitor bone marrow cells.</p> <p>Figure 4.`—Bone marrow of an adult FVB mouse showing cytoplasmic expression of myeloperoxidase in granulocytes.</p> <p>Figure 5.`—Bone marrow of an adult FVB mouse showing cell membrane expression of TER119 on immature and a few mature erythroid cells.</p> <p>Figure 6.`—Bone marrow of an adult FVB mouse showing nuclear expression of GATA1 in immature erythroid cells and mature megakaryocytes.</p></caption><graphic alt-version="no" alternate-form-of="fig1-0192623311430695" position="float" xlink:href="10.1177_0192623311430695-fig1.tif" xlink:type="simple"/></fig><p>CD43, also known as leukosialin, is a protein present on most nonneoplastic granulocytes, T-lymphoid cells and their progenitors, pro B-lymphocytes as well as plasma cells (<xref ref-type="fig" rid="fig1-0192623311430695">Figure 2</xref>), while nonneoplastic mature B-lymphoid cells are CD43 negative. CD43 antigen usually shows a cell membrane pattern, but cells may demonstrate both membrane and diffuse cytoplasmic staining in IHC (<xref ref-type="bibr" rid="bibr4-0192623311430695">Arber and Weiss 1993</xref>). The antigen is expressed in most T-lymphomas/leukemias, pro B-lymphoblastic lymphoma/leukemia, acute myeloid leukemia, and plasma cell diseases. It is also observed on the plasma cells of lymphomas with plasma cell differentiation.</p><p>CD45 (leukocyte common antigen) is a family of protein tyrosine phosphates that are expressed on virtually all hematolymphoid cells and their precursors, with the exception of maturing erythrocytes and megakaryocytes, but it is not present on any non-hematolymphoid cells (<xref ref-type="bibr" rid="bibr135-0192623311430695">Weiss et al. 1993</xref>). CD45 antigen is also not commonly expressed on plasma cells. IHC labeling with CD45 antibody is usually membranous in distribution, but paranuclear staining is occasionally observed. CD45 antibody reacts with all isoforms of the family, while CD45R antibodies react with restricted subsets of the CD45 proteins.</p><p>CD117 (KIT) is a tyrosine kinase receptor protein expressed on the surface of bone marrow precursors (myeloid, erythroid, mouse but not human pro B-blasts and proT-blast cells) and mature mast cells (<xref ref-type="bibr" rid="bibr120-0192623311430695">Sykora et al. 1997</xref>; <xref ref-type="bibr" rid="bibr6-0192623311430695">Arber, Tamayo, and Weiss 1998</xref>; <xref ref-type="bibr" rid="bibr34-0192623311430695">Escribano et al. 1998</xref>; <xref ref-type="bibr" rid="bibr77-0192623311430695">Mazzucchelli and Durum 2007</xref>; <xref ref-type="fig" rid="fig1-0192623311430695">Figure 3</xref>). In the mouse, CD117 is expressed on the cells of myeloid leukemias of the undifferentiated types and of pro B- and pro T-cell lymphoblastic lymphomas/leukemias. It is a useful marker in the diagnosis of mast cell disorders and gastrointestinal stromal tumors (<xref ref-type="bibr" rid="bibr6-0192623311430695">Arber, Tamayo, and Weiss 1998</xref>).</p></sec><sec id="section5-0192623311430695"><title>Common Granulocyte and Monocyte Antigens: MPO, CD68, Ly6B, Ly6G, Lysozyme</title><p>Myeloperoxidase (MPO) is a constituent of neutrophil primary granules and is expressed in the immature and mature stages of both neutrophils and eosinophils (<xref ref-type="bibr" rid="bibr98-0192623311430695">Pinkus and Pinkus 1991</xref>; <xref ref-type="bibr" rid="bibr28-0192623311430695">De 1999</xref>). The staining pattern is cytoplasmic (<xref ref-type="fig" rid="fig1-0192623311430695">Figure 4</xref>). Erythroid precursors, megakaryocytes, mast cells, lymphoid cells, and plasma cells are not immunoreactive for MPO. Cells of the monocytic lineage react variably (typically weakly positive or nonreactive), but MPO is not expressed in resident macrophages (Taachini-Cottier et al. 2000). MPO is a sensitive and specific marker of the myeloid lineage in leukemias. Mouse and human Kupffer cells as well as human activated microglia have also been reported to express MPO (<xref ref-type="bibr" rid="bibr106-0192623311430695">Rensen et al. 2009</xref>; <xref ref-type="bibr" rid="bibr14-0192623311430695">Brown et al. 2001</xref>; <xref ref-type="bibr" rid="bibr87-0192623311430695">Nagra et al. 1997</xref>). However, the authors have not observed MPO expression by these cells in rodents, and others have reported that rat Kupffer cells do not express MPO (<xref ref-type="bibr" rid="bibr2-0192623311430695">Amanzada et al. 2011</xref>).</p><p>CD68 is a glycoprotein associated with lysosomes that is expressed in the cytoplasm of most cells of the monocyte/macrophage lineage. Intracytoplasmic immunoreactivity with CD68 antibody is observed in Schwann cells of nerves with Wallerian degeneration, Schwann cells of traumatic neuroma, neurofibroma and granular cell tumor (<xref ref-type="bibr" rid="bibr60-0192623311430695">Kaiserling et al. 1993</xref>). CD68 antibody also reacts with melanocytes and mast cells (Weiss 1994; <xref ref-type="bibr" rid="bibr72-0192623311430695">Li et al. 1996</xref>). The monoclonal CD68 antibodies KP1 and PG-M1 react with monocytes/macrophages. While KP1 reacts with human monocytes/macrophages and myeloid progenitor cells, PG-M1 reactivity is restricted to the monocyte/macrophage lineage (<xref ref-type="bibr" rid="bibr36-0192623311430695">Falini et al. 1993</xref>). Our experience suggests that the rat antimouse CD68 (clone MCA 1957) antibody and the rat ED1 (CD68) antibody react with monocytes/macrophages but not with other myeloid cells.</p><p>The <italic>Ly6 </italic>haplotype family, which includes the <italic>Ly6b </italic>and <italic>Ly6g</italic> haplotypes, has many members. The LY6B haplotype antigen is expressed in the 129, AKR, C57BL/6, C57BL/10, C58, DBA, and SJL mouse strains; whereas the LY6G haplotype antigen is expressed in the A2G, A/Sn, ASW, BALB/c, C3H/He, and CBA mouse strains (<xref ref-type="bibr" rid="bibr56-0192623311430695">Hirsch and Gordon 1983</xref>; <xref ref-type="bibr" rid="bibr109-0192623311430695">Rosas et al 2010</xref>).</p><p>The LY6B haplotype is synonymous with the 7/4 antigen, a differentiation antigen associated with neutrophils and monocytes that is lost as monocytes differentiate into macrophages and that is not expressed by mature mouse tissue-resident macrophages. Monoclonal antibody 7/4 labels immature and mature neutrophils and monocytes but not macrophages, eosinophils, mast cells, erythroid cells, or lymphocytes (<xref ref-type="bibr" rid="bibr56-0192623311430695">Hirsch and Gordon 1983</xref>).</p><p>In murine animals, the LY6G haplotype is expressed by neutrophils, a subset of eosinophils, and transiently during the developmental stages of monocytes (<xref ref-type="bibr" rid="bibr68-0192623311430695">Lagasse and Weissman 1996</xref>; <xref ref-type="bibr" rid="bibr73-0192623311430695">Lopez et al. 1984</xref>). The monoclonal LY6G antibody NIMP-R14 labels neutrophils, developing monocytes, and subsets of eosinophils; but it does not label macrophages, mast cells, erythroid cells, or lymphocytes (<xref ref-type="bibr" rid="bibr86-0192623311430695">Nagendra and Schlueter 2004</xref>).</p><p>Lysozyme is a marker of myeloid cells, monocytes/histiocytes, and their neoplasms (<xref ref-type="bibr" rid="bibr52-0192623311430695">Hard and Snowden 1991</xref>; <xref ref-type="bibr" rid="bibr132-0192623311430695">Ward and Sheldon 1993</xref>). Its IHC staining pattern is cytoplasmic.</p></sec><sec id="section6-0192623311430695"><title>Erythroid Antigens: Glycophorin A, TER119, GATA1</title><p>Glycophorin A (CD235a) is a major sialoglycoprotein of the erythrocyte membrane. In mice and rats, the intensity of glycophorin A expression increases as cells mature from the basophilic erythroblast stage to the erythrocyte, and glycophorin A accumulates during the induction of murine erythroleukemia (<xref ref-type="bibr" rid="bibr76-0192623311430695">Matsui et al. 1985</xref>; <xref ref-type="bibr" rid="bibr63-0192623311430695">Kina et al. 2000</xref>). Glycophorin A antibody I-20 labels mouse and rat glycophorin A; it is used to diagnose erythroid leukemia and it does not label myeloid cells or lymphocytes. The IHC staining pattern is membranous. Erythroid stages from normal late erythroblasts to mature erythrocytes are heavily stained, while early erythroblasts are weakly stained (<xref ref-type="bibr" rid="bibr111-0192623311430695">Sadahira et al. 1999</xref>).</p><p>TER119 is a molecule associated with cell-surface glycophorin A, but it is not identical to glycophorin A. It is specifically expressed on the membranes of erythroid cells at the proerythroblast stage through the mature erythrocyte stage (<xref ref-type="bibr" rid="bibr63-0192623311430695">Kina et al. 2000</xref>; <xref ref-type="fig" rid="fig1-0192623311430695">Figure 5</xref>). Hematopoietic stem cells, monocytes, granulocytes, mast cells, and lymphoid cells do not express the TER-119 antigen; nor do murine erythroleukemia cell lines or erythroid leukemia cells (<xref ref-type="bibr" rid="bibr63-0192623311430695">Kina et al. 2000</xref>; <xref ref-type="bibr" rid="bibr126-0192623311430695">Torchia et al. 2007</xref>).</p><p>GATA1 is a transcription factor expressed in the nuclei of erythroid cells, megakaryocytes, eosinophils, basophils, and mast cells (<xref ref-type="bibr" rid="bibr142-0192623311430695">Zon et al. 1991</xref>; <xref ref-type="fig" rid="fig1-0192623311430695">Figure 6</xref>). GATA1 is expressed in erythroid and megakaryocytic leukemia cells (<xref ref-type="bibr" rid="bibr51-0192623311430695">Hao et al. 2006</xref>; <xref ref-type="bibr" rid="bibr126-0192623311430695">Torchia et al. 2007</xref>), but it is reportedly not expressed in immature mouse neoplastic mast cells (<xref ref-type="bibr" rid="bibr142-0192623311430695">Zon et al. 1991</xref>). The authors have found mast-cell expression of GATA1 in paraffin-embedded tissue to be inconsistent.</p></sec><sec id="section7-0192623311430695"><title>Megakaryocyte Antigens: CD34, CD41, CD61, CD79a, Clusterin, GATA1, RUNX1, and von Willebrand</title><p>Several antigens are reported to be expressed by megakaryocytes, including CD34, CD41, CD61, CD79a, clusterin, GATA1 (<xref ref-type="fig" rid="fig1-0192623311430695">Figure 6</xref>), RUNX1, and von Willebrand factor (<xref ref-type="bibr" rid="bibr79-0192623311430695">McComb et al. 1982</xref>; <xref ref-type="bibr" rid="bibr29-0192623311430695">Debili et al. 1992</xref>; <xref ref-type="bibr" rid="bibr32-0192623311430695">Elagib et al. 2003</xref>; <xref ref-type="bibr" rid="bibr74-0192623311430695">Lorsbach et al. 2004</xref>). CD31 has also been reported to be expressed by human megakaryocytes, but the authors have been unable to confirm this observation in mouse megakaryocytes (<xref ref-type="bibr" rid="bibr108-0192623311430695">Romeo et al. 2002</xref>; <xref ref-type="bibr" rid="bibr85-0192623311430695">Muler et al. 2002</xref>; <xref ref-type="bibr" rid="bibr99-0192623311430695">Pusztaszeri et al. 2006</xref>). The most useful markers for identifying normal and abnormal megakaryocytes are CD34, CD61, GATA1, RUNX1, and von Willebrand factor (vWF) (<xref ref-type="bibr" rid="bibr22-0192623311430695">Chuang et al. 2000</xref>; <xref ref-type="bibr" rid="bibr113-0192623311430695">Schick et al. 1993</xref>; <xref ref-type="bibr" rid="bibr51-0192623311430695">Hao et al. 2006</xref>). However, CD34 and CD79a labeling of megakaryocytes is clone-specific. CD34 clone MEC14.7, unlike clone Ram34, does not label megakaryocytes (<xref ref-type="fig" rid="fig7-0192623311430695">Figures 7</xref> and <xref ref-type="fig" rid="fig7-0192623311430695">8</xref>). CD79a is not expressed in normal myeloid cells. However, CD79a antibody (clone HM57) has been reported to label normal human megakaryocytes (<xref ref-type="bibr" rid="bibr22-0192623311430695">Chuang et al. 2000</xref>; <xref ref-type="bibr" rid="bibr11-0192623311430695">Bhargava et al. 2007</xref>), and the authors have observed CD79a labeling of megakaryocytes in mice (unpublished data; <xref ref-type="fig" rid="fig7-0192623311430695">Figure 9</xref>). The authors and others have observed that the CD79a clone JCB117 does not label megakaryocytes (<xref ref-type="bibr" rid="bibr11-0192623311430695">Bhargava et al. 2007</xref>; <xref ref-type="fig" rid="fig7-0192623311430695">Figure 10</xref>). Detection of CD34 and CD79a expression in megakaryocytes appears to be antibody clone-dependent, likely owing to detection of different epitopes by the antibody clones. Alternatively, the CD34 and CD79a antibodies are cross-reacting with antigens that are presently of an undetermined nature.</p><fig id="fig7-0192623311430695" position="float"><label>Figure 7.</label><caption><p>Spleen of an adult NMRI mouse showing expression of CD34 on a mature megakaryocyte labeled with clone RAM34.</p> <p>Figure 8.—Spleen of an adult NMRI mouse showing a megakaryocyte that is not labeled for CD34 by clone MEC 14.7.</p> <p>Figure 9.—Spleen of an adult NMRI mouse showing cytoplasmic expression of CD79a labeled by clone HM57 in a megakaryocyte.</p> <p>Figure 10.—Spleen of an adult NMRI mouse showing a megakaryocyte that is not labeled for CD79a expression by clone JCB 117. The cell is surrounded by lymphocytes that show cytoplasmic expression of CD79a.</p> <p>Figure 11.—Bone marrow of an adult NMRI mouse showing cytoplasmic expression of CD61 in a mature megakaryocyte.</p> <p>Figure 12.—Spleen of an adult NMRI mouse showing nuclear expression of RUNX1 in a mature megakaryocyte and granulocytes in various stages of maturation.</p></caption><graphic alt-version="no" alternate-form-of="fig7-0192623311430695" position="float" xlink:href="10.1177_0192623311430695-fig2.tif" xlink:type="simple"/></fig><p>CD41 has a cytoplasmic expression pattern early in megakaryocyte maturation (Gerwitz 1995). The antigen is valuable in immunophenotyping mouse megakaryocytes and murine megakaryocyte leukemia, especially when used in conjunction with CD61 (<xref ref-type="bibr" rid="bibr57-0192623311430695">Hisa et al. 2004</xref>; <xref ref-type="bibr" rid="bibr51-0192623311430695">Hao et al. 2006</xref>).</p><p>CD61 plays an important role in platelet aggregation as a receptor for von Willebrand factor. Normal platelets and megakaryocytes, and most megakaryocytic leukemia are positive for CD61 (<xref ref-type="bibr" rid="bibr51-0192623311430695">Hao et al. 2006</xref>; <xref ref-type="fig" rid="fig7-0192623311430695">Figure 11</xref>).</p><p>RUNX1, also known as AML1, is a transcription factor that regulates differentiation of several hematopoietic lineages. RUNX1 is expressed in the nuclei of lymphoid and myeloid cells, including megakaryocytes, but not in erythroid-cell nuclei in adult mice (Consetti and Calabi 1997; <xref ref-type="bibr" rid="bibr32-0192623311430695">Elagib et al. 2003</xref>; <xref ref-type="fig" rid="fig7-0192623311430695">Figure 12</xref>). This marker, used in conjunction with a panel of myeloid markers, can aid in the differentiation between megakaryocytic and erythroid leukemia (<xref ref-type="bibr" rid="bibr51-0192623311430695">Hao et al. 2006</xref>).</p><p>Von Willebrand factor (vWF), also known as Factor VIII related antigen, is commonly used as an endothelial cell marker. vWF and CD61 are highly specific for megakaryocytes and platelets (Chaung et al. 2000; <xref ref-type="bibr" rid="bibr113-0192623311430695">Schick et al. 1993</xref>; <xref ref-type="fig" rid="fig13-0192623311430695">Figure 13</xref>), and together these two markers can be useful in diagnosis of megakaryocyte disorders and leukemia.</p><fig id="fig13-0192623311430695" position="float"><label>Figure 13.</label><caption><p>Bone marrow of an NMRI mouse showing cytoplasmic expression of von Willebrand factor (Factor VIII) in mature megakaryocytes.</p> <p>Figure 14. —Thymus of an adult B6,129 mouse. In this H&amp;E section it is difficult to determine from morphology alone whether the granulocytes in the tissue are neutrophils, eosinophils, or a mixture of both cell types.</p> <p>Figure 15.—The granulocytes shown express cytoplasmic myeloperoxidase, which is consistent with either neutrophils or eosinophils.</p> <p>Figure 16.—Many of the granulocytes shown in <xref ref-type="fig" rid="fig13-0192623311430695">Figure 14</xref> show pink cytoplasm with the Luna stain (a histochemical stain that stains eosinophils pink), but the granulocytes are not labeled by LY6B, clone 7/4 antibody, which stains neutrophils in the C57BL/6 and 129 mouse strains (not shown).</p> <p>Figure 17.—The granulocytes shown in <xref ref-type="fig" rid="fig13-0192623311430695">Figure 16</xref> are labeled by antibody to eosinophil major basic protein, consistent with their identification as eosinophils.</p> <p>Figure 18.—Lymph node from an adult B6,129 mouse with sinus mast cells showing membrane expression of CD34.</p></caption><graphic alt-version="no" alternate-form-of="fig13-0192623311430695" position="float" xlink:href="10.1177_0192623311430695-fig3.tif" xlink:type="simple"/></fig></sec><sec id="section8-0192623311430695"><title>Eosinophil Antigens: Major Basic Protein</title><p>Under some circumstances, light microscopy with hematoxylin and eosin stain cannot reveal whether a granulocyte in an inflammatory cell infiltrate is a neutrophil or an eosinophil (<xref ref-type="fig" rid="fig13-0192623311430695">Figure 14</xref>). Myeloperoxidase, unfortunately, is not helpful in differentiating between these two granulocytes, as MPO is expressed in both eosinophils and neutrophils (<xref ref-type="fig" rid="fig13-0192623311430695">Figure 15</xref>). Astro blue/vital new red, Congo red, Sirius red, and Luna are histochemical stains that are reported to stain eosinophils. We have used the Luna stain to determine whether the cells are eosinophils (<xref ref-type="fig" rid="fig13-0192623311430695">Figure 16</xref>). However, consistent quality appears to depend on the differentiation step of the Luna procedure. Therefore, IHC is the preferred approach. Unfortunately, IHC for eosinophil peroxidase requires the use of frozen tissue. However, antibody to eosinophil major basic protein is very effective in labeling eosinophils in paraffin-embedded tissue (<xref ref-type="fig" rid="fig13-0192623311430695">Figure 17</xref>).</p></sec></sec><sec id="section9-0192623311430695"><title>Mast Cell Antigens: CD34, CD117, GATA1, Histamine, Tryptase</title><p>Mast cell precursors leave the bone marrow before their terminal maturation and home to peripheral tissues as morphologically unidentifiable agranular mast cells. There they differentiate into identifiable mast cells (Hallgren et al. 2007). Two mast cell subtypes in rodents have been distinguished on the basis of different fixatives, proteases expressed, and histochemical staining properties (<xref ref-type="bibr" rid="bibr138-0192623311430695">Welle 1997</xref>).</p><p>First, the atypical, T cell–dependent mucosal mast cells (MMC) are found mainly in the mucosa of the gastrointestinal tract and in the lamina propria of the respiratory tract. The T cell–dependent proliferation of MMC has been shown to be mediated by cytokines IL-3, -4, -9, and -10. Second, T cell–independent mast cells known as connective tissue mast cells (CTMC) occur mainly in the submucosa of the gastrointestinal tract, in the skin, and in the peritoneum. Fibroblast-derived factors, for example, SCF, appear to mediate the development of this subtype.</p><p>In addition to their respective T cell–dependent and –independent proliferation, the two mast cell subtypes are distinguished by size, proteoglycan, and histamine content. MMC granules consist of a relatively soluble matrix containing chondroitin sulfate and little histamine. Their anionic site is blocked by aldehyde, and therefore special fixation and staining conditions are required to reveal this cell type. After fixation in some common formalin-based fixatives, the MMC granules may become resistant to metachromatic staining (<xref ref-type="bibr" rid="bibr33-0192623311430695">Enerback 1981</xref>). Fixatives that rapidly penetrate the cell and strongly acid-staining conditions are ideal for this cell type. CTMCs contain heparin and a large quantity of histamine, allowing metachromatic staining of these mast cells with basic dyes such as toluidine blue or Giemsa.</p><p>CD34 and CD117 are membrane antigens and GATA1 is a nuclear antigen (<xref ref-type="fig" rid="fig13-0192623311430695">Figures 18</xref>, <xref ref-type="fig" rid="fig19-0192623311430695">19</xref>, <xref ref-type="fig" rid="fig19-0192623311430695">20</xref>). Consequently, they are not dependent on the staining characteristics of the mast cell granules; nor is the immunoreactivity of histamine and tryptase affected by formalin-based fixatives (<xref ref-type="bibr" rid="bibr67-0192623311430695">Kunder et al. 2007</xref>). Therefore, antibodies to CD34, CD117, and GATA1 can be used to identify both mucosal and connective-tissue mast cell precursors and degranulated mast cells (<xref ref-type="fig" rid="fig19-0192623311430695">Figure 21</xref>), when standard histochemistry approaches using toluidine blue, Giemsa, or Leder chloracetate esterase stains would not be effective (<xref ref-type="bibr" rid="bibr31-0192623311430695">Drew et al. 2002</xref>; <xref ref-type="fig" rid="fig19-0192623311430695">Figures 22</xref>, <xref ref-type="fig" rid="fig19-0192623311430695">23</xref>, and <xref ref-type="fig" rid="fig19-0192623311430695">24</xref>). MMC and CTMC are equally dependent on stem cell factor and CD117 for development and maturation, and both express CD34, which further supports the use of CD117 and CD34 as excellent pan-mast cell markers for IHC (<xref ref-type="bibr" rid="bibr31-0192623311430695">Drew et al. 2002</xref>; <xref ref-type="bibr" rid="bibr49-0192623311430695">Hallgren and Gurish 2007</xref>).</p><fig id="fig19-0192623311430695" position="float"><label>Figure 19.</label><caption><p>Lymph node from an adult B6,129 mouse with sinusoidal mast cells showing membrane expression of CD117.</p> <p>Figure 20.—Spleen from an adult B6,129 mouse with sinusoidal mast cells showing nuclear expression of GATA1.</p> <p>Figure 21.—An H&amp;E section of a lymph node from an adult B6,129 mouse. Cells show abundant pink cytoplasm and vague granularity suggestive of degranulated mast cells.</p> <p>Figure 22.—With toluidine blue stain, the lymph node shown in <xref ref-type="fig" rid="fig13-0192623311430695">Figure 18</xref> reveals a cell with metachromatic cytoplasmic granules consistent with a mast cell.</p> <p>Figure 23.—Giemsa stain of a spleen from an adult B6,129 mouse with several cells showing metachromatic granules consistent with mast cells.</p> <p>Figure 24.—A Leder stain of a lymph node from an adult B6,129 mouse shows several sinusoidal mononuclear cells (left side) and medullary cord granulocytes (right side) with granules positive for chloracetate esterase, consistent with mast cells and neutrophils, respectively.</p></caption><graphic alt-version="no" alternate-form-of="fig19-0192623311430695" position="float" xlink:href="10.1177_0192623311430695-fig4.tif" xlink:type="simple"/></fig><p>CD68, commonly used as a macrophage marker, is also expressed in mast cells but is considered a nonspecific marker of mast cells (<xref ref-type="bibr" rid="bibr136-0192623311430695">Weiss et al. 1994</xref>; <xref ref-type="bibr" rid="bibr72-0192623311430695">Li et al. 1996</xref>).</p><p>Histamine is an organic nitrogen protein produced in the cytosol and stored in the cytoplasmic granules of mast cells and basophils in mice, rats, and other species. IgE triggers sensitized mast cells and basophils to release histamine, eliciting an inflammatory response. IHC with antihistamine antibody is used to detect mast cells in tissues (<xref ref-type="fig" rid="fig25-0192623311430695">Figure 25</xref>). Non-mast cell histamine is found in several tissues, such as the brain and the enterochromaffin-like cell of the stomach.</p><fig id="fig25-0192623311430695" position="float"><label>Figure 25.</label><caption><p>Spleen from an adult B6,129 mouse with cells containing cytoplasmic granules that are labeled by antihistamine antibody, consistent with mast cells.</p> <p>Figure 26.—Lung from an adult FVB mouse showing cytoplasmic expression of CD68 in alveolar macrophages.</p> <p>Figure 27.—Lung from an adult FVB mouse showing cell membrane expression of F4/80 on alveolar macrophages.</p> <p>Figure 28.—Spleen from an adult FVB mouse showing cytoplasmic expression of IBA1 in marginal zone macrophages, follicular dendritic cells, interdigitating dendritic cells, and numerous red pulp macrophages.</p> <p>Figure 29.—Lung from an adult FVB mouse showing cytoplasmic expression of lysozyme in alveolar macrophages.</p> <p>Figure 30.—Lung from an adult FVB mouse showing cytoplasmic and light membrane expression of MAC2 in alveolar macrophages.</p></caption><graphic alt-version="no" alternate-form-of="fig25-0192623311430695" position="float" xlink:href="10.1177_0192623311430695-fig5.tif" xlink:type="simple"/></fig><p>Tryptase is a cytoplasmic serine protease expressed almost exclusively in mast cells. Its immunoreactivity is not affected by formalin-based fixatives, and it is reported to be helpful in diagnosing mast cell neoplasms (<xref ref-type="bibr" rid="bibr67-0192623311430695">Kunder et al. 2007</xref>). However, others report that only a few mucosal mast cells express tryptase (<xref ref-type="bibr" rid="bibr17-0192623311430695">Chen et al. 1993</xref>). Therefore, its value in diagnostic IHC for mucosal mast cells or neoplasms arising from these cells remains to be determined. Although tryptase is highly specific, this observation further supports the use of CD34 and CD117 as the preferred IHC pan-mast cell markers.</p></sec><sec id="section10-0192623311430695"><title>Tissue Histiocyte (Macrophage) Antigens: CD68, CD163, F4/80, IBA1, Lysozyme, MAC2, MAC3, S100P, Arginase 1, INOS2, YM1</title><p>Macrophages display a wide variety of phenotypes, depending on their tissue localization (<xref ref-type="table" rid="table4-0192623311430695">Table 4</xref>; <xref ref-type="fig" rid="fig25-0192623311430695">Figures 26</xref>, <xref ref-type="fig" rid="fig25-0192623311430695">27</xref>, <xref ref-type="fig" rid="fig25-0192623311430695">28</xref>, <xref ref-type="fig" rid="fig25-0192623311430695">29</xref>, <xref ref-type="fig" rid="fig25-0192623311430695">30</xref>, and <xref ref-type="fig" rid="fig31-0192623311430695">31</xref>), the cytokine environment, and the time point in the inflammatory process. Consequently, macrophages comprise multiple heterogeneous subsets, necessitating the use of a panel of antibodies to confirm them as macrophages. The more common tissue macrophage biomarkers are CD68, CD163, F4/80, IBA1, MAC2, and MAC3. Other antigens expressed by macrophages are CD45, lysozyme, and S100P.</p><table-wrap id="table4-0192623311430695" position="float"><label>Table 4.</label><caption><p>Anatomic tissue distribution of immunoreactivity of mouse macrophage antigens.</p></caption><graphic alt-version="no" alternate-form-of="table4-0192623311430695" position="float" xlink:href="10.1177_0192623311430695-table4.tif" xlink:type="simple"/><table><thead><tr><th colspan="1" rowspan="1">Macrophage location</th><th colspan="1" rowspan="1">CD68</th><th colspan="1" rowspan="1">F4/80</th><th colspan="1" rowspan="1">IBA1</th><th colspan="1" rowspan="1">Lysozyme</th><th colspan="1" rowspan="1">MAC2</th><th colspan="1" rowspan="1">MAC3</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Thymus</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"> Cortex</td><td colspan="1" rowspan="1">+/–<sup><xref ref-type="table-fn" rid="table-fn5-0192623311430695">a</xref></sup></td><td align="center" colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">+</td><td align="center" colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+</td></tr><tr><td colspan="1" rowspan="1"> Medulla</td><td colspan="1" rowspan="1">+/–</td><td colspan="1" rowspan="1">IC<sup><xref ref-type="table-fn" rid="table-fn6-0192623311430695">b</xref></sup></td><td colspan="1" rowspan="1">++</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">++</td><td colspan="1" rowspan="1">++</td></tr><tr><td colspan="1" rowspan="1">Spleen</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"> White pulp</td><td align="center" colspan="1" rowspan="1">–</td><td align="center" colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">+</td><td align="center" colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+</td></tr><tr><td colspan="1" rowspan="1"> Marginal zone</td><td colspan="1" rowspan="1">Rare</td><td align="center" colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">++</td><td align="center" colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">+</td><td align="center" colspan="1" rowspan="1">–</td></tr><tr><td colspan="1" rowspan="1"> Red pulp</td><td align="center" colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">++</td><td colspan="1" rowspan="1">++</td><td align="center" colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">++</td></tr><tr><td colspan="1" rowspan="1">Lymph node</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"> Capsular sinus</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+/–</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">IC</td></tr><tr><td colspan="1" rowspan="1"> Follicular DC</td><td align="center" colspan="1" rowspan="1">–</td><td align="center" colspan="1" rowspan="1">–</td><td align="center" colspan="1" rowspan="1">–</td><td align="center" colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">+</td><td align="center" colspan="1" rowspan="1">–</td></tr><tr><td colspan="1" rowspan="1"> Paracortical DC</td><td colspan="1" rowspan="1">+/–</td><td align="center" colspan="1" rowspan="1">–</td><td align="center" colspan="1" rowspan="1">–</td><td align="center" colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+</td></tr><tr><td colspan="1" rowspan="1"> Medullary cords</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">++</td><td align="center" colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+</td></tr><tr><td colspan="1" rowspan="1"> Medullary sinus</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">++</td><td colspan="1" rowspan="1">+/–</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+</td></tr><tr><td colspan="1" rowspan="1">Lung, alveolus</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+/–</td><td align="center" colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">++</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+</td></tr><tr><td colspan="1" rowspan="1">Liver, Kupffer cell</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+/–</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+</td></tr></tbody></table><table-wrap-foot><fn id="table-fn4-0192623311430695"><p>Table is a composite analysis of multiple sources: <xref ref-type="bibr" rid="bibr44-0192623311430695">Gordon et al. (1992)</xref>; <xref ref-type="bibr" rid="bibr100-0192623311430695">Rabinowitz and Gordon (1991)</xref>; <xref ref-type="bibr" rid="bibr117-0192623311430695">Soga, et al. (1997)</xref>; author experience.</p></fn><fn id="table-fn5-0192623311430695"><p><sup>a</sup>Expression is semiquantitative; + present; ++ high; +/– low or varies with cell activation.</p></fn><fn id="table-fn6-0192623311430695"><p><sup>b</sup>IC = Inconclusive data.</p></fn></table-wrap-foot></table-wrap><p>CD68 is an intracellular glycoprotein present in lysosomes and phagosomes and is expressed in the cytoplasm of most tissue macrophages (<xref ref-type="fig" rid="fig25-0192623311430695">Figure 26</xref>). Although the antigen is commonly used as a macrophage marker, it is not a specific marker for cells of monocyte/macrophage derivation, as other cells that contain lysosomes or phagosomes, such as mast cells, melanocytes, and so forth, may be immunoreactive (<xref ref-type="bibr" rid="bibr136-0192623311430695">Weiss et al. 1994</xref>).</p><p>CD163 is a glycoprotein belonging to the scavenger receptor cystine–rich superfamily (<xref ref-type="bibr" rid="bibr69-0192623311430695">Lau et al. 2004</xref>). Its expression is largely restricted to monocytes and tissue macrophages. CD163 immunoreactivity is observed in resident macrophages of all normal tissues, except splenic white pulp and germinal cell tingible body macrophages. CD163 antibody is a more specific marker of disorders of monocyte/macrophage origin than CD68 antibody. In the brain, CD163 expression, unlike that of IBA1, is restricted to the perivascular, meningeal, and choroid plexus macrophages (Kim et al. 2006; <xref ref-type="bibr" rid="bibr95-0192623311430695">Perry et al. 1994</xref>).</p><p>F4/80 is a glycoprotein with 80% surface membrane expression and 20% cytoplasmic expression (<xref ref-type="bibr" rid="bibr44-0192623311430695">Gordon et al. 1992</xref>; <xref ref-type="bibr" rid="bibr94-0192623311430695">Perry et al. 1992</xref>). In formalin fixed paraffin embedded tissue, F4/80-expressing macrophages in lymphoid organs are restricted to splenic red pulp, lymph node medullary cords, and are scattered in the thymic corticomedullary junction region. F4/80 is also expressed in the liver Kupffer cells and alveolar macrophages (<xref ref-type="bibr" rid="bibr75-0192623311430695">Malorny et al. 1986</xref>; <xref ref-type="table" rid="table4-0192623311430695">Table 4</xref>; <xref ref-type="fig" rid="fig25-0192623311430695">Figure 27</xref>). F4/80 antibody labels circulating monocytes very weakly if at all and does not label lymphocytes or neutrophils (<xref ref-type="bibr" rid="bibr75-0192623311430695">Malorny et al. 1986</xref>; <xref ref-type="bibr" rid="bibr123-0192623311430695">Taylor et al. 2005</xref>). However, caution is warranted when evaluating inflammatory tissues. Interferon-gamma down-regulates F4/80 expression, and F4/80 antibody is reported to label eosinophils and neovascularized tissue endothelial cells (<xref ref-type="bibr" rid="bibr80-0192623311430695">McGarry and Stewart 1991</xref>; <xref ref-type="bibr" rid="bibr45-0192623311430695">Gordon et al. 1986</xref>; <xref ref-type="bibr" rid="bibr47-0192623311430695">Gouon-Evans et al. 2002</xref>). The latter may be problematic when assessing cellular infiltrates in tumor transplant studies.</p><p>Ionized calcium–binding adapter molecule 1 (IBA1) is identical to allograft inflammatory factor-1 (AIF-1) antigen (<xref ref-type="table" rid="table4-0192623311430695">Table 4</xref>; <xref ref-type="fig" rid="fig25-0192623311430695">Figure 28</xref>). The protein is localized in the cytoplasm and the nucleus of cells. IBA1 is commonly recognized as a microglia marker and may also be regarded as a pan-macrophage marker. All subpopulations of macrophages examined to date except alveolar macrophages express the antigen (<xref ref-type="bibr" rid="bibr66-0192623311430695">Kohler et al. 2007</xref>). It is an excellent marker of the macrophages of the splenic marginal zone in formalin fixed paraffin embedded tissue (<xref ref-type="fig" rid="fig25-0192623311430695">Figure 28</xref>).</p><p>Lysozyme is expressed in the cytoplasm of mouse and rat hematopoietic and non-hematopoietic cells (<xref ref-type="bibr" rid="bibr118-0192623311430695">Speece 1964</xref>; <xref ref-type="bibr" rid="bibr65-0192623311430695">Klockars and Osserman 1974</xref>). Lysozyme is a useful but nonspecific marker of granulocytes, monocytes, tissue macrophages, and their neoplasms (<xref ref-type="bibr" rid="bibr131-0192623311430695">Ward and Rehm 1990</xref>; <xref ref-type="bibr" rid="bibr132-0192623311430695">Ward and Sheldon 1993</xref>; <xref ref-type="bibr" rid="bibr96-0192623311430695">Pileri et al. 2002</xref>; <xref ref-type="bibr" rid="bibr50-0192623311430695">Hao et al. 2010</xref>). The alveolar macrophage has stronger lysozyme expression (<xref ref-type="fig" rid="fig25-0192623311430695">Figure 29</xref>) than other tissue macrophages and is expressed variably in tissue histiocytic sarcomas (<xref ref-type="bibr" rid="bibr65-0192623311430695">Klockars and Osserman 1974</xref>; <xref ref-type="bibr" rid="bibr132-0192623311430695">Ward and Sheldon 1993</xref>; <xref ref-type="table" rid="table4-0192623311430695">Table 4</xref>). The renal proximal convoluted tubules are the most noted non-hematopoietic cells to contain lysozyme. Large volumes of the enzyme are sometimes evident by IHC in the renal tubules in association with some rodent histiocytic sarcomas (<xref ref-type="bibr" rid="bibr52-0192623311430695">Hard and Snowden 1991</xref>). This finding is likely to be associated with tubular absorption of glomerular filtration fluid containing enzyme released into the blood by tumor cells.</p><p>MAC2 (Galectin 3) is the intracellular protein galactose-specific lectin 3. Expression of the MAC2 protein correlates with maturation of a subset of macrophages (<xref ref-type="bibr" rid="bibr70-0192623311430695">Leenen et al. 1994</xref>). Upon activation, it is an inducible component of the macrophage cell surface. By immunohistochemistry, MAC2 has a cytoplasmic and membrane-staining pattern, which sometimes imparts the appearance of nuclear expression (<xref ref-type="bibr" rid="bibr50-0192623311430695">Hao et al. 2010</xref>; <xref ref-type="fig" rid="fig25-0192623311430695">Figure 30</xref>). MAC2 protein is detectable on thymic, follicular, and interdigitating dendritic cells, marginal zone macrophages, and all resident tissue macrophages (<xref ref-type="table" rid="table4-0192623311430695">Table 4</xref>; <xref ref-type="fig" rid="fig25-0192623311430695">Figures 30</xref> and <xref ref-type="fig" rid="fig31-0192623311430695">31</xref>). The antigen is not expressed on lymphoid cells. Some antibodies will immunoreact with the MAC2/e binding protein expressed on neutrophils. The protein is also expressed in a highly specific pattern on certain epithelial cells. It is present on bronchial epithelium, some renal tubules, intestinal epithelium, skin keratinocytes, hair follicles, choroid plexus, and ependymal cells.</p><fig id="fig31-0192623311430695" position="float"><label>Figure 31.</label><caption><p>Spleen from an adult FVB mouse showing cytoplasmic expression of MAC2 in marginal zone macrophages, follicular dendritic cells, and a scattering of red pulp macrophages.</p> <p>Figure 32.—Uterine histiocytic sarcoma from an adult B6,129 mouse showing intermittent tumor cells with nuclear and cytoplasmic expression of S-100P.</p> <p>Figure 33.—Lymph node from an adult B6,129 mouse showing macrophages with cytoplasmic and nuclear arginase 1 immunoreactivity.</p> <p>Figure 34.—Liver from an adult B6,129 mouse showing multiple lymphogranulomas with cytoplasmic iNos2 expression in the epithelioid macrophages.</p> <p>Figure 35.—Connective tissue wall of a skin abscess in an adult CrlCD1 mouse showing neutrophils with cytoplasmic expression of YM1 (CHI3l3).</p> <p>Figure 36.—Lung from an adult NMRI mouse showing alveolar macrophages with cytoplasmic expression of YM1.</p></caption><graphic alt-version="no" alternate-form-of="fig31-0192623311430695" position="float" xlink:href="10.1177_0192623311430695-fig6.tif" xlink:type="simple"/></fig><p>MAC3 is a glycoprotein found on macrophages, dendritic cells, megakaryocytes, and granulocytes, but it is not expressed on any other hematopoietic cell type. Expression is also found on epithelial and endothelial cells in a variety of tissues (<xref ref-type="bibr" rid="bibr37-0192623311430695">Flotte 1983</xref>). The staining of lymphatic and vascular endothelial cells makes the interpretation of the MAC3 pattern difficult in lymphoid organs. Both liver hepatocytes and Kupffer cells are reactive with MAC3 antibodies.</p><p>S100 protein (S100P) is dimeric, comprising alpha and beta subunits. Hence, it has three isoforms: S100ao (alpha dimeric), S100a (alpha-beta isoforms), and S100b (beta dimer). The content of the alpha subunit is considerably lower than that of the beta subunit in the usual S100P preparation used to generate S100P antibody. Therefore, localization of S100P by IHC is actually an indicator of the beta subunit (containing S100a [αβ] and S100β [ββ]) but not of the S100ao protein (<xref ref-type="bibr" rid="bibr122-0192623311430695">Takahashi et al. 1984</xref>). Most S100P antibodies label Langerhans cells and interdigitating dendritic cells in the T-cell zone of lymphoid tissues and their respective neoplasms. Ordinary macrophages, alveolar macrophages, follicular dendritic cells, and blood monocytes contain only the alpha subunit. Therefore, they label only very weakly if at all with most S100P antibodies. However, depending on the specific antibody used, follicular dendritic cells may also label with S100P antibody (<xref ref-type="bibr" rid="bibr19-0192623311430695">Chilosi et al. 1985</xref>; <xref ref-type="bibr" rid="bibr15-0192623311430695">Carbone et al. 1986</xref>). S100P expression occurs in 33% of human histiocytic sarcomas (<xref ref-type="bibr" rid="bibr96-0192623311430695">Pileri et al. 2002</xref>). We have observed S100P expression infrequently in some mouse histiocytic sarcomas (<xref ref-type="fig" rid="fig31-0192623311430695">Figure 32</xref>). The incidence of S100P expression in rodent histiocytic sarcomas warrants further investigation. Because the level of S100P in rodent tissues is less than that in humans (<xref ref-type="bibr" rid="bibr93-0192623311430695">Pedrocchi et al. 1993</xref>; <xref ref-type="bibr" rid="bibr27-0192623311430695">Davies et al. 1995</xref>), the incidence of S100P expression in rodent histiocytic sarcoma may be less than that reported in humans. There are contradictions in the literature and the commercial data sheets as to the acceptable distribution pattern for positive immunoreactivity. Some data sheets indicate that the correct pattern of expression is the cytoplasm. Some investigators report that nuclear staining with or without cytoplasmic staining is a true positive reaction (<xref ref-type="bibr" rid="bibr20-0192623311430695">Chu et al. 1999</xref>), while others report that immunoreactivity for S100P should be both nuclear and cytoplasmic to be regarded as valid (<xref ref-type="bibr" rid="bibr139-0192623311430695">Wick 2006</xref>).</p><p>Arginase 1 is a cytosolic enzyme that catalyzes the conversion of arginine to ornithine and has an IHC diffuse cytoplasmic and patchy nuclear immunoreactivity pattern (<xref ref-type="fig" rid="fig31-0192623311430695">Figure 33</xref>). It is a biomarker of M2 macrophages, which are macrophages activated by CD4Th2 cytokines IL4 and IL13 (known as the alternative macrophage activation pathway).</p><p>Inducible NO synthase 2 (iNOS2) is a cytoplasmic biomarker of activated neutrophils and macrophages activated by CD4Th1 proinflammatory cytokines IFN-gamma and TNF-alpha (<xref ref-type="fig" rid="fig31-0192623311430695">Figure 34</xref>). Inactivated resting rodent neutrophils and macrophages have very low or nondetectable expression of iNOS2, and expression is greatly enhanced upon activation (<xref ref-type="bibr" rid="bibr88-0192623311430695">Nair et al. 2003</xref>; <xref ref-type="bibr" rid="bibr78-0192623311430695">McCafferty et al. 1999</xref>; <xref ref-type="bibr" rid="bibr107-0192623311430695">Richter et al. 1999</xref>).</p><p>The YM1 (CHI3l3) protein is one of the chitinase family proteins, but it has no chitinase activity. The YM1 protein is expressed in neutrophils (<xref ref-type="fig" rid="fig31-0192623311430695">Figure 35</xref>) and by CD4Th2, IL4, IL13 activated macrophages associated with inflammation (<xref ref-type="bibr" rid="bibr133-0192623311430695">Ward et al. 2001</xref>; <xref ref-type="bibr" rid="bibr58-0192623311430695">Hung et al. 2002</xref>; Nio et al. 2004; <xref ref-type="bibr" rid="bibr82-0192623311430695">Milner et al. 2010</xref>).</p><p>Macrophages activated by the CD4Th2 alternative pathway are known as M2 macrophages. Alveolar macrophages in the lung constitutively express YM1 under normal conditions (<xref ref-type="fig" rid="fig31-0192623311430695">Figure 36</xref>) and activated M2 macrophages transiently express YM1 (<xref ref-type="bibr" rid="bibr133-0192623311430695">Ward et al. 2001</xref>; <xref ref-type="bibr" rid="bibr58-0192623311430695">Hung et al. 2002</xref>; <xref ref-type="bibr" rid="bibr82-0192623311430695">Milner et al. 2010</xref>).</p></sec><sec id="section11-0192623311430695"><title>Lymphocyte Antigens</title><sec id="section12-0192623311430695"><title>B-Lymphocyte Lineage Antigens: CD45R/B220, CD117, CD43, TdT, CD79a, CD138, PAX5, IRF4</title><p>Mouse precursor B-cells arise from the bone marrow, then migrate to secondary lymphoid tissue, such as lymph nodes, spleen, and mucosa-associated lymphoid tissue. In the bone marrow, B-cells progress through sequential developmental stages classified as pro B-cell, pre B-cell, and immature B-cell (<xref ref-type="table" rid="table5-0192623311430695">Table 5</xref>). After migrating from the bone marrow, immature B-cells undergo mature B-cell differentiation in the lymphoid organ follicles. After subsequent migration through the follicular germinal center, they further differentiate into plasma cells. Different B-cell-related antigens are expressed at different stages of differentiation (<xref ref-type="table" rid="table5-0192623311430695">Table 5</xref>). B-cell neoplasms may arise at any stage of B-cell differentiation; therefore, their expression of stage-specific antigens is the basis for immunophenotyping these neoplasms (<xref ref-type="bibr" rid="bibr83-0192623311430695">Morse et al. 2002</xref>; <xref ref-type="bibr" rid="bibr119-0192623311430695">Swerdlow et al. 2008</xref>).</p><table-wrap id="table5-0192623311430695" position="float"><label>Table 5.</label><caption><p>Antigens associated with mouse B-cell differentiation detectable by IHC in formalin-fixed, paraffin-embedded tissues.<sup><xref ref-type="table-fn" rid="table-fn7-0192623311430695">1</xref></sup></p></caption><graphic alt-version="no" alternate-form-of="table5-0192623311430695" position="float" xlink:href="10.1177_0192623311430695-table5.tif" xlink:type="simple"/><table><thead><tr><th colspan="1" rowspan="1"/><th colspan="3" rowspan="1">Pro-B cell</th><th colspan="2" rowspan="1">Pre-B cell</th><th colspan="2" rowspan="1">B cell</th></tr><tr><th colspan="1" rowspan="1">Antigen</th><th colspan="1" rowspan="1">Early</th><th colspan="1" rowspan="1">INT</th><th colspan="1" rowspan="1">Late</th><th colspan="1" rowspan="1">Large</th><th colspan="1" rowspan="1">Small</th><th colspan="1" rowspan="1">Immature</th><th colspan="1" rowspan="1">Mature</th><th colspan="1" rowspan="1">Plasma cell</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">CD117</td><td colspan="3" rowspan="1"><sup><xref ref-type="table-fn" rid="table-fn8-0192623311430695">2</xref></sup></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">TdT</td><td colspan="2" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">CD43</td><td colspan="3" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">PAX5</td><td colspan="1" rowspan="1"/><td colspan="6" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">CD45R/B220</td><td colspan="1" rowspan="1"/><td colspan="2" rowspan="1"/><td colspan="4" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"><sub>c</sub>µ heavy chains<sup><xref ref-type="table-fn" rid="table-fn9-0192623311430695">3</xref></sup></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="5" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"><sub>s</sub>IgM<sup><xref ref-type="table-fn" rid="table-fn9-0192623311430695">3</xref></sup></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="3" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Ig light chains</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="2" rowspan="1"/></tr></tbody></table><table-wrap-foot><fn id="table-fn7-0192623311430695"><p><sup>1</sup>Table is a composite based on data from multiple sources: <xref ref-type="bibr" rid="bibr91-0192623311430695">Osmond et al. (1998)</xref>; <xref ref-type="bibr" rid="bibr53-0192623311430695">Hardy et al. (2007)</xref>.</p></fn><fn id="table-fn8-0192623311430695"><p><sup>2</sup>Line thickness indicates level of expression by flow cytometry.</p></fn><fn id="table-fn9-0192623311430695"><p><sup>3</sup>c = cytoplasmic; s = surface.</p></fn></table-wrap-foot></table-wrap><p>CD45R/B220 is considered a pan B-cell antigen. Flow cytometry studies have shown it to be expressed at low levels as early as the pro-B stage, with expression increasing as differentiation progresses (<xref ref-type="bibr" rid="bibr91-0192623311430695">Osmond et al. 1998</xref>; <xref ref-type="bibr" rid="bibr53-0192623311430695">Hardy et al. 2007</xref>). The intensity level of CD45R/B220 at the pro-B stage can be too low for IHC detection. CD45R/220 is strongly expressed on mature B-cells (<xref ref-type="fig" rid="fig37-0192623311430695">Figure 37</xref>), but it is lost just prior to terminal differentiation into plasma cells. The CD45R/B220 antigen is also expressed on subsets of T-cells, NK-cells, and dendritic cells (<xref ref-type="bibr" rid="bibr12-0192623311430695">Blasius et al. 2007</xref>; Vosshenvich et al. 2007). Expression is not seen on normal myeloid cells, erythroid cells, or monocytes/macrophages. The exact proportion of the various mouse lymphomas that express CD45R/B220 antigen detectable with IHC is not well documented. However, two IHC studies comparing CD45R/B220 and Pax 5 expression in mouse lymphomas indicate that a high proportion of B-lymphoblastic lymphomas and 20% or more of splenic marginal zone lymphomas lack detectable CD45R/B220 expression (<xref ref-type="bibr" rid="bibr67-0192623311430695">Kunder et al. 2007</xref>; <xref ref-type="bibr" rid="bibr104-0192623311430695">Rehg and Sundberg 2008</xref>). CD45R/B220 is essentially negative in T-cell lymphomas, except in some genetically engineered mice (<xref ref-type="bibr" rid="bibr67-0192623311430695">Kunder et al. 2007</xref>; <xref ref-type="bibr" rid="bibr104-0192623311430695">Rehg and Sundberg 2008</xref>).</p><fig id="fig37-0192623311430695" position="float"><label>Figure 37.</label><caption><p>Lymph node from an adult FVB mouse showing a follicle with cell membrane expression of CD45R/B220 in the follicular germinal center cells and mantle cells.</p> <p>Figure 38.—B-cell lymphoma in the bone marrow of an adult B6,129 mouse showing nuclear expression of TdT.</p> <p>Figure 39.—Spleen from an adult NMRI mouse showing cytoplasmic expression of CD79a in the follicular mantle and marginal zone lymphocytes. The germinal center cells show very little or no CD79a expression, suggesting down-regulation of CD79a expression has been activated in the germinal center cells.</p> <p>Figure 40.—Lymph node from an adult B6,129 mouse showing plasma cells with and without cytoplasmic expression of CD79a.</p> <p>Figure 41.—Lymph node from an adult B6,129 mouse showing CD138 cell membrane expression in medullary cord plasma cells.</p> <p>Figure 42.—Lymph node from an adult FVB mouse showing nuclear expression of Pax5 in the follicular germinal center cells and mantle cells.</p></caption><graphic alt-version="no" alternate-form-of="fig7-0192623311430695" position="float" xlink:href="10.1177_0192623311430695-fig7.tif" xlink:type="simple"/></fig><p>CD117 is expressed through the three pro-B stages, and expression is down-regulated after heavy chain rearrangement. Consequently, CD117 is not expressed in mouse B-cell lymphomas that are not of the pro-B cell type. In contrast, CD117 is not expressed during the human pro-B cell development stages; nor is it expressed in childhood precursor B-lymphoblastic leukemias/lymphomas (<xref ref-type="bibr" rid="bibr120-0192623311430695">Sykora et al. 1997</xref>; <xref ref-type="bibr" rid="bibr34-0192623311430695">Escribano et al. 1998</xref>).</p><p>CD43 in the mouse is expressed in the progenitor, pro-B, and early pre-B stages and is down-regulated in subsequent stages of B-cell development. However, expression is up-regulated in plasma cells. Mature nonmalignant B-cells and most human and mouse follicular and splenic marginal zone lymphomas do not express CD43, but most pro-B and a few pre-B lymphoblastic lymphomas do express CD43 (<xref ref-type="bibr" rid="bibr23-0192623311430695">Contos et al. 1992</xref>; <xref ref-type="bibr" rid="bibr4-0192623311430695">Arber and Weiss 1993</xref>; <xref ref-type="bibr" rid="bibr38-0192623311430695">Franco et al. 2003</xref>; <xref ref-type="bibr" rid="bibr104-0192623311430695">Rehg and Sundberg 2008</xref>). A high percentage of human chronic lymphocytic lymphomas/leukemias express CD43, but this remains to be determined in mice.</p><p>TdT (terminal deoxyribonucleotidyl transferase) is expressed in the pro B-cell stage of B-cell development and is down-regulated at later stages (<xref ref-type="bibr" rid="bibr18-0192623311430695">Chilosi 1995</xref>). In the mouse, TdT expression appears to be limited to pro-B lymphoblastic lymphomas, whereas in humans TdT is frequently expressed in both pro- and pre-B cell lymphoblastic lymphomas (Rehg and Sundberg 2008; <xref ref-type="bibr" rid="bibr13-0192623311430695">Borowitz and Chan 2008</xref>). TdT antibody shows a nuclear staining pattern; cytoplasmic staining in the absence of nuclear immunoreactivity should be considered nonspecific (<xref ref-type="bibr" rid="bibr20-0192623311430695">Chu et al. 1999</xref>; <xref ref-type="fig" rid="fig37-0192623311430695">Figure 38</xref>).</p><p>CD79a is an intracellular component of the B-cell receptor signal transduction pathway. Weak CD79a expression appears in the pro-B stage, and expression intensifies and persists throughout the various stages of B-cell differentiation. CD79a is more strongly expressed in follicular marginal and mantle zone B-cells than in germinal center B-cells (<xref ref-type="fig" rid="fig37-0192623311430695">Figure 39</xref>), suggesting that activation of GC cells into mature B-cells down-regulates CD79a expression. CD79a expression ceases around the onset of plasma cell differentiation, with only a proportion of plasma cells expressing CD79a (<xref ref-type="fig" rid="fig37-0192623311430695">Figure 40</xref>). The immunoreactive staining pattern is cytoplasmic and may be undetectable or weak in immature germinal center cells and plasma cells (<xref ref-type="fig" rid="fig37-0192623311430695">Figures 39</xref> and <xref ref-type="fig" rid="fig37-0192623311430695">40</xref>).</p><p>The CD79acy antibody recognizes virtually all mouse B-cell lymphomas, but its IHC reliability with regard to rodent plasmacytomas remains to be determined (<xref ref-type="bibr" rid="bibr67-0192623311430695">Kunder et al. 2007</xref>). CD79a has not been reported to be expressed in normal mouse T-cells. However, CD79a is reported to be expressed occasionally in normal human thymocytes, and others report CD79a stains normal human myeloid cells but the myeloid staining is clone-dependent (<xref ref-type="bibr" rid="bibr54-0192623311430695">Hashimoto et al. 2002</xref>; <xref ref-type="bibr" rid="bibr11-0192623311430695">Bhargava et al. 2007</xref>). CD79a antibody is also reported to stain some myeloid leukemias and T-lymphoblastic lymphoma in humans (<xref ref-type="bibr" rid="bibr97-0192623311430695">Pilozzi et al. 1998</xref>; <xref ref-type="bibr" rid="bibr11-0192623311430695">Bhargava et al. 2007</xref>), but it remains to be determined whether it does so in mice.</p><p>CD138 (syndecan1) is a glycoprotein expressed on epithelial, mesenchymal, and lymphoid cells. Flow cytometry analysis has demonstrated that in the bone marrow, CD138 is expressed on all mouse B-precursor cell stages and is lost immediately before release of immature B-lymphocytes into the circulation. CD138 is not expressed on circulating and peripheral B-lymphocytes. However, the antigen is expressed upon differentiation of mature B-cells into plasma cells (<xref ref-type="bibr" rid="bibr112-0192623311430695">Sanderson et al. 1989</xref>; <xref ref-type="bibr" rid="bibr128-0192623311430695">Tung et al. 2006</xref>).</p><p>CD138 has a cell membrane IHC staining pattern. However, it may be undetectable if the tissue is not adequately fixed. CD138 is a well-accepted IHC marker of plasma cells and plasmacytoma cells in mice and humans (<xref ref-type="bibr" rid="bibr67-0192623311430695">Kunder et al. 2007</xref>; <xref ref-type="bibr" rid="bibr90-0192623311430695">O’Connell et al. 2004</xref>; <xref ref-type="fig" rid="fig37-0192623311430695">Figure 41</xref>).</p><p>CD138 expression has been observed in human B-lymphoblastic leukemia cells (<xref ref-type="bibr" rid="bibr116-0192623311430695">Seftalioglu and Karakus 2003</xref>), but it is not known whether CD138 is expressed in rodent B-lymphoblastic lymphomas. Abnormal T-cells in Igµ-deficient/Lpr mice are reported to express CD138 (<xref ref-type="bibr" rid="bibr115-0192623311430695">Seagal et al. 2003</xref>).</p><p>PAX5 (paired box–5) is a nuclear protein in the paired-box-containing (PAX) family of transcription factors. PAX5 protein is expressed during the early pro B-cell stage of development and through the pre B-cell and mature B-cell stages, but expression is absent in plasma cells (<xref ref-type="bibr" rid="bibr9-0192623311430695">Barberis et al. 1990</xref>; <xref ref-type="bibr" rid="bibr1-0192623311430695">Adams et al. 1992</xref>). Rare non-lymphoid tissues express PAX5. Mesonephric rests, epididymal cells, testes, and neurons in adult CNS tissue express PAX5 (<xref ref-type="bibr" rid="bibr9-0192623311430695">Barberis et al. 1990</xref>; <xref ref-type="bibr" rid="bibr1-0192623311430695">Adams et al. 1992</xref>; <xref ref-type="bibr" rid="bibr127-0192623311430695">Torlakovic et al. 2006</xref>).</p><p>The PAX5 IHC staining pattern is nuclear (<xref ref-type="fig" rid="fig37-0192623311430695">Figure 42</xref>). PAX5 appears to be a more sensitive IHC marker than CD45R/B220 for lymphomas (<xref ref-type="bibr" rid="bibr104-0192623311430695">Rehg and Sundberg 2008</xref>). This apparent difference in sensitivity between PAX5 and CD45R/B220 detection is more than likely associated with the low level of CD45R/B220 on pro-B cells and some marginal zone lymphomas and the consequent lack of sensitivity of IHC to detect the low levels of CD45R/B220 on these cells. PAX5 is also more specific than CD79a for human B-lymphoblastic lymphoma and leukemia (<xref ref-type="bibr" rid="bibr97-0192623311430695">Pilozzi et al. 1998</xref>; <xref ref-type="bibr" rid="bibr125-0192623311430695">Tiacci et al. 2004</xref>). It remains to be determined whether the specificity between PAX5 and CD79a differ in diagnosing lymphoid neoplasms in mice. The lymphomas in genetically engineered mice that express CD3 and CD45R/B220 are not immunoreactive with anti-PAX5 antibodies, confirming that these lymphomas are T-cell lymphomas with aberrant CD45R/B220 expression (<xref ref-type="bibr" rid="bibr104-0192623311430695">Rehg and Sundberg 2008</xref>).</p><p>The <italic>IRF4/MUM1</italic> (interferon regulator factor 4/multiple myeloma oncogene 1) gene encodes a transcription factor that plays a key role in the development of lymphoid cells. In the hematolymphoid system, the IRF4/MUM1 protein is expressed primarily in B-cells and activated T-lymphoid cells (<xref ref-type="bibr" rid="bibr48-0192623311430695">Gualco et al. 2010</xref>). In B-cells, IRF4/MUM1 is expressed in a small subset of germinal center cells committed to plasmacytic or memory cell differentiation and in plasma cells. IRF4/MUM1 antibody stains the nuclei and cytoplasm of cells expressing the antigen. IRF4/MUM1 protein is expressed predominantly in human lymphoid neoplasms thought to be derived from late-stage mature (GC/post GC) B-cells (<xref ref-type="bibr" rid="bibr35-0192623311430695">Falini et al. 2000</xref>), but the type of mouse lymphomas that express IRF4 remains to be characterized. However, the authors have found IRF4/MUM1 antigen to be an excellent marker of plasma cell neoplasms in mice (<xref ref-type="fig" rid="fig43-0192623311430695">Figure 43</xref>).</p><fig id="fig43-0192623311430695" position="float"><label>Figure 43.</label><caption><p>Bone marrow of an adult B6,129 mouse showing plasma cell tumor cells expressing nuclear and cytoplasm IRF4.</p> <p>Figure 44.—Spleen from an adult FVB mouse showing follicular germinal center cells expressing nuclear BCL6.</p> <p>Figure 45.—Spleen from an adult FVB mouse showing follicular germinal center cells expressing cytoplasmic PNA.</p> <p>Figure 46.—Spleen from an adult FVB mouse showing IgM expression in the mantle and marginal zone cells. The marginal zone macrophages, T-cells in the periarteriolar lymphocyte sheath (PALS) and the germinal center cells do not express IgM. The latter result suggests that the germinal center cells have undergone heavy chain switching from IgM to another heavy chain Ig.</p> <p>Figure 47.—Spleen from an adult FVB mouse showing kappa light chain expression in the germinal center, mantle, and marginal zone cells; but the T cells in the PALS do not show kappa light chain expression.</p> <p>Figure 48.—Spleen from an adult FVB mouse showing membrane expression of CD3 in T-cells.</p></caption><graphic alt-version="no" alternate-form-of="fig43-0192623311430695" position="float" xlink:href="10.1177_0192623311430695-fig8.tif" xlink:type="simple"/></fig></sec><sec id="section13-0192623311430695"><title>Other B-Cell Antigens: BCL6, Peanut Agglutinin (PNA), Immunoglobulins</title><p>BCL6 is expressed mainly in normal germinal center B-cells (centroblasts and centrocytes; <xref ref-type="fig" rid="fig43-0192623311430695">Figure 44</xref>). In IHC, BCL6 is localized in the nucleus and has a microgranular or diffuse pattern. It is recommended that freshly cut paraffin sections be used, as slides stored for a long time may show a false-negative result (<xref ref-type="bibr" rid="bibr64-0192623311430695">King at al. 2000</xref>). BCL6 is not expressed in marginal and mantle B cells, plasma cells, or bone marrow B-cell precursors. BCL6 is an excellent biomarker of follicular lymphoma, which shows an expression pattern similar to that of normal reactive B-germinal center cells.</p><p>Peanut agglutinin (PNA) is a lectin on the surface of germinal center cells and immature T-cells of mice and humans (Rose et al. 1980; <xref ref-type="bibr" rid="bibr40-0192623311430695">Galili et al. 1981</xref>; <xref ref-type="bibr" rid="bibr103-0192623311430695">Ree and Hsu 1983</xref>; <xref ref-type="fig" rid="fig43-0192623311430695">Figure 45</xref>). PNA is also expressed in the cytoplasm of follicular and interdigitating dendritic cells.</p><p>Immunoglobulins are uniquely expressed by B-cells and serve as antigen recognition molecules. B-cells can express each of the heavy chain classes IgM, IgG, IgA, and IgE, and an individual B-cell can express more than one heavy chain class (<xref ref-type="fig" rid="fig43-0192623311430695">Figure 46</xref>). Cytoplasmic µ heavy chain is the first form of Ig expressed during B-cell ontogeny. Cytoplasmic or intracellular immunoglobulin (cIg) is present within B-cells at two points during ontogeny, the immature, pre-B cell stage and the secretory plasma cell stage. Pre-B cells contain cytoplasmic µIgM heavy chains but lack cytoplasmic light chains and surface immunoglobulin (sIg). As developing B-cells progress from the pre-B to the immature transition stage, IgM also appears on the B-cell membrane (sIgM) and cytoplasmic kappa/lambda light chains are expressed. However, because these B-cell stages have scanty cytoplasm, IHC cannot differentiate between cytoplasmic and surface IgM associated with the cells. Whereas two thirds of human B-cells express kappa light chains and one-third express lambda light chains, 95% of mouse immature naive, mature B-cells, and plasma cells express kappa light chains (Woloschak and Kroc 1987; <xref ref-type="fig" rid="fig43-0192623311430695">Figure 47</xref>). Consequently, IHC is not useful for the detection of monoclonal B-cell proliferations in mice. However, the demonstration of cytoplasmic µ heavy chains without light chains in malignant lymphoblasts assists in defining pre B-lymphoblastic lymphoma/leukemia.</p></sec><sec id="section14-0192623311430695"><title>Plasma Cell Antigens: CD43, CD79a, CD138, IRF4</title><p>Plasma cell antigens are not specific, but highly sensitive antibodies to the CD43, CD79a, CD138, and IRF4 antigens are very useful in identifying plasma cells (<xref ref-type="fig" rid="fig37-0192623311430695">Figures 40</xref>, <xref ref-type="fig" rid="fig37-0192623311430695">41</xref>, and 43) in the context of the cytologic morphology of the cells and the lack of the cells labeling with antibodies for PAX5 and/or CD45R/B220.</p></sec><sec id="section15-0192623311430695"><title>T-/NK-Cell Antigens: CD3, CD4, CD8, CD5, CD49b, Granzyme B, Perforin, FOXP3</title><p>T-cells arise from bone marrow but differentiate in the thymus. T-cell development in the thymus is characterized by distinct and sequential patterns of antigen expression as determined by flow cytometry (<xref ref-type="table" rid="table6-0192623311430695">Table 6</xref>). Initially thymocytes were subdivided as double negative (DN), double positive (DP), or single positive (SP) based on the expression of the CD4 and CD8 receptors. The DN stage is heterogeneous and in mice can be further subdivided into four distinct subsets (ProT<sub>1</sub>, ProT<sub>2</sub>, Pre-T<sub>1</sub>, Pre-T<sub>2</sub>) based on the expression of CD2, CD3, CD5, CD7, CD43, CD44, CD25, and CD117 as well as TdT (<xref ref-type="bibr" rid="bibr71-0192623311430695">Lesley et al. 1988</xref>; <xref ref-type="bibr" rid="bibr42-0192623311430695">Godfrey et al. 1993</xref>). Unfortunately, only five of these antigens (CD3, CD5, CD43, CD117, and TdT) can be assayed in FFPE mouse tissue.</p><table-wrap id="table6-0192623311430695" position="float"><label>Table 6.</label><caption><p>Antigen expression during mouse T-cell development.</p></caption><graphic alt-version="no" alternate-form-of="table6-0192623311430695" position="float" xlink:href="10.1177_0192623311430695-table6.tif" xlink:type="simple"/><table><thead><tr><th colspan="1" rowspan="1"/><th colspan="5" rowspan="1">Thymus-cortex</th><th colspan="1" rowspan="1">Thymus-medulla</th><th colspan="1" rowspan="1"/></tr><tr><th colspan="1" rowspan="1">Antigen</th><th colspan="1" rowspan="1">Pro-T<sub>1</sub></th><th colspan="1" rowspan="1">Pro-T<sub>2</sub></th><th colspan="1" rowspan="1">Pre-T<sub>1</sub></th><th colspan="1" rowspan="1">Pre-T<sub>2</sub></th><th colspan="1" rowspan="1">DP</th><th colspan="1" rowspan="1">SP</th><th colspan="1" rowspan="1">Mature peripheral lymphoid tissue</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">CD7</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+/–</td></tr><tr><td colspan="1" rowspan="1">CD5<sup><xref ref-type="table-fn" rid="table-fn11-0192623311430695">a</xref></sup></td><td align="center" colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+</td></tr><tr><td colspan="1" rowspan="1">CD2</td><td align="center" colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+</td></tr><tr><td colspan="1" rowspan="1">CD3<sup><xref ref-type="table-fn" rid="table-fn11-0192623311430695">a</xref></sup></td><td colspan="1" rowspan="1">C</td><td colspan="1" rowspan="1">C</td><td colspan="1" rowspan="1">C</td><td colspan="1" rowspan="1">C</td><td colspan="1" rowspan="1">C</td><td colspan="1" rowspan="1">S</td><td colspan="1" rowspan="1">S</td></tr><tr><td colspan="1" rowspan="1">CD43<sup><xref ref-type="table-fn" rid="table-fn11-0192623311430695">a</xref></sup></td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+</td></tr><tr><td colspan="1" rowspan="1">TdT<sup>a</sup></td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+</td><td align="center" colspan="1" rowspan="1">–</td><td align="center" colspan="1" rowspan="1">–</td></tr><tr><td colspan="1" rowspan="1">CD117 (KIT)</td><td colspan="1" rowspan="1">++</td><td colspan="1" rowspan="1">++</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">Low</td><td align="center" colspan="1" rowspan="1">–</td><td align="center" colspan="1" rowspan="1">–</td></tr><tr><td colspan="1" rowspan="1">CD4</td><td align="center" colspan="1" rowspan="1">–</td><td align="center" colspan="1" rowspan="1">–</td><td align="center" colspan="1" rowspan="1">–</td><td align="center" colspan="1" rowspan="1">–</td><td align="center" colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+ or –</td><td colspan="1" rowspan="1">+ or –</td></tr><tr><td colspan="1" rowspan="1">CD8</td><td align="center" colspan="1" rowspan="1">–</td><td align="center" colspan="1" rowspan="1">–</td><td align="center" colspan="1" rowspan="1">–</td><td align="center" colspan="1" rowspan="1">–</td><td align="center" colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+ or –</td><td colspan="1" rowspan="1">+ or –</td></tr><tr><td colspan="1" rowspan="1">CD44</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+</td><td align="center" colspan="1" rowspan="1">–</td><td align="center" colspan="1" rowspan="1">–</td><td align="center" colspan="1" rowspan="1">–</td><td align="center" colspan="1" rowspan="1">–</td><td align="center" colspan="1" rowspan="1">–</td></tr><tr><td colspan="1" rowspan="1">CD25</td><td align="center" colspan="1" rowspan="1">–</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+</td><td align="center" colspan="1" rowspan="1">–</td><td align="center" colspan="1" rowspan="1">–</td><td align="center" colspan="1" rowspan="1">–</td><td align="center" colspan="1" rowspan="1">–</td></tr></tbody></table><table-wrap-foot><fn id="table-fn10-0192623311430695"><p>Table is a composite of data based on flow cytometry from multiple sources: <xref ref-type="bibr" rid="bibr16-0192623311430695">Ceredig (2002)</xref>; <xref ref-type="bibr" rid="bibr30-0192623311430695">Dik et al. (2005)</xref>; <xref ref-type="bibr" rid="bibr134-0192623311430695">Weerkamp et al. (2006)</xref>; <xref ref-type="bibr" rid="bibr10-0192623311430695">Bhandoola and Sambandam (2006)</xref>; <xref ref-type="bibr" rid="bibr77-0192623311430695">Mazzucchelli and Durum (2007)</xref>. Abbreviations: C = cytoplasm; S = surface; DP = double positive; SP = single positive. Expression is semiquantitative; + present; ++ high.</p></fn><fn id="table-fn11-0192623311430695"><p><sup>a</sup>IHC antigens detectable in FFPE.</p></fn></table-wrap-foot></table-wrap><p>IHC for these five antigens allows the classification of mouse T-cell lymphoma into only three groups: early T-lymphoblastic lymphoma (CD3+, CD5+, CD43+, TdT+, CD117+), late T-lymphoblastic lymphoma (CD3+, CD5+, CD43+, TdT+, CD117−), and mature T-cell lymphoma (CD3+, CD5+, CD43+, TdT−, CD117−). However, in some instances, T-cell lymphomas lack CD3 expression.</p><p>CD3 is a lineage-specific protein considered a pan-T-cell marker. It is a multidomain component of the T-cell receptor complex that is normally located in the cytoplasm of immature T-lymphoblasts and on the surface membrane of mature T-lymphocytes (<xref ref-type="fig" rid="fig43-0192623311430695">Figure 48</xref>). Unfortunately, it may be hard by IHC to distinguish intracellular localization and surface membrane CD3 expression in cells with scanty cytoplasm. Therefore, an immunopositive CD3 lymphoma should also be labeled with TdT antibody to determine whether the lymphoma is either a T-lymphoblastic lymphoma or a mature T-cell lymphoma.</p><p>At times, IHC and flow cytometry appear to yield discrepant results regarding T-lymphoblastic lymphoma when polyclonal CD3 antibody is used. The polyclonal CD3 antibody commonly used in IHC targets both the cytoplasmic epsilon unit and the surface units of the CD3 complex. If a flow cytometry laboratory labels only for surface antigens, the vast majority of T-lymphoblastic lymphomas will be negative by using a polyclonal CD3 antibody, since T-lymphoblastic lymphomas rarely express surface CD3 units. Consequently, IHC and flow cytometry studies may give discrepant results. To diagnose a mouse T-lymphoblastic lymphoma by surface markers, a flow cytometry lab must use antibodies that label CD44 and CD25, which are early T-cell surface antigens. Alternatively, the lymphoma cells could be permeabilized to allow the polyclonal antibody to penetrate the cell membrane and label the cytoplasmic CD3 epsilon antigen. CD3 is not expressed in B-cells, macrophages, myeloid cells, or their neoplasms (<xref ref-type="bibr" rid="bibr105-0192623311430695">Reinherz and Schlossman 1980</xref>; <xref ref-type="bibr" rid="bibr67-0192623311430695">Kunder et al. 2007</xref>).</p><p>CD4 and CD8 are glycoproteins expressed on the surface membrane of mutually exclusive, functionally distinct T-cell populations. CD4 is expressed on T-cells, monocytes, macrophages, Langerhans cells, and other dendritic cells, but not B-cells. CD8 antigen is expressed on cells with cytotoxic activity, including cytotoxic T-cells and a subset of NK cells. Unfortunately, frozen tissue is still required for detection of these two antigens in mice (<xref ref-type="fig" rid="fig49-0192623311430695">Figures 49</xref> and <xref ref-type="fig" rid="fig49-0192623311430695">50</xref>). Therefore, these two antigens will not be further discussed in this review.</p><fig id="fig49-0192623311430695" position="float"><label>Figure 49.</label><caption><p>Frozen section of spleen from an adult B6,129 mouse showing cell membrane expression of CD4 on T-cells.</p> <p>Figure 50.—Frozen section of spleen from an adult B6,129 mouse showing cell membrane expression of CD8 on T-cells.</p> <p>Figure 51.—Spleen from an adult FVB mouse showing cell membrane expression of CD5 on T-cells.</p> <p>Figure 52.—Spleen from an adult FVB mouse showing cell membrane expression of CD43 on T-cells.</p> <p>Figure 53.—Spleen from an adult FVB mouse showing nuclear expression of FOXP3 in T regulatory cells in the PALS.</p> <p>Figure 54.—Spleen from an adult FVB mouse showing CD21/CD35 complex expression of moderate intensity in the follicular dendritic cells imparting a reticular pattern to the germinal center. The marginal zone cells show low-intensity expression of CD21/CD35.</p></caption><graphic alt-version="no" alternate-form-of="fig49-0192623311430695" position="float" xlink:href="10.1177_0192623311430695-fig9.tif" xlink:type="simple"/></fig><p>CD5 is a glycoprotein expressed on the surface of most immature and mature T-cells (<xref ref-type="fig" rid="fig49-0192623311430695">Figure 51</xref>). Consequently, CD5 antigen is expressed on the majority of T-lymphomas of the lymphoblastic and mature type (<xref ref-type="bibr" rid="bibr67-0192623311430695">Kunder et al. 2007</xref>). CD5 is not expressed on precursor B-lymphoblastic lymphoma cells, but it has been reported to be present at a low level by flow cytometry on all B-cell lymphoid tumors except B-lymphoblastic lymphoma (<xref ref-type="bibr" rid="bibr83-0192623311430695">Morse et al. 2002</xref>). However, the latter has not been the authors’ experience or that of others with IHC (<xref ref-type="bibr" rid="bibr67-0192623311430695">Kunder et al. 2007</xref>; Fredrickson et al. 1999), suggesting that the expression level of CD5 on mouse B-cells is below the threshold level of IHC detection.</p><p>An IHC diagnosis of T-lymphoblastic lymphoma should be made with caution if cytoplasmic CD3 is negative, as CD5 expression has also been seen in human myeloid leukemia. It is not known whether this is the case in mice. Presently, TdT expression in the mouse is reported to be restricted to lymphoid cells. Therefore, the current state of knowledge about TdT expression in the mouse and the lack of CD5 expression on mouse B-lymphoblasts suggests that a diagnosis of T-lymphoblastic leukemia should be considered for a leukemia that lacks CD3 expression but expresses both CD5 and TdT and is PAX5-negative.</p><p>CD43 is present on the surface of immature and mature T-cells and NK cells (<xref ref-type="fig" rid="fig49-0192623311430695">Figure 52</xref>). NK cells do not express surface CD3 or CD5, but activated NK cells and NK cell lymphomas contain the epsilon unit of CD3 in their cytoplasm. Consequently, a high percentage of NK cells will be labeled by polyclonal CD3 antibody. For that reason, a panel of NK markers should be applied to a lymphoid tumor that is labeled by polyclonal CD3 antibody and is CD5- and TdT-negative. Mice do not express CD56, which is one of the human NK cell markers (<xref ref-type="bibr" rid="bibr55-0192623311430695">Hayakawa et al. 2006</xref>).</p><p>CD49b is expressed on a subset of T-cells and most NK cells, while the NK1.1 (CD161c) and NK1.2 antigens are mouse strain-restricted. Anti-CD49b antibody was recently reported to be used to detect NK cells and T-cells in FFPE mouse tissue (<xref ref-type="bibr" rid="bibr62-0192623311430695">Kaufman et al. 2010</xref>).</p><p>Granzyme B and perforin are cytotoxic proteins located in the cytoplasm of cytotoxic T-cells and NK cells, including the hepatic NK cells. Granzyme B is also in the granules of mouse eosinophils and mast cells (Costan et al. 2001; <xref ref-type="bibr" rid="bibr92-0192623311430695">Pardo et al. 2007</xref>). These antigens are also seen in malignancies of human cytotoxic T-cells and NK cells and in large granular cell leukemia (LGL) in F344 rats, but their IHC reliability remains to be confirmed in mouse lymphoid malignancies (<xref ref-type="bibr" rid="bibr59-0192623311430695">Jaffe 1996</xref>; <xref ref-type="bibr" rid="bibr124-0192623311430695">Thomas et al. 2007</xref>).</p><p>FOXP3 (forkhead box p3, also known as SCUFRIN and JM2) is a protein expressed on thymic CD4+CD25+ T-regulatory (Treg) cells and some but not all inducible Treg cells (<xref ref-type="fig" rid="fig49-0192623311430695">Figure 53</xref>).</p></sec><sec id="section16-0192623311430695"><title>Other Lymphocyte Antigens: BCL2, CD11c, CD40, CD30, CD21/CD35, CD10</title><p>BCL2 is a cytoplasmic anti-apoptotic protein that is present in a wide variety of hematolymphoid and non-hematolymphoid cells. In human hematopathology, BCL2 is used as a differential marker in the diagnosis of follicular lymphoma versus reactive follicular hyperplasia. BCL2 staining is negative in reactive follicular germinal cell hyperplasia, whereas adult human neoplastic follicular germinal centers are BCL2-positive. Unlike adult human follicular lymphomas, those in mice do not express BCL2 (<xref ref-type="bibr" rid="bibr67-0192623311430695">Kunder et al. 2007</xref>). BCL2 is not useful in the diagnosis of other mouse lymphomas, as the protein is commonly expressed and often over expressed in various mouse lymphoma types (<xref ref-type="bibr" rid="bibr67-0192623311430695">Kunder et al. 2007</xref>).</p><p>CD11c is constitutively expressed by monocytes, tissue macrophages, dendritic cell subsets, granulocytes, and Kupffer cells. It is also expressed by activated T- and B-cells and NK cells. It is not expressed on follicular dendritic cells or cutaneous Langerhans cells. It is commonly used to detect dendritic cells by flow cytometry. At the present time, frozen tissue is required for IHC.</p><p>CD40 is not lineage-restricted. The antigen is expressed on activated T-cells, interdigitating dendritic cells and mature and immature B-cells, but it is absent from early pro-B-cells and plasma cells.</p><p>CD30 is an activation marker, which is found on activated B- and T-cells, but it is not found on resting B-cells, T-cells, or macrophages (<xref ref-type="bibr" rid="bibr114-0192623311430695">Schwarting et al. 1989</xref>). The CD30 staining pattern may be membrane, paranuclear, or both. Diffuse cytoplasmic positivity may be seen, but it is considered an artifact unless it is seen with membrane or paranuclear staining. In human hematopathology, the antigen is used as a marker for anaplastic large cell lymphomas and Reed-Sternberg (RS) cells in Hodgkin lymphoma (<xref ref-type="bibr" rid="bibr20-0192623311430695">Chu et al. 1999</xref>). It is reported to be expressed by RS-like cells in mouse B-cell lymphomas with Hodgkin-like features (<xref ref-type="bibr" rid="bibr101-0192623311430695">Raffegerst et al. 2009</xref>). This finding may be a significant diagnostic aid when it has been confirmed.</p><p>The CD21/35 complexes in the mouse are antigens that serve as receptors for the C3d and C3b complement components. CD21/35 complex expression is strongest on the germinal center follicular dendritic cells and their neoplasms and on a subset of B-cells (<xref ref-type="fig" rid="fig49-0192623311430695">Figure 54</xref>). It is not expressed by B-precursors, immature B-cells, resting and stimulated T-cells, monocytes/macrophages, granulocytes, or NK cells. Antibody to the CD21/CD35 complex is useful for demonstrating the presence and character of germinal centers within lymphoid proliferations and the association of germinal centers within cases of follicular lymphoma. CD21 is also a marker of splenic littoral cell angioma, which is a tumor of the cells lining splenic sinusoids (<xref ref-type="bibr" rid="bibr3-0192623311430695">Arber et al. 1997</xref>; <xref ref-type="bibr" rid="bibr89-0192623311430695">Neuhauser et al. 2000</xref>).</p><p>CD10, also known as common acute lymphoblastic lymphoma antigen (CALLA), is a marker used in human hematopathology to identify early lymphoid progenitor cells and immature B-cells in adult bone marrow and to identify germinal center cells and their respective neoplasms (<xref ref-type="bibr" rid="bibr5-0192623311430695">Arber and Weiss 1997</xref>). Unlike humans, mice do not express CD10 in their hematolymphoid cells, but immunohistological and flow cytometric analysis indicate a virtually identical distribution of CD10 in human and mouse non-hematolymphoid tissues (<xref ref-type="bibr" rid="bibr61-0192623311430695">Kalled et al. 1995</xref>).</p></sec></sec><sec id="section17-0192623311430695"><title>Examples of the Use of IHC in FFPE Sections to Evaluate the Mouse Hematopoietic and Lymphoid Systems</title><sec id="section18-0192623311430695"><title>Assessment of the Normal Expression Patterns of Hematolymphoid Cells in Lymphoid Tissue and Bone Marrow</title><p>B-lymphocytes, T-lymphocytes, and macrophages have specific anatomical distribution patterns in the thymus, spleen, and lymph nodes. These patterns can best be appreciated by using antibody specific to B-cell, T-cell, and macrophage/dendritic cell antigens (<xref ref-type="fig" rid="fig55-0192623311430695">Figures 55</xref>, <xref ref-type="fig" rid="fig55-0192623311430695">56</xref>, <xref ref-type="fig" rid="fig55-0192623311430695">57</xref>, <xref ref-type="fig" rid="fig55-0192623311430695">58</xref>, <xref ref-type="fig" rid="fig55-0192623311430695">59</xref>, and 60). The thymic cortex and medulla, the two major anatomic compartments of the thymus, can be clearly defined with antibody to the T-lymphocyte CD3 antigen (<xref ref-type="fig" rid="fig55-0192623311430695">Figure 55</xref>). The periarteriolar lymphoid sheath of the white pulp of the spleen, which is populated predominantly with T-lymphocytes, is clearly delineated by antibodies to CD3, CD5, or CD43 antigens expressed on T-lymphocytes (<xref ref-type="fig" rid="fig55-0192623311430695">Figure 56</xref>). Conversely, antibodies to the B-cell antigens CD45R/B220 or Pax 5 will demonstrate the germinal centers, mantle cells and marginal zone cells of the splenic follicles and the germinal centers and mantle cells of the lymph node follicles (<xref ref-type="fig" rid="fig37-0192623311430695">Figures 37</xref>, <xref ref-type="fig" rid="fig37-0192623311430695">42</xref>, <xref ref-type="fig" rid="fig55-0192623311430695">57</xref>, and 58). Antibodies to the macrophage MAC2 and F4/80 antigens can be useful in distinguishing different macrophage populations in lymphoid organs (<xref ref-type="fig" rid="fig55-0192623311430695">Figures 59</xref> and <xref ref-type="fig" rid="fig55-0192623311430695">60</xref>).</p><fig id="fig55-0192623311430695" position="float"><label>Figure 55.</label><caption><p>Thymus from an adult FVB mouse showing CD3 expression on the cortical and medullary T-cells.</p> <p>Figure 56.—Spleen from an adult FVB mouse showing CD3 expression of T-cells in the PALS regions of the white pulp (follicles). CD3, CD5 or CD43 antibody is very useful in delineating the PALS regions of the spleen.</p> <p>Figure 57.—Spleen from an adult FVB mouse showing CD45R/B220 expression of B-cells forming the follicles. CD45R/B220 or Pax5 antibody is very useful in delineating the cortices of the splenic white pulp.</p> <p>Figure 58.—Lymph node from an adult FVB mouse showing the utility of C45R/B220 antibody in assessing the prominence and size of the B-cell follicles of a lymph node.</p> <p>Figure 59.—Lymph node from an adult FVB mouse showing MAC2 expression in the macrophages and dendritic cells located in the follicle, germinal center, paracortical region and medullary cords.</p> <p>Figure 60.—Lymph node from an adult FVB mouse showing F4/80 expression in the medullary cord macrophages. Note that the dendritic cells in the follicle, germinal center, and paracortical region do not express F4/80.</p></caption><graphic alt-version="no" alternate-form-of="fig55-0192623311430695" position="float" xlink:href="10.1177_0192623311430695-fig10.tif" xlink:type="simple"/></fig></sec><sec id="section19-0192623311430695"><title>Diagnosis of Hematolymphoid Disorders</title><p>Although conventional morphology remains the gold standard for evaluation of hematolymphoid proliferations in paraffin-embedded tissue, immunophenotyping is playing an ever greater role in the diagnosis and classification of these proliferations (<xref ref-type="bibr" rid="bibr83-0192623311430695">Morse et al. 2002</xref>; <xref ref-type="bibr" rid="bibr67-0192623311430695">Kunder et al. 2007</xref>; <xref ref-type="bibr" rid="bibr119-0192623311430695">Swerdlow et al. 2008</xref>). Myeloid and lymphoid proliferations manifest antigen expressions that typify a stage of their development and maturation. Consequently, the proliferative cells may express antigens of early precursor cells, various intermediate developmental stages, or late mature cell stages. With a panel of antibodies to specific cellular lineages it is often possible to determine whether a proliferation is of the myeloid, erythroid, megakaryocytic, lymphoid, plasma cell, histiocytic, or mast cell lineage.</p></sec><sec id="section20-0192623311430695"><title>Diagnosis of Myeloid Proliferations</title><p>The most useful antigen markers for myeloid proliferation are CD34, CD43, CD45, CD68, MPO, lysozyme, GATA1, glycophorin A, TER119, and von Willebrand factor (Factor VIII).</p><p><xref ref-type="fig" rid="fig61-0192623311430695">Figures 61</xref>, <xref ref-type="fig" rid="fig61-0192623311430695">62</xref>, <xref ref-type="fig" rid="fig61-0192623311430695">63</xref>, <xref ref-type="fig" rid="fig61-0192623311430695">64</xref>, and <xref ref-type="fig" rid="fig61-0192623311430695">65</xref> show examples of myeloid leukemia in an adult B6,129 mouse. Infiltrates of a proliferative population of monomorphic cells with morphologic features of blasts and immature myeloid forms are seen in the bone marrow (<xref ref-type="fig" rid="fig61-0192623311430695">Figure 61</xref>), liver, and spleen. Because there are many blast cells, a lymphoblastic proliferation must be ruled out. Therefore, the tissues are labeled with antibodies to the first six antigens of the panel and the lymphoid antigens CD3 and Pax5 to determine whether the proliferation is of myeloid or lymphoid lineage. The IHC analysis reveals that the cells express CD34, CD43, lysozyme, and MPO but not CD68, CD3, or Pax 5, consistent with an acute myeloid leukemia (<xref ref-type="fig" rid="fig61-0192623311430695">Figures 62</xref>–<xref ref-type="fig" rid="fig61-0192623311430695">65</xref>).</p><fig id="fig61-0192623311430695" position="float"><label>Figure 61.</label><caption><p>Bone marrow from an adult B6,129 mouse showing replacement of the normal trilineage bone marrow population by a highly proliferative monomorphous population of immature myeloid cells. Note the atypical tripolar mitotic figure.</p> <p>Figure 62.—Scattered among the abnormal proliferative myeloid cells shown in <xref ref-type="fig" rid="fig61-0192623311430695">Figure 61</xref> are nodular foci of blast cells expressing CD34.</p> <p>Figure 63.—The nodular foci of blast cells from <xref ref-type="fig" rid="fig61-0192623311430695">Figure 62</xref> also express CD43.</p> <p>Figure 64.—The immature myeloid cells between the nodular foci shown in <xref ref-type="fig" rid="fig61-0192623311430695">Figure 62</xref> express cytoplasmic lysozyme. Ring and other immature cellular forms are present in the population.</p> <p>Figure 65.—The immature myeloid cells between the nodular foci shown in <xref ref-type="fig" rid="fig61-0192623311430695">Figure 62</xref> also express cytoplasmic myeloperoxidase.</p> <p>Figure 66.—Bone marrow from an adult B6,129 mouse showing replacement of the normal trilineage population by a population of variable-sized cells, some having blastic features and other small cells having condensed chromatin and pink cytoplasm suggestive of erythroid cell differentiation.</p></caption><graphic alt-version="no" alternate-form-of="fig61-0192623311430695" position="float" xlink:href="10.1177_0192623311430695-fig11.tif" xlink:type="simple"/></fig><p><xref ref-type="fig" rid="fig61-0192623311430695">Figures 66</xref> to <xref ref-type="fig" rid="fig67-0192623311430695">68</xref> show an example of erythroid leukemia. The proliferation involves the spleen, liver, lung, and bone marrow of an adult B6,129 mouse and consists of cells of variable size having blast features and small cells with condensed chromatin and pale pink cytoplasm suggestive of erythroid differentiation (<xref ref-type="fig" rid="fig61-0192623311430695">Figure 66</xref>). The myeloid panel of antibodies reveals expression of GATA1 and glycophorin A (<xref ref-type="fig" rid="fig67-0192623311430695">Figures 67</xref> and <xref ref-type="fig" rid="fig67-0192623311430695">68</xref>), but none of the other antigens. The absence of CD34, MPO, and von Willebrand factor labeling is consistent with a pure erythroid leukemia.</p><fig id="fig67-0192623311430695" position="float"><label>Figure 67.</label><caption><p>The population of cells shown in <xref ref-type="fig" rid="fig61-0192623311430695">Figure 66</xref> show nuclear expression of GATA1, consistent with erythroid or megakaryocytic differentiation.</p> <p>Figure 68.—The population of cells shown in <xref ref-type="fig" rid="fig61-0192623311430695">Figure 66</xref> show cellular membrane expression of glycophorin A. The cell morphology and immunohistochemistry (IHC) profile are consistent with a population of erythroid differentiation.</p> <p>Figure 69.—Spleen from an adult B6/129 mouse showing red pulp fibrosis associated with cells that have round and irregular nuclei admixed with binucleated and multinucleated cells with blastic nuclear chromatin features.</p> <p>Figure 70.—The atypical cells with blastic features shown in <xref ref-type="fig" rid="fig67-0192623311430695">Figure 69</xref> show cytoplasmic expression of von Willebrand factor with a granular pattern, consistent with the cells being of megakaryocytic lineage.</p> <p>Figure 71.—Lymph node from an adult B6,129 mouse showing lymphocytes with blastic nuclear features (fine chromatin, small or inconspicuous nucleoli and sparse cytoplasm).</p> <p>Figure 72.—The cells shown in <xref ref-type="fig" rid="fig67-0192623311430695">Figure 71</xref> with morphologic features of lymphoblasts express CD117 (KIT) on the cell membrane.</p></caption><graphic alt-version="no" alternate-form-of="fig67-0192623311430695" position="float" xlink:href="10.1177_0192623311430695-fig12.tif" xlink:type="simple"/></fig><p><xref ref-type="fig" rid="fig67-0192623311430695">Figures 69</xref> and <xref ref-type="fig" rid="fig67-0192623311430695">70</xref> show an example of a megakaryocyte proliferation in an adult B6,129 mouse. The proliferation involves the spleen; the bone marrow shows extensive fibrosis associated with cells that have round and irregular nuclei admixed with binucleated and multinucleated cells with blastic nuclear chromatin features and sparse cytoplasm (<xref ref-type="fig" rid="fig67-0192623311430695">Figure 69</xref>). The myeloid panel of antibodies reveals that the blastic cells express nuclear GATA1 and cytoplasmic von Willebrand factor with a granular pattern (<xref ref-type="fig" rid="fig67-0192623311430695">Figure 70</xref>). The cells are not labeled by any of the other myeloid panel antibodies, PAX5 or CD3. Therefore, the immunophenotype is compatible with a megakaryocytic proliferative disorder. The complete blood count (CBC) showed mark thrombocytosis without blasts.</p></sec><sec id="section21-0192623311430695"><title>Diagnosis of Lymphoma</title><p>Lymphoma represents a large category of lymphoid neoplasms and it is beyond the scope of this review to address the various classifications and their immunophenotypes. See <xref ref-type="bibr" rid="bibr83-0192623311430695">Morse et al. (2002)</xref> for a review of lymphoma classifications in the mouse. Here we provide an illustration of the principles of diagnosing a subclass of lymphoblastic lymphoma by IHC. The proliferation shown in <xref ref-type="fig" rid="fig67-0192623311430695">Figure 71</xref> is composed of cells with a lymphoblastic morphology. The tumor cells are not immunoreactive for CD45R/B220 or CD3 and the proliferation was initially diagnosed as lymphoblastic lymphoma, not otherwise specified (NOS). In a retrospective lymphoma study, the lymphoma cells labeled with CD117 (KIT), CD43, TdT, and Pax 5 (<xref ref-type="fig" rid="fig67-0192623311430695">Figures 72</xref>–<xref ref-type="fig" rid="fig73-0192623311430695">75</xref>), but not cytoplasmic µIgM heavy chains. The lymphoblastic, NOS case was therefore reclassified as pro-B lymphoblastic lymphoma based on the antigen expression scheme of B-cell ontogeny in <xref ref-type="table" rid="table5-0192623311430695">Table 5</xref> (<xref ref-type="bibr" rid="bibr104-0192623311430695">Rehg and Sundberg 2008</xref>).</p><fig id="fig73-0192623311430695" position="float"><label>Figure 73.</label><caption><p>The cells shown in <xref ref-type="fig" rid="fig67-0192623311430695">Figure 71</xref> with morphologic features of lymphoblasts express CD43 on the cell membrane.</p> <p>Figure 74.—Many of the cells shown in <xref ref-type="fig" rid="fig67-0192623311430695">Figure 71</xref> with morphologic features of lymphoblasts express nuclear TdT.</p> <p>Figure 75.—The cells shown in <xref ref-type="fig" rid="fig67-0192623311430695">Figure 71</xref> with morphologic features of lymphoblasts express nuclear PAX5. The cell morphology and immunophenotype demonstrated in <xref ref-type="fig" rid="fig67-0192623311430695">Figures 72</xref>, <xref ref-type="fig" rid="fig73-0192623311430695">73</xref>, <xref ref-type="fig" rid="fig73-0192623311430695">74</xref>, and <xref ref-type="fig" rid="fig73-0192623311430695">75</xref> are consistent with a pro-B-lymphoblastic lymphoma.</p> <p>Figure 76.—Spleen from an adult B6,129 mouse showing diffuse expansion and converging (bridging) of the follicular marginal zone cells, consistent with a marginal zone lymphoma.</p> <p>Figure 77.—The lymphoma shown in <xref ref-type="fig" rid="fig73-0192623311430695">Figure 76</xref> consists of medium to large round cells with nuclear features of centroblasts.</p> <p>Figure 78.—The lymphoma cells shown in <xref ref-type="fig" rid="fig73-0192623311430695">Figures 76</xref> and <xref ref-type="fig" rid="fig73-0192623311430695">77</xref> labeled with CD45R/B220 antibody do not show expression of CD45R/B220, whereas the follicle mantle cells show expression of CD45R/B220. The lack of CD45R/B220 expression is atypical in marginal zone cells.</p></caption><graphic alt-version="no" alternate-form-of="fig73-0192623311430695" position="float" xlink:href="10.1177_0192623311430695-fig13.tif" xlink:type="simple"/></fig></sec><sec id="section22-0192623311430695"><title>Loss of an Antigen Commonly Associated with a Cell</title><p>The splenic marginal zone cells normally express the pan-B-cell antigen CD45R/B220. However, approximately 20% of splenic marginal zone lymphomas do not express CD45R/B220 (<xref ref-type="bibr" rid="bibr104-0192623311430695">Rehg and Sundberg 2008</xref>). <xref ref-type="fig" rid="fig73-0192623311430695">Figures 76</xref> and <xref ref-type="fig" rid="fig73-0192623311430695">77</xref> illustrate a splenic marginal zone lymphoma in an adult B6,129 mouse, showing a mixture of small and large cells with abundant pink cytoplasm that do not express CD45R/B220 (<xref ref-type="fig" rid="fig73-0192623311430695">Figure 78</xref>) but do express nuclear Pax5 (<xref ref-type="fig" rid="fig79-0192623311430695">Figure 79</xref>), confirming the lymphoma’s B-cell lineage.</p><fig id="fig79-0192623311430695" position="float"><label>Figure 79.</label><caption><p>In the case shown in <xref ref-type="fig" rid="fig73-0192623311430695">Figures 76</xref> and <xref ref-type="fig" rid="fig73-0192623311430695">77</xref>, the lymphoma cells associated with the marginal zone and red pulp show nuclear expression of Pax 5, consistent with a B-cell marginal zone lymphoma.</p> <p>Figure 80.—Spleen from a normal adult B6,129 mouse showing a mild infiltrate of neutrophils in association with red pulp lymphocytes and macrophages.</p> <p>Figure 81.—The mouse spleen shown in <xref ref-type="fig" rid="fig79-0192623311430695">Figure 80</xref> shows little to no cytoplasmic expression of iNOS2 in neutrophils, typical of a healthy mouse.</p> <p>Figure 82.—Spleen from an adult B6,129 mouse showing red pulp fibrosis associated with an increased number of red pulp macrophages and neutrophils.</p> <p>Figure 83.—In the mouse spleen shown in <xref ref-type="fig" rid="fig79-0192623311430695">Figure 82</xref>, the neutrophils express high levels of cytoplasmic iNOS2, typical of activated neutrophils.</p> <p>Figure 84.—Liver from an adult B6,129 mouse showing a lymphogranuloma with lymphocytes surrounding epithelioid macrophages.</p></caption><graphic alt-version="no" alternate-form-of="fig79-0192623311430695" position="float" xlink:href="10.1177_0192623311430695-fig14.tif" xlink:type="simple"/></fig><p>It is also not uncommon for T-cell lymphomas to lose one or more of the four (CD2, CD3, CD5, CD7) pan-T-cell antigens. Antigen loss is defined by some as staining of less than 50% of the total T-cells.</p></sec><sec id="section23-0192623311430695"><title>Changes in the Expression of Antigens Associated with a Cell</title><p>Neutrophils often occur in large numbers in the spleen and they may be associated with physiological extramedullary hyperplasia in response for an increased production of the granulocytes or they may be an inflammatory infiltrate (reaction). A major differentiating factor between these two host reactions is whether the neutrophil is in an activated state. Unlike resting neutrophils, activated neutrophils show strong cytoplasmic expression of iNOS2 (<xref ref-type="bibr" rid="bibr107-0192623311430695">Richter et al. 1999</xref>; McCaffery et al. 1999; <xref ref-type="bibr" rid="bibr84-0192623311430695">Morton et al. 2008</xref>). <xref ref-type="fig" rid="fig79-0192623311430695">Figures 80</xref> and <xref ref-type="fig" rid="fig79-0192623311430695">81</xref>, correlate resting neutrophils with weak low levels of iNOS2 and activated neutrophils with strong high levels of iNOS2 (<xref ref-type="fig" rid="fig79-0192623311430695">Figures 82</xref> and <xref ref-type="fig" rid="fig79-0192623311430695">83</xref>). The enhanced iNOS expression by the neutrophils is consistent with their being activated and of an inflammatory nature.</p></sec><sec id="section24-0192623311430695"><title>Determination of Cell Types Associated with an Inflammatory Lesion</title><p>In an inflammatory cell reaction, the antigen expression on macrophages depends on their microenvironment. Macrophage activation as a feature of cellular immunity to intracellular infectious pathogens depends on the products of specifically activated T-helper lymphocytes and NK cells. Mouse macrophages associated with inflammatory reactions in response to infectious agents are activated through either the classic Th1 pathway or the alternative Th2 pathway and are referred to as M1 or M2 macrophages, respectively. M1 macrophages express high levels of iNOS2 and down-regulate F4/80 expression upon activation by the CD4 TH1 proinflammatory cytokines IFN-gamma and TNF-alpha. M2 macrophages express high levels of arginase, YM1, FIZZI, and mannose receptor (MRC1) upon activation by the CD4 TH2 cytokines IL4 and IL13 (<xref ref-type="bibr" rid="bibr88-0192623311430695">Nair et al. 2003</xref>; <xref ref-type="bibr" rid="bibr46-0192623311430695">Gordon and Martinez 2010</xref>).</p><p><xref ref-type="fig" rid="fig79-0192623311430695">Figures 84</xref> through 88 illustrate an H&amp;E of a liver lymphogranulomatous lesion (<xref ref-type="fig" rid="fig79-0192623311430695">Figure 84</xref>) with CD3+ lymphocytes (<xref ref-type="fig" rid="fig85-0192623311430695">Figure 85</xref>) surrounding epithelioid macrophages that express MAC2 and iNOS2 but lack F4/80 expression (<xref ref-type="fig" rid="fig85-0192623311430695">Figures 86</xref>–<xref ref-type="fig" rid="fig85-0192623311430695">88</xref>). The immunophenotype of the lesion is consistent with classic CD4Th1-pathway macrophage activation.</p><fig id="fig85-0192623311430695" position="float"><label>Figure 85.</label><caption><p>The liver lymphogranuloma shown in <xref ref-type="fig" rid="fig79-0192623311430695">Figure 84</xref> shows epithelioid macrophages surrounded by lymphocytes, many of which express CD3 (consistent with T-cells).</p> <p>Figure 86.—In the mouse liver shown in <xref ref-type="fig" rid="fig79-0192623311430695">Figure 84</xref>, the Kupffer cells and the epithelioid macrophages in the lymphogranuloma show cytoplasmic MAC2 expression.</p> <p>Figure 87.—In the mouse liver shown in <xref ref-type="fig" rid="fig79-0192623311430695">Figure 84</xref>, the Kupffer cells show membrane expression of F4/80, whereas the epithelioid macrophages in the lymphogranuloma do not express F4/80.</p> <p>Figure 88.—In the mouse liver shown in <xref ref-type="fig" rid="fig79-0192623311430695">Figure 84</xref>, the epithelioid macrophages in the lymphogranuloma show cytoplasmic expression of iNos2, characteristic of M1 macrophages activated through the classic CD4Th1 pathway.</p> <p>Figure 89.—Lung from an 8-week-old BALB/c mouse infected with influenza virus showing an inflammatory-cell infiltrate with small and large mononuclear cells and granulocytes. Figure 90.—In the mouse lung inflammatory cell infiltrate shown in <xref ref-type="fig" rid="fig85-0192623311430695">Figure 89</xref>, the small mononuclear cells show CD3 expression indicative of T-lymphocytes.</p></caption><graphic alt-version="no" alternate-form-of="fig85-0192623311430695" position="float" xlink:href="10.1177_0192623311430695-fig15.tif" xlink:type="simple"/></fig><p>To understand the pathogenesis of an infectious disease process, it is often necessary to understand how the host responds to the pathogen. <xref ref-type="fig" rid="fig85-0192623311430695">Figures 89</xref> through 93 illustrate an H&amp;E-stained lung section (<xref ref-type="fig" rid="fig85-0192623311430695">Figure 89</xref>) with a subacute inflammatory-cell reaction to influenza virus infection in a BALB/c mouse. The inflammatory-cell reaction consists of CD3+ lymphocytes (<xref ref-type="fig" rid="fig85-0192623311430695">Figure 90</xref>), Ly6G+ neutrophils (<xref ref-type="fig" rid="fig91-0192623311430695">Figure 91</xref>), and F4/80-positive macrophages (<xref ref-type="fig" rid="fig91-0192623311430695">Figure 92</xref>) that express arginase (<xref ref-type="fig" rid="fig91-0192623311430695">Figure 93</xref>), consistent with an M2 phenotype of the CD4Th2 alternative macrophage activation pathway. These are typical inflammatory phenotypes of viral infections in the BALB/c mouse.</p><fig id="fig91-0192623311430695" position="float"><label>Figure 91.</label><caption><p>In the mouse lung inflammatory cell infiltrate shown in <xref ref-type="fig" rid="fig85-0192623311430695">Figure 89</xref>, the granulocytes show cytoplasmic expression of Ly6G, characteristic of neutrophils.</p> <p>Figure 92.—In the mouse lung inflammatory cell infiltrate shown in <xref ref-type="fig" rid="fig85-0192623311430695">Figure 89</xref>, the large mononuclear cells show pale cytoplasmic and moderate dark membrane expression of F4/80.</p> <p>Figure 93.—In the mouse lung inflammatory cell infiltrate shown in <xref ref-type="fig" rid="fig85-0192623311430695">Figure 89</xref>, some of the large mononuclear cells show cytoplasmic expression of arginase 1, characteristic of M2 macrophages activated through the CD4Th2 alternative pathway.</p></caption><graphic alt-version="no" alternate-form-of="fig91-0192623311430695" position="float" xlink:href="10.1177_0192623311430695-fig16.tif" xlink:type="simple"/></fig><p>In conclusion, the availability of antibodies for IHC analysis of formalin-fixed, paraffin-embedded tissue enables the pathologist to identify marker antigens of specific cells of the hematopoietic and lymphoid systems as they relate to specific anatomic structures and up regulation or down regulation of antigen expression in a cell or tissue. Finally, IHC can be helpful in diagnosing and classifying reactive and neoplastic lesions and characterizing the infiltrating cells in infectious and inflammatory processes.</p></sec></sec></body><back><ack><title>Acknowledgments</title><p>The authors thank Sharon Noran and Drs. John Choi and Laura Janke for reading the manuscript and editorial suggestions and Dr. Peter Vogel for photograph editing. This publication was supported in part by grant P30C CA 21765 from the National Cancer Institute and by the American Lebanese Syrian Associated Charities (ALSAC). Its contents are solely the responsibility of the authors and do not necessarily represent the official view of the National Cancer Institute.</p></ack><fn-group><fn fn-type="conflict" id="fn1-0192623311430695"><p>This publication was supported in part by grant P30C CA 21765 from the National Cancer Institute and by the American Lebanese Syrian Associated Charities (ALSAC).</p></fn></fn-group><ref-list><title>References</title><ref id="bibr1-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Adams</surname><given-names>B.</given-names></name><name name-style="western"><surname>Dorfler</surname><given-names>P.</given-names></name><name name-style="western"><surname>Aguzzi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kozmik</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Urbanek</surname><given-names>P.</given-names></name><name name-style="western"><surname>Maurer-Fogy</surname><given-names>I.</given-names></name><name name-style="western"><surname>Busslinger</surname><given-names>M.</given-names></name></person-group> (<year>1992</year>). <article-title>Pax-5 encodes the transcription factor BSAP and is expressed in B lymphocytes, the developing CNS, and adult testis</article-title>. <source>Genes Dev</source> <volume>6</volume>, <fpage>1589</fpage>–<lpage>607</lpage>.</citation></ref><ref id="bibr2-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Amanzada</surname><given-names>A.</given-names></name><name name-style="western"><surname>Malik</surname><given-names>I. A.</given-names></name><name name-style="western"><surname>Nischwitz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sultan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Naz</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ramadori</surname><given-names>G.</given-names></name></person-group> (<year>2011</year>). <article-title>Myeloperoxidase and elastase are only expressed by neutrophils in normal and in inflamed liver</article-title>. <source>Histochem Cell Biol</source> <volume>135</volume>, <fpage>305</fpage>–<lpage>15</lpage>.</citation></ref><ref id="bibr3-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Arber</surname><given-names>D. A.</given-names></name><name name-style="western"><surname>Strickler</surname><given-names>J. G.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y. Y.</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>L. M.</given-names></name></person-group> (<year>1997</year>). <article-title>Splenic vascular tumors: a histologic, immunophenotypic, and virologic study</article-title>. <source>Am J Surg Pathol</source> <volume>21</volume>, <fpage>827</fpage>–<lpage>35</lpage>.</citation></ref><ref id="bibr6-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Arber</surname><given-names>D. A.</given-names></name><name name-style="western"><surname>Tamayo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>L. M.</given-names></name></person-group> (<year>1998</year>). <article-title>Paraffin section detection of the c-kit gene product (CD117) in human tissues: Value in the diagnosis of mast cell disorders</article-title>. <source>Hum Pathol</source> <volume>29</volume>, <fpage>498</fpage>–<lpage>504</lpage>.</citation></ref><ref id="bibr4-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Arber</surname><given-names>D. A.</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>L. M.</given-names></name></person-group> (<year>1993</year>). <article-title>CD43: A review</article-title>. <source>Appl Immunochistochem</source> <volume>1</volume>, <fpage>88</fpage>–<lpage>96</lpage>.</citation></ref><ref id="bibr5-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Arber</surname><given-names>D. A.</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>L.M.</given-names></name></person-group> (<year>1997</year>). <article-title>CD 10: A review</article-title>. <source>Appl Immunohistochem</source> <volume>5</volume>, <fpage>125</fpage>–<lpage>40</lpage>.</citation></ref><ref id="bibr7-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Ardavin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Shortman</surname><given-names>K.</given-names></name></person-group> (<year>1992</year>). <article-title>Cell surface marker analysis of mouse thymic dendritic cells</article-title>. <source>Eur J Immunol</source> <volume>22</volume>, <fpage>859</fpage>–<lpage>62</lpage>.</citation></ref><ref id="bibr8-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Arinobu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Iwasaki</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gurish</surname><given-names>M. F.</given-names></name><name name-style="western"><surname>Mizuno</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shigematsu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ozawa</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tenen</surname><given-names>D. G.</given-names></name><name name-style="western"><surname>Austen</surname><given-names>K. F.</given-names></name><name name-style="western"><surname>Akashi</surname><given-names>K.</given-names></name></person-group> (<year>2005</year>). <article-title>Developmental checkpoints of the basophil/mast cell lineages in adult murine hematopoiesis</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>102</volume>, <fpage>18105</fpage>–<lpage>10</lpage>.</citation></ref><ref id="bibr9-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Barberis</surname><given-names>A.</given-names></name><name name-style="western"><surname>Widenhorn</surname><given-names>K.</given-names></name><name name-style="western"><surname>Vitelli</surname><given-names>L.</given-names></name><name name-style="western"><surname>Busslinger</surname><given-names>M.</given-names></name></person-group> (<year>1990</year>). <article-title>A novel B-cell lineage-specific transcription factor present at early but not late stages of differentiation</article-title>. <source>Genes Dev</source> <volume>4</volume>, <fpage>849</fpage>–<lpage>59</lpage>.</citation></ref><ref id="bibr10-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Bhandoola</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sambandam</surname><given-names>A.</given-names></name></person-group> (<year>2006</year>). <article-title>From stem cell to T cell: One route or many?</article-title> <source>Nat Rev Immunol</source> <volume>6</volume>, <fpage>117</fpage>–<lpage>26</lpage>.</citation></ref><ref id="bibr11-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Bhargava</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kallakury</surname><given-names>B. V.</given-names></name><name name-style="western"><surname>Ross</surname><given-names>J. S.</given-names></name><name name-style="western"><surname>Azumi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bagg</surname><given-names>A.</given-names></name></person-group> (<year>2007</year>). <article-title>CD79a is heterogeneously expressed in neoplastic and normal myeloid precursors and megakaryocytes in an antibody clone-dependent manner</article-title>. <source>Am J Clin Pathol</source> <volume>128</volume>, <fpage>306</fpage>–<lpage>13</lpage>.</citation></ref><ref id="bibr12-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Blasius</surname><given-names>A. L.</given-names></name><name name-style="western"><surname>Barchet</surname><given-names>W.</given-names></name><name name-style="western"><surname>Cella</surname><given-names>M.</given-names></name><name name-style="western"><surname>Colonna</surname><given-names>M.</given-names></name></person-group> (<year>2007</year>). <article-title>Development and function of murine B220+CD11c+NK1.1+ cells identify them as a subset of NK cells</article-title>. <source>J Exp Med</source> <volume>204</volume>, <fpage>2561</fpage>–<lpage>8</lpage>.</citation></ref><ref id="bibr13-0192623311430695"><citation citation-type="book" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Borowitz</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>J. K. C.</given-names></name></person-group> (<year>2008</year>). <article-title>B lymphoblastic leukaemia/lymphoma, not otherwise specified</article-title>. In <source>WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues</source> (<person-group person-group-type="editor"><name name-style="western"><surname>Swerdlow</surname><given-names>S.</given-names></name><name name-style="western"><surname>Campo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Harris</surname><given-names>N.</given-names></name><name name-style="western"><surname>Jaffe</surname><given-names>E.</given-names></name><name name-style="western"><surname>Piler</surname><given-names>S.</given-names></name><name name-style="western"><surname>Stein</surname><given-names>H.</given-names></name><name name-style="western"><surname>Thiele</surname><given-names>J.</given-names></name><name name-style="western"><surname>Vardiman</surname><given-names>J.</given-names></name></person-group>, eds.), p. <fpage>168</fpage>. <publisher-name>International Agency for Research on Cancer</publisher-name>, <publisher-loc>World Health Organization, Washington, DC</publisher-loc>.</citation></ref><ref id="bibr14-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Brown</surname><given-names>K. E.</given-names></name><name name-style="western"><surname>Brunt</surname><given-names>E. M.</given-names></name><name name-style="western"><surname>Heinecke</surname><given-names>J. W.</given-names></name></person-group> (<year>2001</year>). <article-title>Immunohistochemical detection of myeloperoxidase and its oxidation products in Kupffer cells of human liver</article-title>. <source>Am J Pathol</source> <volume>159</volume>, <fpage>2081</fpage>–<lpage>8</lpage>.</citation></ref><ref id="bibr15-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Carbone</surname><given-names>A.</given-names></name><name name-style="western"><surname>Manconi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Poletti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Colombatti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tirelli</surname><given-names>U.</given-names></name><name name-style="western"><surname>Volpe</surname><given-names>R.</given-names></name></person-group> (<year>1986</year>). <article-title>S-100 protein, fibronectin, and laminin immunostaining in lymphomas of follicular center cell origin</article-title>. <source>Cancer</source> <volume>58</volume>, <fpage>2169</fpage>–<lpage>76</lpage>.</citation></ref><ref id="bibr16-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Ceredig</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rolink</surname><given-names>T.</given-names></name></person-group> (<year>2002</year>). <article-title>A positive look at double-negative thymocytes</article-title>. <source>Nat Rev Immunol</source> <volume>2</volume>, <fpage>888</fpage>–<lpage>97</lpage>.</citation></ref><ref id="bibr17-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Irani</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Bradford</surname><given-names>T. R.</given-names></name><name name-style="western"><surname>Craig</surname><given-names>S. S.</given-names></name><name name-style="western"><surname>Newlands</surname><given-names>G.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>H.</given-names></name><name name-style="western"><surname>Huff</surname><given-names>T.</given-names></name><name name-style="western"><surname>Simmons</surname><given-names>W. H.</given-names></name><name name-style="western"><surname>Schwartz</surname><given-names>L. B.</given-names></name></person-group> (<year>1993</year>). <article-title>Localization of rat tryptase to a subset of the connective tissue type of mast cell</article-title>. <source>J Histochem Cytochem</source> <volume>41</volume>, <fpage>961</fpage>–<lpage>9</lpage>.</citation></ref><ref id="bibr18-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Chilosi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pizzolo</surname><given-names>G.</given-names></name></person-group> (<year>1995</year>). <article-title>Review of terminal deoxynecleotidyl transferase</article-title>. <source>Appl Immunohistochem</source> <volume>3</volume>, <fpage>209</fpage>–<lpage>21</lpage>.</citation></ref><ref id="bibr19-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Chilosi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pizzolo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Caligaris-Cappio</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ambrosetti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vinante</surname><given-names>F.</given-names></name><name name-style="western"><surname>Morittu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bonetti</surname><given-names>F.</given-names></name><name name-style="western"><surname>Fiore-Donati</surname><given-names>L.</given-names></name><name name-style="western"><surname>Janossy</surname><given-names>G.</given-names></name></person-group> (<year>1985</year>). <article-title>Immunohistochemical demonstration of follicular dendritic cells in bone marrow involvement of B-cell chronic lymphocytic leukemia</article-title>. <source>Cancer</source> <volume>56</volume>, <fpage>328</fpage>–<lpage>32</lpage>.</citation></ref><ref id="bibr20-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Chu</surname><given-names>P. G.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>K. L.</given-names></name><name name-style="western"><surname>Arber</surname><given-names>D. A.</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>L. M.</given-names></name></person-group> (<year>1999</year>). <article-title>Practical applications of immunohistochemistry in hematolymphoid neoplasms</article-title>. <source>Ann Diagn Pathol</source> <volume>3</volume>, <fpage>104</fpage>–<lpage>33</lpage>.</citation></ref><ref id="bibr21-0192623311430695"><citation citation-type="book" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Chu</surname><given-names>P. G.</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>L.</given-names></name></person-group> (<year>2009</year>). <source>Modern Immunohistochemistry</source>. <publisher-name>Cambridge University Press</publisher-name>, <publisher-loc>Cambridge, UK</publisher-loc>.</citation></ref><ref id="bibr22-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Chuang</surname><given-names>S. S.</given-names></name><name name-style="western"><surname>Jung</surname><given-names>Y. C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C. Y.</given-names></name></person-group> (<year>2000</year>). <article-title>von Willebrand factor is the most reliable immunohistochemical marker for megakaryocytes of myelodysplastic syndrome and chronic myeloproliferative disorders</article-title>. <source>Am J Clin Pathol</source> <volume>113</volume>, <fpage>506</fpage>–<lpage>11</lpage>.</citation></ref><ref id="bibr23-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Contos</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Kornstein</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Innes</surname><given-names>D. J.</given-names></name><name name-style="western"><surname>Ben-Ezra</surname><given-names>J.</given-names></name></person-group> (<year>1992</year>). <article-title>The utility of CD20 and CD43 in subclassification of low-grade B-cell lymhoma on paraffin sections</article-title>. <source>Mod Pathol</source> <volume>5</volume>, <fpage>631</fpage>–<lpage>3</lpage>.</citation></ref><ref id="bibr24-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Corsetti</surname><given-names>M. T.</given-names></name><name name-style="western"><surname>Calabi</surname><given-names>F.</given-names></name></person-group> (<year>1997</year>). <article-title>Lineage- and stage-specific expression of runt box polypeptides in primitive and definitive hematopoiesis</article-title>. <source>Blood</source> <volume>89</volume>, <fpage>2359</fpage>–<lpage>68</lpage>.</citation></ref><ref id="bibr25-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Costain</surname><given-names>D. J.</given-names></name><name name-style="western"><surname>Guha</surname><given-names>A. K.</given-names></name><name name-style="western"><surname>Liwski</surname><given-names>R. S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>T. D.</given-names></name></person-group> (<year>2001</year>). <article-title>Murine hypodense eosinophils induce tumour cell apoptosis by a granzyme B-dependent mechanism</article-title>. <source>Cancer Immunol Immunother</source> <volume>50</volume>, <fpage>293</fpage>–<lpage>9</lpage>.</citation></ref><ref id="bibr26-0192623311430695"><citation citation-type="book" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Dabbs</surname><given-names>D. J.</given-names></name></person-group> (<year>2010</year>). <source>Diagnostic Immunohistochemistry</source>. <publisher-name>Elsevier</publisher-name>, <publisher-loc>New York, NY</publisher-loc>.</citation></ref><ref id="bibr27-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Davies</surname><given-names>M.</given-names></name><name name-style="western"><surname>Harris</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rudland</surname><given-names>P.</given-names></name><name name-style="western"><surname>Barraclough</surname><given-names>R.</given-names></name></person-group> (<year>1995</year>). <article-title>Expression of the rat, S-100-related, calcium-binding protein gene, p9Ka, in transgenic mice demonstrates different patterns of expression between these two species</article-title>. <source>DNA Cell Biol</source> <volume>14</volume>, <fpage>825</fpage>–<lpage>32</lpage>.</citation></ref><ref id="bibr28-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>De</surname><given-names>Z. J.</given-names></name></person-group> (<year>1999</year>). <article-title>Myeloid cell-lineage and premylocytic-stage-specific-expression of the mouse myeloperoxidase gene is controlled at initiation as well as elongation levels of transcription</article-title>. <source>Cell Research</source> <volume>9</volume>, <fpage>107</fpage>–<lpage>34</lpage>.</citation></ref><ref id="bibr29-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Debili</surname><given-names>N.</given-names></name><name name-style="western"><surname>Issaad</surname><given-names>C.</given-names></name><name name-style="western"><surname>Masse</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Guichard</surname><given-names>J.</given-names></name><name name-style="western"><surname>Katz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Breton-Gorius</surname><given-names>J.</given-names></name><name name-style="western"><surname>Vainchenker</surname><given-names>W.</given-names></name></person-group> (<year>1992</year>). <article-title>Expression of CD34 and platelet glycoproteins during human megakaryocytic differentiation</article-title>. <source>Blood</source> <volume>80</volume>, <fpage>3022</fpage>–<lpage>35</lpage>.</citation></ref><ref id="bibr30-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Dik</surname><given-names>W. A.</given-names></name><name name-style="western"><surname>Pike-Overzet</surname><given-names>K.</given-names></name><name name-style="western"><surname>Weerkamp</surname><given-names>F.</given-names></name><name name-style="western"><surname>de Ridder</surname><given-names>D.</given-names></name><name name-style="western"><surname>de Haas</surname><given-names>E. F.</given-names></name><name name-style="western"><surname>Baert</surname><given-names>M. R.</given-names></name><name name-style="western"><surname>van der Spek</surname><given-names>P.</given-names></name><name name-style="western"><surname>Koster</surname><given-names>E. E.</given-names></name><name name-style="western"><surname>Reinders</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>van Dongen</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>Langerak</surname><given-names>A. W.</given-names></name><name name-style="western"><surname>Staal</surname><given-names>F. J.</given-names></name></person-group> (<year>2005</year>). <article-title>New insights on human T cell development by quantitative T cell receptor gene rearrangement studies and gene expression profiling</article-title>. <source>J Exp Med</source> <volume>201</volume>, <fpage>1715</fpage>–<lpage>23</lpage>.</citation></ref><ref id="bibr31-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Drew</surname><given-names>E.</given-names></name><name name-style="western"><surname>Merkens</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chelliah</surname><given-names>S.</given-names></name><name name-style="western"><surname>Doyonnas</surname><given-names>R.</given-names></name><name name-style="western"><surname>McNagny</surname><given-names>K. M.</given-names></name></person-group> (<year>2002</year>). <article-title>CD34 is a specific marker of mature murine mast cells</article-title>. <source>Exp Hematol</source> <volume>30</volume>, <fpage>1211</fpage>–<lpage>8</lpage>.</citation></ref><ref id="bibr32-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Elagib</surname><given-names>K. E.</given-names></name><name name-style="western"><surname>Racke</surname><given-names>F. K.</given-names></name><name name-style="western"><surname>Mogass</surname><given-names>M.</given-names></name><name name-style="western"><surname>Khetawat</surname><given-names>R.</given-names></name><name name-style="western"><surname>Delehanty</surname><given-names>L. L.</given-names></name><name name-style="western"><surname>Goldfarb</surname><given-names>A. N.</given-names></name></person-group> (<year>2003</year>). <article-title>RUNX1 and GATA-1 coexpression and cooperation in megakaryocytic differentiation</article-title>. <source>Blood</source> <volume>101</volume>, <fpage>4333</fpage>–<lpage>41</lpage>.</citation></ref><ref id="bibr33-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Enerback</surname><given-names>L.</given-names></name></person-group> (<year>1981</year>). <article-title>The gut mucosal mast cell</article-title>. <source>Monogr Allergy</source> <volume>17</volume>, <fpage>222</fpage>–<lpage>32</lpage>.</citation></ref><ref id="bibr34-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Escribano</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ocqueteau</surname><given-names>M.</given-names></name><name name-style="western"><surname>Almeida</surname><given-names>J.</given-names></name><name name-style="western"><surname>Orfao</surname><given-names>A.</given-names></name><name name-style="western"><surname>San Miguel</surname><given-names>J. F.</given-names></name></person-group> (<year>1998</year>). <article-title>Expression of the c-kit (CD117) molecule in normal and malignant hematopoiesis</article-title>. <source>Leuk Lymphoma</source> <volume>30</volume>, <fpage>459</fpage>–<lpage>66</lpage>.</citation></ref><ref id="bibr35-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Falini</surname><given-names>B.</given-names></name><name name-style="western"><surname>Fizzotti</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pucciarini</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bigerna</surname><given-names>B.</given-names></name><name name-style="western"><surname>Marafioti</surname><given-names>T.</given-names></name><name name-style="western"><surname>Gambacorta</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pacini</surname><given-names>R.</given-names></name><name name-style="western"><surname>Alunni</surname><given-names>C.</given-names></name><name name-style="western"><surname>Natali-Tanci</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ugolini</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sebastiani</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cattoretti</surname><given-names>G.</given-names></name><name name-style="western"><surname>Pileri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dalla-Favera</surname><given-names>R.</given-names></name><name name-style="western"><surname>Stein</surname><given-names>H.</given-names></name></person-group> (<year>2000</year>). <article-title>A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells</article-title>. <source>Blood</source> <volume>95</volume>, <fpage>2084</fpage>–<lpage>92</lpage>.</citation></ref><ref id="bibr36-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Falini</surname><given-names>B.</given-names></name><name name-style="western"><surname>Flenghi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pileri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gambacorta</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bigerna</surname><given-names>B.</given-names></name><name name-style="western"><surname>Durkop</surname><given-names>H.</given-names></name><name name-style="western"><surname>Eitelbach</surname><given-names>F.</given-names></name><name name-style="western"><surname>Thiele</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pacini</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cavaliere</surname><given-names>A.</given-names></name><name name-style="western"><surname>Masssimo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cardarelli</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sabattini</surname><given-names>E.</given-names></name><name name-style="western"><surname>Poggi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Stein</surname><given-names>H.</given-names></name></person-group> (<year>1993</year>). <article-title>PG-M1: A new monoclonal antibody directed against a fixative-resistant epitope on the macrophage-restricted form of the CD68 molecule</article-title>. <source>Am J Pathol</source> <volume>142</volume>, <fpage>1359</fpage>–<lpage>72</lpage>.</citation></ref><ref id="bibr37-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Flotte</surname><given-names>T. J.</given-names></name><name name-style="western"><surname>Springer</surname><given-names>T. A.</given-names></name><name name-style="western"><surname>Thorbecke</surname><given-names>G. J.</given-names></name></person-group> (<year>1983</year>). <article-title>Dendritic cell and macrophage staining by monoclonal antibodies in tissue sections and epidermal sheets</article-title>. <source>Am J Pathol</source> <volume>111</volume>, <fpage>112</fpage>–<lpage>24</lpage>.</citation></ref><ref id="bibr38-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Franco</surname><given-names>V.</given-names></name><name name-style="western"><surname>Florena</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Lannitto</surname><given-names>E.</given-names></name></person-group> (<year>2003</year>). <article-title>Splenic marginal zone lymphoma</article-title>. <source>Blood</source> <volume>101</volume>, <fpage>2464</fpage>–<lpage>72</lpage>.</citation></ref><ref id="bibr39-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Fredrickson</surname><given-names>T. N.</given-names></name><name name-style="western"><surname>Langdon</surname><given-names>W. Y.</given-names></name><name name-style="western"><surname>Hoffman</surname><given-names>P. M.</given-names></name><name name-style="western"><surname>Hartley</surname><given-names>J. W.</given-names></name><name name-style="western"><surname>Morse</surname><given-names>H. C.,</given-names> <suffix>III</suffix></name></person-group> (<year>1984</year>). <article-title>Histologic and cell surface antigen studies of hematopoietic tumors induced by Cas-Br-M murine leukemia virus</article-title>. <source>J Natl Cancer Inst</source> <volume>72</volume>, <fpage>447</fpage>–<lpage>54</lpage>.</citation></ref><ref id="bibr40-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Galili</surname><given-names>U.</given-names></name><name name-style="western"><surname>Galili</surname><given-names>N.</given-names></name><name name-style="western"><surname>Or</surname><given-names>R.</given-names></name><name name-style="western"><surname>Polliack</surname><given-names>A.</given-names></name></person-group> (<year>1981</year>). <article-title>Analysis of the peanut agglutinin-binding site as a differentiation marker of normal and malignant human lymphoid cells</article-title>. <source>Clin Exp Immunol</source> <volume>43</volume>, <fpage>311</fpage>–<lpage>8</lpage>.</citation></ref><ref id="bibr41-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Gewirtz</surname><given-names>A. M.</given-names></name></person-group> (<year>1995</year>). <article-title>Megakaryocytopoiesis: the state of the art</article-title>. <source>Thromb Haemost</source> <volume>74</volume>, <fpage>204</fpage>–<lpage>9</lpage>.</citation></ref><ref id="bibr42-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Godfrey</surname><given-names>D. I.</given-names></name><name name-style="western"><surname>Kennedy</surname><given-names>J.</given-names></name><name name-style="western"><surname>Suda</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zlotnik</surname><given-names>A.</given-names></name></person-group> (<year>1993</year>). <article-title>A developmental pathway involving four phenotypically and functionally distinct subsets of CD3-CD4-CD8- triple-negative adult mouse thymocytes defined by CD44 and CD25 expression</article-title>. <source>J Immunol</source> <volume>150</volume>, <fpage>4244</fpage>–<lpage>52</lpage>.</citation></ref><ref id="bibr43-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Godfrey</surname><given-names>D. I.</given-names></name><name name-style="western"><surname>Zlotnik</surname><given-names>A.</given-names></name><name name-style="western"><surname>Suda</surname><given-names>T.</given-names></name></person-group> (<year>1992</year>). <article-title>Phenotypic and functional characterization of c-kit expression during intrathymic T cell development</article-title>. <source>J Immunol</source> <volume>149</volume>, <fpage>2281</fpage>–<lpage>5</lpage>.</citation></ref><ref id="bibr44-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Gordon</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lawson</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rabinowitz</surname><given-names>S.</given-names></name><name name-style="western"><surname>Crocker</surname><given-names>P. R.</given-names></name><name name-style="western"><surname>Morris</surname><given-names>L.</given-names></name><name name-style="western"><surname>Perry</surname><given-names>V. H.</given-names></name></person-group> (<year>1992</year>). <article-title>Antigen markers of macrophage differentiation in murine tissues</article-title>. <source>Curr Top Microbiol Immunol</source> <volume>181</volume>, <fpage>1</fpage>–<lpage>37</lpage>.</citation></ref><ref id="bibr45-0192623311430695"><citation citation-type="book" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Gordon</surname><given-names>S. C. P.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.-H.</given-names></name><name name-style="western"><surname>Morris</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rabinowitz</surname><given-names>S.</given-names></name></person-group> (<year>1986</year>). <article-title>Trophic and defense functions of murine macrophages</article-title>. In <source>Mechaninisms of Host Resistance to Infectious Agents, Tumors, and Allografts</source> (<person-group person-group-type="editor"><name name-style="western"><surname>Steinman</surname><given-names>R. M.</given-names></name><name name-style="western"><surname>North</surname><given-names>R. J.</given-names></name></person-group>, eds.). <publisher-name>Rockefeller University Press</publisher-name>, <publisher-loc>New York, NY</publisher-loc>.</citation></ref><ref id="bibr46-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Gordon</surname><given-names>S.</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>F. O.</given-names></name></person-group> (<year>2010</year>). <article-title>Alternative activation of macrophages: Mechanism and functions</article-title>. <source>Immunity</source> <volume>32</volume>, <fpage>593</fpage>–<lpage>604</lpage>.</citation></ref><ref id="bibr47-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Gouon-Evans</surname><given-names>V.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>E. Y.</given-names></name><name name-style="western"><surname>Pollard</surname><given-names>J. W.</given-names></name></person-group> (<year>2002</year>). <article-title>Requirement of macrophages and eosinophils and their cytokines/chemokines for mammary gland development</article-title>. <source>Breast Cancer Res</source> <volume>4</volume>, <fpage>155</fpage>–<lpage>64</lpage>.</citation></ref><ref id="bibr48-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Gualco</surname><given-names>G.</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>L. M.</given-names></name><name name-style="western"><surname>Bacchi</surname><given-names>C. E.</given-names></name></person-group> (<year>2010</year>). <article-title>MUM1/IRF4: A review</article-title>. <source>Appl Immunohistochem Mol Morphol</source> <volume>18</volume>, <fpage>301</fpage>–<lpage>10</lpage>.</citation></ref><ref id="bibr49-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Hallgren</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gurish</surname><given-names>M. F.</given-names></name></person-group> (<year>2007</year>). <article-title>Pathways of murine mast cell development and trafficking: tracking the roots and routes of the mast cell</article-title>. <source>Immunol Rev</source> <volume>217</volume>, <fpage>8</fpage>–<lpage>18</lpage>.</citation></ref><ref id="bibr50-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Hao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Fredrickson</surname><given-names>T. N.</given-names></name><name name-style="western"><surname>Chattopadhyay</surname><given-names>S. K.</given-names></name><name name-style="western"><surname>Han</surname><given-names>W.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>C. F.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ward</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Hartley</surname><given-names>J. W.</given-names></name><name name-style="western"><surname>Morse</surname><given-names>H. C., </given-names><suffix>III</suffix></name></person-group> (<year>2010</year>). <article-title>The histopathologic and molecular basis for the diagnosis of histiocytic sarcoma and histiocyte-associated lymphoma of mice</article-title>. <source>Vet Pathol</source> <volume>47</volume>, <fpage>434</fpage>–<lpage>45</lpage>.</citation></ref><ref id="bibr51-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Hao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>M. S.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J. X.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>C. H.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>C. F.</given-names></name><name name-style="western"><surname>Naghashfar</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Hartley</surname><given-names>J. W.</given-names></name><name name-style="western"><surname>Fredrickson</surname><given-names>T. N.</given-names></name><name name-style="western"><surname>Ward</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Morse</surname><given-names>H. C.</given-names><suffix>III</suffix></name></person-group> (<year>2006</year>). <article-title>Histologic and molecular characterizations of megakaryocytic leukemia in mice</article-title>. <source>Leuk Res</source> <volume>30</volume>, <fpage>397</fpage>–<lpage>406</lpage>.</citation></ref><ref id="bibr52-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Hard</surname><given-names>G. C.</given-names></name><name name-style="western"><surname>Snowden</surname><given-names>R. T.</given-names></name></person-group> (<year>1991</year>). <article-title>Hyaline droplet accumulation in rodent kidney proximal tubules: An association with histiocytic sarcoma</article-title>. <source>Toxicol Pathol</source> <volume>19</volume>, <fpage>88</fpage>–<lpage>97</lpage>.</citation></ref><ref id="bibr53-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Hardy</surname><given-names>R. R.</given-names></name><name name-style="western"><surname>Kincade</surname><given-names>P. W.</given-names></name><name name-style="western"><surname>Dorshkind</surname><given-names>K.</given-names></name></person-group> (<year>2007</year>). <article-title>The protean nature of cells in the B lymphocyte lineage</article-title>. <source>Immunity</source> <volume>26</volume>, <fpage>703</fpage>–<lpage>14</lpage>.</citation></ref><ref id="bibr54-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Hashimoto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yamashita</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Mon</surname><given-names>N.</given-names></name></person-group> (<year>2002</year>). <article-title>Immunohistochemical detection of CD79a expression in precursor T-cell lymphoblastic lymphoma/leukaemias</article-title>. <source>J Pathol</source> <volume>197</volume>, <fpage>341</fpage>–<lpage>7</lpage>.</citation></ref><ref id="bibr55-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Hayakawa</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Huntington</surname><given-names>N. D.</given-names></name><name name-style="western"><surname>Nutt</surname><given-names>S. L.</given-names></name><name name-style="western"><surname>Smyth</surname><given-names>M. J.</given-names></name></person-group> (<year>2006</year>). <article-title>Functional subsets of mouse natural killer cells</article-title>. <source>Immunol Rev</source> <volume>214</volume>, <fpage>47</fpage>–<lpage>55</lpage>.</citation></ref><ref id="bibr56-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Hirsch</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>S.</given-names></name></person-group> (<year>1983</year>). <article-title>Polymorphic expression of a neutrophil differentiation antigen revealed by monoclonal antibody 7/4</article-title>. <source>Immunogenetics</source> <volume>18</volume>, <fpage>229</fpage>–<lpage>39</lpage>.</citation></ref><ref id="bibr57-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Hisa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Spence</surname><given-names>S. E.</given-names></name><name name-style="western"><surname>Rachel</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Fujita</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ward</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Devor-Henneman</surname><given-names>D. E.</given-names></name><name name-style="western"><surname>Saiki</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kutsuna</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tessarollo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jenkins</surname><given-names>N. A.</given-names></name><name name-style="western"><surname>Copeland</surname><given-names>N. G.</given-names></name></person-group> (<year>2004</year>). <article-title>Hematopoietic, angiogenic and eye defects in Meis1 mutant animals</article-title>. <source>Embo J</source> <volume>23</volume>, <fpage>450</fpage>–<lpage>9</lpage>.</citation></ref><ref id="bibr58-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Hung</surname><given-names>S. I.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>A. C.</given-names></name><name name-style="western"><surname>Kato</surname><given-names>I.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>N. C.</given-names></name></person-group> (<year>2002</year>). <article-title>Transient expression of Ym1, a heparin-binding lectin, during developmental hematopoiesis and inflammation</article-title>. <source>J Leukoc Biol</source> <volume>72</volume>, <fpage>72</fpage>–<lpage>82</lpage>.</citation></ref><ref id="bibr59-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Jaffe</surname><given-names>E. S.</given-names></name></person-group> (<year>1996</year>). <article-title>Classification of natural killer (NK) cell and NK-like T-cell malignancies</article-title>. <source>Blood</source> <volume>87</volume>, <fpage>1207</fpage>–<lpage>10</lpage>.</citation></ref><ref id="bibr60-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Kaiserling</surname><given-names>E.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>J. C.</given-names></name><name name-style="western"><surname>Ruck</surname><given-names>P.</given-names></name><name name-style="western"><surname>Horny</surname><given-names>H. P.</given-names></name></person-group> (<year>1993</year>). <article-title>Aberrant expression of macrophage-associated antigens (CD68 and Ki-M1P) by Schwann cells in reactive and neoplastic neural tissue. Light- and electron-microscopic findings</article-title>. <source>Mod Pathol</source> <volume>6</volume>, <fpage>463</fpage>–<lpage>8</lpage>.</citation></ref><ref id="bibr61-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Kalled</surname><given-names>S. L.</given-names></name><name name-style="western"><surname>Siva</surname><given-names>N.</given-names></name><name name-style="western"><surname>Stein</surname><given-names>H.</given-names></name><name name-style="western"><surname>Reinherz</surname><given-names>E. L.</given-names></name></person-group> (<year>1995</year>). <article-title>The distribution of CD10 (NEP 24.11, CALLA) in humans and mice is similar in non-lymphoid organs but differs within the hematopoietic system: Absence on murine T and B lymphoid progenitors</article-title>. <source>Eur J Immunol</source> <volume>25</volume>, <fpage>677</fpage>–<lpage>87</lpage>.</citation></ref><ref id="bibr62-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Kaufman</surname><given-names>G.</given-names></name><name name-style="western"><surname>d’Ovidio</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kaldawy</surname><given-names>A.</given-names></name><name name-style="western"><surname>Assy</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ullmann</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Etzioni</surname><given-names>A.</given-names></name><name name-style="western"><surname>Paus</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gilhar</surname><given-names>A.</given-names></name></person-group> (<year>2010</year>). <article-title>An unexpected twist in alopecia areata pathogenesis: Are NK cells protective and CD49b+ T cells pathogenic?</article-title> <source>Exp Dermatol</source> <volume>19</volume>, <fpage>e347</fpage>–<lpage>9</lpage>.</citation></ref><ref id="bibr63-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Kina</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ikuta</surname><given-names>K.</given-names></name><name name-style="western"><surname>Takayama</surname><given-names>E.</given-names></name><name name-style="western"><surname>Wada</surname><given-names>K.</given-names></name><name name-style="western"><surname>Majumdar</surname><given-names>A. S.</given-names></name><name name-style="western"><surname>Weissman</surname><given-names>I. L.</given-names></name><name name-style="western"><surname>Katsura</surname><given-names>Y.</given-names></name></person-group> (<year>2000</year>). <article-title>The monoclonal antibody TER-119 recognizes a molecule associated with glycophorin A and specifically marks the late stages of murine erythroid lineage</article-title>. <source>Br J Haematol</source> <volume>109</volume>, <fpage>280</fpage>–<lpage>7</lpage>.</citation></ref><ref id="bibr64-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>King</surname><given-names>B. E.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Locker</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kant</surname><given-names>J.</given-names></name><name name-style="western"><surname>Okuyama</surname><given-names>K.</given-names></name><name name-style="western"><surname>Falini</surname><given-names>B.</given-names></name><name name-style="western"><surname>Swerdlow</surname><given-names>S. H.</given-names></name></person-group> (<year>2000</year>). <article-title>Immunophenotypic and genotypic markers of follicular center cell neoplasia in diffuse large B-cell lymphomas</article-title>. <source>Mod Pathol</source> <volume>13</volume>, <fpage>1219</fpage>–<lpage>31</lpage>.</citation></ref><ref id="bibr65-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Klockars</surname><given-names>M.</given-names></name><name name-style="western"><surname>Osserman</surname><given-names>E. F.</given-names></name></person-group> (<year>1974</year>). <article-title>Localization of lysozyme in normal rat tissues by an immunoperoxidase method</article-title>. <source>J Histochem Cytochem</source> <volume>22</volume>, <fpage>139</fpage>–<lpage>46</lpage>.</citation></ref><ref id="bibr66-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Kohler</surname><given-names>C.</given-names></name></person-group> (<year>2007</year>). <article-title>Allograft inflammatory factor-1/Ionized calcium-binding adapter molecule 1 is specifically expressed by most subpopulations of macrophages and spermatids in testis</article-title>. <source>Cell Tissue Res</source> <volume>330</volume>, <fpage>291</fpage>–<lpage>302</lpage>.</citation></ref><ref id="bibr67-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Kunder</surname><given-names>S.</given-names></name><name name-style="western"><surname>Calzada-Wack</surname><given-names>J.</given-names></name><name name-style="western"><surname>Holzlwimmer</surname><given-names>G.</given-names></name><name name-style="western"><surname>Muller</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kloss</surname><given-names>C.</given-names></name><name name-style="western"><surname>Howat</surname><given-names>W.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hofler</surname><given-names>H.</given-names></name><name name-style="western"><surname>Warren</surname><given-names>M.</given-names></name><name name-style="western"><surname>Quintanilla-Martinez</surname><given-names>L.</given-names></name></person-group> (<year>2007</year>). <article-title>A comprehensive antibody panel for immunohistochemical analysis of formalin-fixed, paraffin-embedded hematopoietic neoplasms of mice: Analysis of mouse specific and human antibodies cross-reactive with murine tissue</article-title>. <source>Toxicol Pathol</source> <volume>35</volume>, <fpage>366</fpage>–<lpage>75</lpage>.</citation></ref><ref id="bibr68-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Lagasse</surname><given-names>E.</given-names></name><name name-style="western"><surname>Weissman</surname><given-names>I. L.</given-names></name></person-group> (<year>1996</year>). <article-title>Flow cytometric identification of murine neutrophils and monocytes</article-title>. <source>J Immunol Methods</source> <volume>197</volume>, <fpage>139</fpage>–<lpage>50</lpage>.</citation></ref><ref id="bibr69-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Lau</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>P. G.</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>L. M.</given-names></name></person-group> (<year>2004</year>). <article-title>A specific marker of macrophages in paraffin-embedded tissue samples</article-title>. <source>Am J Clin Pathol</source> <volume>122</volume>, <fpage>794</fpage>–<lpage>801</lpage>.</citation></ref><ref id="bibr70-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Leenen</surname><given-names>P. J.</given-names></name><name name-style="western"><surname>de Bruijn</surname><given-names>M. F.</given-names></name><name name-style="western"><surname>Voerman</surname><given-names>J. S.</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>P. A.</given-names></name><name name-style="western"><surname>van Ewijk</surname><given-names>W.</given-names></name></person-group> (<year>1994</year>). <article-title>Markers of mouse macrophage development detected by monoclonal antibodies</article-title>. <source>J Immunol Methods</source> <volume>174</volume>, <fpage>5</fpage>–<lpage>19</lpage>.</citation></ref><ref id="bibr71-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Lesley</surname><given-names>J.</given-names></name><name name-style="western"><surname>Schulte</surname><given-names>R.</given-names></name><name name-style="western"><surname>Trotter</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hyman</surname><given-names>R.</given-names></name></person-group> (<year>1988</year>). <article-title>Qualitative and quantitative heterogeneity in Pgp-1 expression among murine thymocytes</article-title>. <source>Cell Immunol</source> <volume>112</volume>, <fpage>40</fpage>–<lpage>54</lpage>.</citation></ref><ref id="bibr72-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>W. V.</given-names></name><name name-style="western"><surname>Kapadia</surname><given-names>S. B.</given-names></name><name name-style="western"><surname>Sonmez-Alpan</surname><given-names>E.</given-names></name><name name-style="western"><surname>Swerdlow</surname><given-names>S. H.</given-names></name></person-group> (<year>1996</year>). <article-title>Immunohistochemical characterization of mast cell disease in paraffin sections using tryptase, CD68, myeloperoxidase, lysozyme, and CD20 antibodies</article-title>. <source>Mod Pathol</source> <volume>9</volume>, <fpage>982</fpage>–<lpage>8</lpage>.</citation></ref><ref id="bibr73-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Lopez</surname><given-names>A. F.</given-names></name><name name-style="western"><surname>Strath</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sanderson</surname><given-names>C. J.</given-names></name></person-group> (<year>1984</year>). <article-title>Differentiation antigens on mouse eosinophils and neutrophils identified by monoclonal antibodies</article-title>. <source>Br J Haematol</source> <volume>57</volume>, <fpage>489</fpage>–<lpage>94</lpage>.</citation></ref><ref id="bibr74-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Lorsbach</surname><given-names>R. B.</given-names></name><name name-style="western"><surname>Moore</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ang</surname><given-names>S. O.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>W.</given-names></name><name name-style="western"><surname>Lenny</surname><given-names>N.</given-names></name><name name-style="western"><surname>Downing</surname><given-names>J. R.</given-names></name></person-group> (<year>2004</year>). <article-title>Role of RUNX1 in adult hematopoiesis: Analysis of RUNX1-IRES-GFP knock-in mice reveals differential lineage expression</article-title>. <source>Blood</source> <volume>103</volume>, <fpage>2522</fpage>–<lpage>9</lpage>.</citation></ref><ref id="bibr75-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Malorny</surname><given-names>U.</given-names></name><name name-style="western"><surname>Michels</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sorg</surname><given-names>C.</given-names></name></person-group> (<year>1986</year>). <article-title>A monoclonal antibody against an antigen present on mouse macrophages and absent from monocytes</article-title>. <source>Cell Tissue Res</source> <volume>243</volume>, <fpage>421</fpage>–<lpage>8</lpage>.</citation></ref><ref id="bibr76-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Matsui</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Natori</surname><given-names>S.</given-names></name><name name-style="western"><surname>Obinata</surname><given-names>M.</given-names></name></person-group> (<year>1985</year>). <article-title>Induction of glycophorin gene expression in cultured murine erythroleukemia cells</article-title>. <source>Differentiation</source> <volume>29</volume>, <fpage>268</fpage>–<lpage>74</lpage>.</citation></ref><ref id="bibr77-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Mazzucchelli</surname><given-names>R.</given-names></name><name name-style="western"><surname>Durum</surname><given-names>S. K.</given-names></name></person-group> (<year>2007</year>). <article-title>Interleukin-7 receptor expression: Intelligent design</article-title>. <source>Nat Rev Immunol</source> <volume>7</volume>, <fpage>144</fpage>–<lpage>54</lpage>.</citation></ref><ref id="bibr78-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>McCafferty</surname><given-names>D. M.</given-names></name><name name-style="western"><surname>Miampamba</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sihota</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sharkey</surname><given-names>K. A.</given-names></name><name name-style="western"><surname>Kubes</surname><given-names>P.</given-names></name></person-group> (<year>1999</year>). <article-title>Role of inducible nitric oxide synthase in trinitrobenzene sulphonic acid induced colitis in mice</article-title>. <source>Gut</source> <volume>45</volume>, <fpage>864</fpage>–<lpage>73</lpage>.</citation></ref><ref id="bibr79-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>McComb</surname><given-names>R. D.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>T. R.</given-names></name><name name-style="western"><surname>Pizzo</surname><given-names>S. V.</given-names></name><name name-style="western"><surname>Bigner</surname><given-names>D. D.</given-names></name></person-group> (<year>1982</year>). <article-title>Specificity and sensitivity of immunohistochemical detection of factor VIII/von Willebrand factor antigen in formalin-fixed paraffin-embedded tissue</article-title>. <source>J Histochem Cytochem</source> <volume>30</volume>, <fpage>371</fpage>–<lpage>7</lpage>.</citation></ref><ref id="bibr80-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>McGarry</surname><given-names>M. P.</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>C. C.</given-names></name></person-group> (<year>1991</year>). <article-title>Murine eosinophil granulocytes bind the murine macrophage-monocyte specific monoclonal antibody F4/80</article-title>. <source>J Leukoc Biol</source> <volume>50</volume>, <fpage>471</fpage>–<lpage>8</lpage>.</citation></ref><ref id="bibr81-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Mikaelian</surname><given-names>I.</given-names></name><name name-style="western"><surname>Nanney</surname><given-names>L. B.</given-names></name><name name-style="western"><surname>Parman</surname><given-names>K. S.</given-names></name><name name-style="western"><surname>Kusewitt</surname><given-names>D. F.</given-names></name><name name-style="western"><surname>Ward</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Naf</surname><given-names>D.</given-names></name><name name-style="western"><surname>Krupke</surname><given-names>D. M.</given-names></name><name name-style="western"><surname>Eppig</surname><given-names>J. T.</given-names></name><name name-style="western"><surname>Bult</surname><given-names>C. J.</given-names></name><name name-style="western"><surname>Seymour</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ichiki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sundberg</surname><given-names>J. P.</given-names></name></person-group> (<year>2004</year>). <article-title>Antibodies that label paraffin-embedded mouse tissues: A collaborative endeavor</article-title>. <source>Toxicol Pathol</source> <volume>32</volume>, <fpage>181</fpage>–<lpage>91</lpage>.</citation></ref><ref id="bibr82-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Milner</surname><given-names>J. D.</given-names></name><name name-style="western"><surname>Orekov</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ward</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Torres-Velez</surname><given-names>F.</given-names></name><name name-style="western"><surname>Junttila</surname><given-names>I.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>G.</given-names></name><name name-style="western"><surname>Buller</surname><given-names>M.</given-names></name><name name-style="western"><surname>Morris</surname><given-names>S. C.</given-names></name><name name-style="western"><surname>Finkelman</surname><given-names>F. D.</given-names></name><name name-style="western"><surname>Paul</surname><given-names>W. E.</given-names></name></person-group> (<year>2010</year>). <article-title>Sustained IL-4 exposure leads to a novel pathway for hemophagocytosis, inflammation, and tissue macrophage accumulation</article-title>. <source>Blood</source> <volume>116</volume>, <fpage>2476</fpage>–<lpage>83</lpage>.</citation></ref><ref id="bibr83-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Morse</surname><given-names>H. C.</given-names><suffix>III</suffix></name><name name-style="western"><surname>Anver</surname><given-names>M. R.</given-names></name><name name-style="western"><surname>Fredrickson</surname><given-names>T. N.</given-names></name><name name-style="western"><surname>Haines</surname><given-names>D. C.</given-names></name><name name-style="western"><surname>Harris</surname><given-names>A. W.</given-names></name><name name-style="western"><surname>Harris</surname><given-names>N. L.</given-names></name><name name-style="western"><surname>Jaffe</surname><given-names>E. S.</given-names></name><name name-style="western"><surname>Kogan</surname><given-names>S. C.</given-names></name><name name-style="western"><surname>MacLennan</surname><given-names>I. C.</given-names></name><name name-style="western"><surname>Pattengale</surname><given-names>P. K.</given-names></name><name name-style="western"><surname>Ward</surname><given-names>J. M.</given-names></name></person-group> (<year>2002</year>). <article-title>Bethesda proposals for classification of lymphoid neoplasms in mice</article-title>. <source>Blood</source> <volume>100</volume>, <fpage>246</fpage>–<lpage>58</lpage>.</citation></ref><ref id="bibr84-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Morton</surname><given-names>J.</given-names></name><name name-style="western"><surname>Coles</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wright</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gallimore</surname><given-names>A.</given-names></name><name name-style="western"><surname>Morrow</surname><given-names>J. D.</given-names></name><name name-style="western"><surname>Terry</surname><given-names>E. S.</given-names></name><name name-style="western"><surname>Anning</surname><given-names>P. B.</given-names></name><name name-style="western"><surname>Morgan</surname><given-names>B. P.</given-names></name><name name-style="western"><surname>Dioszeghy</surname><given-names>V.</given-names></name><name name-style="western"><surname>Kuhn</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chaitidis</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hobbs</surname><given-names>A. J.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>S. A.</given-names></name><name name-style="western"><surname>O’Donnell</surname><given-names>V. B.</given-names></name></person-group> (<year>2008</year>). <article-title>Circulating neutrophils maintain physiological blood pressure by suppressing bacteria and IFNgamma-dependent iNOS expression in the vasculature of healthy mice</article-title>. <source>Blood</source> <volume>111</volume>, <fpage>5187</fpage>–<lpage>94</lpage>.</citation></ref><ref id="bibr85-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Muler</surname><given-names>J. H.</given-names></name><name name-style="western"><surname>Valdez</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hayes</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kaminski</surname><given-names>M. S.</given-names></name></person-group> (<year>2002</year>). <article-title>Acute megakaryocytic leukemia presenting as hypercalcemia with skeletal lytic lesions</article-title>. <source>Eur J Haematol</source> <volume>68</volume>, <fpage>392</fpage>–<lpage>6</lpage>.</citation></ref><ref id="bibr86-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Nagendra</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schlueter</surname><given-names>A. J.</given-names></name></person-group> (<year>2004</year>). <article-title>Absence of cross-reactivity between murine Ly-6C and Ly-6G</article-title>. <source>Cytometry A</source> <volume>58</volume>, <fpage>195</fpage>–<lpage>200</lpage>.</citation></ref><ref id="bibr87-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Nagra</surname><given-names>R. M.</given-names></name><name name-style="western"><surname>Becher</surname><given-names>B.</given-names></name><name name-style="western"><surname>Tourtellotte</surname><given-names>W. W.</given-names></name><name name-style="western"><surname>Antel</surname><given-names>J. P.</given-names></name><name name-style="western"><surname>Gold</surname><given-names>D.</given-names></name><name name-style="western"><surname>Paladino</surname><given-names>T.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>J. R.</given-names></name><name name-style="western"><surname>Reynolds</surname><given-names>W. F.</given-names></name></person-group> (<year>1997</year>). <article-title>Immunohistochemical and genetic evidence of myeloperoxidase involvement in multiple sclerosis</article-title>. <source>J Neuroimmunol</source> <volume>78</volume>, <fpage>97</fpage>–<lpage>107</lpage>.</citation></ref><ref id="bibr88-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Nair</surname><given-names>M. G.</given-names></name><name name-style="western"><surname>Cochrane</surname><given-names>D. W.</given-names></name><name name-style="western"><surname>Allen</surname><given-names>J. E.</given-names></name></person-group> (<year>2003</year>). <article-title>Macrophages in chronic type 2 inflammation have a novel phenotype characterized by the abundant expression of Ym1 and Fizz1 that can be partly replicated in vitro</article-title>. <source>Immunol Lett</source> <volume>85</volume>, <fpage>173</fpage>–<lpage>80</lpage>.</citation></ref><ref id="bibr89-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Neuhauser</surname><given-names>T. S.</given-names></name><name name-style="western"><surname>Derringer</surname><given-names>G. A.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>L. D.</given-names></name><name name-style="western"><surname>Fanburg-Smith</surname><given-names>J. C.</given-names></name><name name-style="western"><surname>Miettinen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Saaristo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Abbondanzo</surname><given-names>S. L.</given-names></name></person-group> (<year>2000</year>). <article-title>Splenic angiosarcoma: A clinicopathologic and immunophenotypic study of 28 cases</article-title>. <source>Mod Pathol</source> <volume>13</volume>, <fpage>978</fpage>–<lpage>87</lpage>.</citation></ref><ref id="bibr90-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>O’Connell</surname><given-names>F. P.</given-names></name><name name-style="western"><surname>Pinkus</surname><given-names>J. L.</given-names></name><name name-style="western"><surname>Pinkus</surname><given-names>G. S.</given-names></name></person-group> (<year>2004</year>). <article-title>CD138 (syndecan-1), a plasma cell marker immunohistochemical profile in hematopoietic and nonhematopoietic neoplasms</article-title>. <source>Am J Clin Pathol</source> <volume>121</volume>, <fpage>254</fpage>–<lpage>63</lpage>.</citation></ref><ref id="bibr91-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Osmond</surname><given-names>D. G.</given-names></name><name name-style="western"><surname>Rolink</surname><given-names>A.</given-names></name><name name-style="western"><surname>Melchers</surname><given-names>F.</given-names></name></person-group> (<year>1998</year>). <article-title>Murine B lymphopoiesis: Towards a unified model</article-title>. <source>Immunol Today</source> <volume>19</volume>, <fpage>65</fpage>–<lpage>8</lpage>.</citation></ref><ref id="bibr92-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Pardo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wallich</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ebnet</surname><given-names>K.</given-names></name><name name-style="western"><surname>Iden</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zentgraf</surname><given-names>H.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ekiciler</surname><given-names>A.</given-names></name><name name-style="western"><surname>Prins</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mullbacher</surname><given-names>A.</given-names></name><name name-style="western"><surname>Huber</surname><given-names>M.</given-names></name><name name-style="western"><surname>Simon</surname><given-names>M. M.</given-names></name></person-group> (<year>2007</year>). <article-title>Granzyme B is expressed in mouse mast cells in vivo and in vitro and causes delayed cell death independent of perforin</article-title>. <source>Cell Death Differ</source> <volume>14</volume>, <fpage>1768</fpage>–<lpage>79</lpage>.</citation></ref><ref id="bibr93-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Pedrocchi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hauer</surname><given-names>C. R.</given-names></name><name name-style="western"><surname>Schafer</surname><given-names>B. W.</given-names></name><name name-style="western"><surname>Erne</surname><given-names>P.</given-names></name><name name-style="western"><surname>Heizmann</surname><given-names>C. W.</given-names></name></person-group> (<year>1993</year>). <article-title>Analysis of CA(2+)-binding S100 proteins in human heart by HPLC-electrospray mass spectrometry</article-title>. <source>Biochem Biophys Res Commun</source> <volume>197</volume>, <fpage>529</fpage>–<lpage>35</lpage>.</citation></ref><ref id="bibr94-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Perry</surname><given-names>V. H.</given-names></name><name name-style="western"><surname>Crocker</surname><given-names>P. R.</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>S.</given-names></name></person-group> (<year>1992</year>). <article-title>The blood-brain barrier regulates the expression of a macrophage sialic acid-binding receptor on microglia</article-title>. <source>J Cell Sci</source> <volume>101</volume>, <fpage>201</fpage>–<lpage>7</lpage>.</citation></ref><ref id="bibr95-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Perry</surname><given-names>V. H.</given-names></name><name name-style="western"><surname>Lawson</surname><given-names>L. J.</given-names></name><name name-style="western"><surname>Reid</surname><given-names>D. M.</given-names></name></person-group> (<year>1994</year>). <article-title>Biology of the mononuclear phagocyte system of the central nervous system and HIV infection</article-title>. <source>J Leukoc Biol</source> <volume>56</volume>, <fpage>399</fpage>–<lpage>406</lpage>.</citation></ref><ref id="bibr96-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Pileri</surname><given-names>S. A.</given-names></name><name name-style="western"><surname>Grogan</surname><given-names>T. M.</given-names></name><name name-style="western"><surname>Harris</surname><given-names>N. L.</given-names></name><name name-style="western"><surname>Banks</surname><given-names>P.</given-names></name><name name-style="western"><surname>Campo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>J. K.</given-names></name><name name-style="western"><surname>Favera</surname><given-names>R. D.</given-names></name><name name-style="western"><surname>Delsol</surname><given-names>G.</given-names></name><name name-style="western"><surname>De Wolf-Peeters</surname><given-names>C.</given-names></name><name name-style="western"><surname>Falini</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gascoyne</surname><given-names>R. D.</given-names></name><name name-style="western"><surname>Gaulard</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gatter</surname><given-names>K. C.</given-names></name><name name-style="western"><surname>Isaacson</surname><given-names>P. G.</given-names></name><name name-style="western"><surname>Jaffe</surname><given-names>E. S.</given-names></name><name name-style="western"><surname>Kluin</surname><given-names>P.</given-names></name><name name-style="western"><surname>Knowles</surname><given-names>D. M.</given-names></name><name name-style="western"><surname>Mason</surname><given-names>D. Y.</given-names></name><name name-style="western"><surname>Mori</surname><given-names>S.</given-names></name><name name-style="western"><surname>Muller-Hermelink</surname><given-names>H. K.</given-names></name><name name-style="western"><surname>Piris</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Ralfkiaer</surname><given-names>E.</given-names></name><name name-style="western"><surname>Stein</surname><given-names>H.</given-names></name><name name-style="western"><surname>Su</surname><given-names>I. J.</given-names></name><name name-style="western"><surname>Warnke</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>L. M.</given-names></name></person-group> (<year>2002</year>). <article-title>Tumours of histiocytes and accessory dendritic cells: An immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases</article-title>. <source>Histopathology</source> <volume>41</volume>, <fpage>1</fpage>–<lpage>29</lpage>.</citation></ref><ref id="bibr97-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Pilozzi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Pulford</surname><given-names>K.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>M.</given-names></name><name name-style="western"><surname>Muller-Hermelink</surname><given-names>H. K.</given-names></name><name name-style="western"><surname>Falini</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ralfkiaer</surname><given-names>E.</given-names></name><name name-style="western"><surname>Pileri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pezzella</surname><given-names>F.</given-names></name><name name-style="western"><surname>De Wolf-Peeters</surname><given-names>C.</given-names></name><name name-style="western"><surname>Arber</surname><given-names>D.</given-names></name><name name-style="western"><surname>Stein</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mason</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gatter</surname><given-names>K.</given-names></name></person-group> (<year>1998</year>). <article-title>Co-expression of CD79a (JCB117) and CD3 by lymphoblastic lymphoma</article-title>. <source>J Pathol</source> <volume>186</volume>, <fpage>140</fpage>–<lpage>3</lpage>.</citation></ref><ref id="bibr98-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Pinkus</surname><given-names>G. S.</given-names></name><name name-style="western"><surname>Pinkus</surname><given-names>J. L.</given-names></name></person-group> (<year>1991</year>). <article-title>Myeloperoxidase: A specific marker for myeloid cells in paraffin sections</article-title>. <source>Mod Pathol</source> <volume>4</volume>, <fpage>733</fpage>–<lpage>41</lpage>.</citation></ref><ref id="bibr99-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Pusztaszeri</surname><given-names>M. P.</given-names></name><name name-style="western"><surname>Seelentag</surname><given-names>W.</given-names></name><name name-style="western"><surname>Bosman</surname><given-names>F. T.</given-names></name></person-group> (<year>2006</year>). <article-title>Immunohistochemical expression of endothelial markers CD31, CD34, von Willebrand factor, and Fli-1 in normal human tissues</article-title>. <source>J Histochem Cytochem</source> <volume>54</volume>, <fpage>385</fpage>–<lpage>95</lpage>.</citation></ref><ref id="bibr100-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Rabinowitz</surname><given-names>S. S.</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>S.</given-names></name></person-group> (<year>1991</year>). <article-title>Macrosialin, a macrophage-restricted membrane sialoprotein differentially glycosylated in response to inflammatory stimuli</article-title>. <source>J Exp Med</source> <volume>174</volume>, <fpage>827</fpage>–<lpage>36</lpage>.</citation></ref><ref id="bibr101-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Raffegerst</surname><given-names>S. H.</given-names></name><name name-style="western"><surname>Hoelzlwimmer</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kunder</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mysliwietz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Quintanilla-Martinez</surname><given-names>L.</given-names></name><name name-style="western"><surname>Schendel</surname><given-names>D. J.</given-names></name></person-group> (<year>2009</year>). <article-title>Diverse hematological malignancies including hodgkin-like lymphomas develop in chimeric MHC class II transgenic mice</article-title>. <source>PLoS One</source> <volume>4</volume>, <fpage>e8539</fpage>.</citation></ref><ref id="bibr102-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Ramos-Vara</surname><given-names>J. A.</given-names></name></person-group> (<year>2005</year>). <article-title>Technical aspects of immunohistochemistry</article-title>. <source>Vet Pathol</source> <volume>42</volume>, <fpage>405</fpage>–<lpage>26</lpage>.</citation></ref><ref id="bibr103-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Ree</surname><given-names>H. J.</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>S. M.</given-names></name></person-group> (<year>1983</year>). <article-title>Lectin histochemistry of malignant tumors. I. Peanut agglutinin (PNA) receptors in follicular lymphoma and follicular hyperplasia: An immunohistochemical study</article-title>. <source>Cancer</source> <volume>51</volume>, <fpage>1631</fpage>–<lpage>8</lpage>.</citation></ref><ref id="bibr104-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Rehg</surname><given-names>J. E.</given-names></name><name name-style="western"><surname>Sundberg</surname><given-names>J. P.</given-names></name></person-group> (<year>2008</year>). <article-title>Utility of antiPax5 in the diagnosis of lymphoproliferative disorders and neoplasia in mice</article-title>. <source>Comp Med</source> <volume>58</volume>, <fpage>246</fpage>–<lpage>52</lpage>.</citation></ref><ref id="bibr105-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Reinherz</surname><given-names>E. L.</given-names></name><name name-style="western"><surname>Schlossman</surname><given-names>S. F.</given-names></name></person-group> (<year>1980</year>). <article-title>The differentiation and function of human T lymphocytes</article-title>. <source>Cell</source> <volume>19</volume>, <fpage>821</fpage>–<lpage>7</lpage>.</citation></ref><ref id="bibr106-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Rensen</surname><given-names>S. S.</given-names></name><name name-style="western"><surname>Slaats</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Nijhuis</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jans</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bieghs</surname><given-names>V.</given-names></name><name name-style="western"><surname>Driessen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Malle</surname><given-names>E.</given-names></name><name name-style="western"><surname>Greve</surname><given-names>J. W.</given-names></name><name name-style="western"><surname>Buurman</surname><given-names>W. A.</given-names></name></person-group> (<year>2009</year>). <article-title>Increased hepatic myeloperoxidase activity in obese subjects with nonalcoholic steatohepatitis</article-title>. <source>Am J Pathol</source> <volume>175</volume>, <fpage>1473</fpage>–<lpage>82</lpage>.</citation></ref><ref id="bibr107-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Richter</surname><given-names>N.</given-names></name><name name-style="western"><surname>Petersson</surname><given-names>A. S.</given-names></name><name name-style="western"><surname>Wennmalm</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schimke</surname><given-names>I.</given-names></name></person-group> (<year>1999</year>). <article-title>Detection of an approximately 100 kD protein with strong immunoreactivity to antibodies specific for inducible nitric oxide synthase (iNOS) but without NOS activity in neutrophils of patients suffering from sepsis: Results of a preliminary study</article-title>. <source>Inflamm Res</source> <volume>48</volume>, <fpage>651</fpage>–<lpage>6</lpage>.</citation></ref><ref id="bibr108-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Romeo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chauffaille</surname><given-names>M. L. L. F.</given-names></name><name name-style="western"><surname>Bahia</surname><given-names>D. M. M.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>M. R. R.</given-names></name></person-group> (<year>2002</year>). <article-title>Hyperfibrotic myelodysplaisa: case report with response to steroid therapy</article-title>. <source>Relato De Caso Case Report</source> <volume>38</volume>, <fpage>149</fpage>–<lpage>51</lpage>.</citation></ref><ref id="bibr109-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Rosas</surname><given-names>M.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>B.</given-names></name><name name-style="western"><surname>Stacey</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>S.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>P. R.</given-names></name></person-group> (<year>2010</year>). <article-title>The myeloid 7/4-antigen defines recently generated inflammatory macrophages and is synonymous with Ly-6B</article-title>. <source>J Leukoc Biol</source> <volume>88</volume>, <fpage>169</fpage>–<lpage>80</lpage>.</citation></ref><ref id="bibr110-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Rose</surname><given-names>M. L.</given-names></name><name name-style="western"><surname>Malchiodi</surname><given-names>F.</given-names></name></person-group> (<year>1981</year>). <article-title>Binding of peanut lectin to thymic cortex and germinal centres of lymphoid tissue</article-title>. <source>Immunology</source> <volume>42</volume>, <fpage>583</fpage>–<lpage>91</lpage>.</citation></ref><ref id="bibr111-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Sadahira</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kanzaki</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wada</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yawata</surname><given-names>Y.</given-names></name></person-group> (<year>1999</year>). <article-title>Immunohistochemical identification of erythroid precursors in paraffin embedded bone marrow sections: Spectrin is a superior marker to glycophorin</article-title>. <source>J Clin Pathol</source> <volume>52</volume>, <fpage>919</fpage>–<lpage>21</lpage>.</citation></ref><ref id="bibr112-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Sanderson</surname><given-names>R. D.</given-names></name><name name-style="western"><surname>Lalor</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bernfield</surname><given-names>M.</given-names></name></person-group> (<year>1989</year>). <article-title>B lymphocytes express and lose syndecan at specific stages of differentiation</article-title>. <source>Cell Regul</source> <volume>1</volume>, <fpage>27</fpage>–<lpage>35</lpage>.</citation></ref><ref id="bibr113-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Schick</surname><given-names>P. K.</given-names></name><name name-style="western"><surname>Konkle</surname><given-names>B. A.</given-names></name><name name-style="western"><surname>He</surname><given-names>X.</given-names></name><name name-style="western"><surname>Thornton</surname><given-names>R. D.</given-names></name></person-group> (<year>1993</year>). <article-title>P-selectin mRNA is expressed at a later phase of megakaryocyte maturation than mRNAs for von Willebrand factor and glycoprotein Ib-alpha</article-title>. <source>J Lab Clin Med</source> <volume>121</volume>, <fpage>714</fpage>–<lpage>21</lpage>.</citation></ref><ref id="bibr114-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Schwarting</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gerdes</surname><given-names>J.</given-names></name><name name-style="western"><surname>Durkop</surname><given-names>H.</given-names></name><name name-style="western"><surname>Falini</surname><given-names>B.</given-names></name><name name-style="western"><surname>Pileri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Stein</surname><given-names>H.</given-names></name></person-group> (<year>1989</year>). <article-title>BER-H2: A new anti-Ki-1 (CD30) monoclonal antibody directed at a formol-resistant epitope</article-title>. <source>Blood</source> <volume>74</volume>, <fpage>1678</fpage>–<lpage>89</lpage>.</citation></ref><ref id="bibr115-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Seagal</surname><given-names>J.</given-names></name><name name-style="western"><surname>Leider</surname><given-names>N.</given-names></name><name name-style="western"><surname>Wildbaum</surname><given-names>G.</given-names></name><name name-style="western"><surname>Karin</surname><given-names>N.</given-names></name><name name-style="western"><surname>Melamed</surname><given-names>D.</given-names></name></person-group> (<year>2003</year>). <article-title>Increased plasma cell frequency and accumulation of abnormal syndecan-1plus T-cells in Igmu-deficient/lpr mice</article-title>. <source>Int Immunol</source> <volume>15</volume>, <fpage>1045</fpage>–<lpage>52</lpage>.</citation></ref><ref id="bibr116-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Seftalioglu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Karakus</surname><given-names>S.</given-names></name></person-group> (<year>2003</year>). <article-title>Syndecan-1/CD138 expression in normal myeloid, acute lymphoblastic and myeloblastic leukemia cells</article-title>. <source>Acta Histochem</source> <volume>105</volume>, <fpage>213</fpage>–<lpage>21</lpage>.</citation></ref><ref id="bibr117-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Soga</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yagi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kayaba</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ishii</surname><given-names>T.</given-names></name><name name-style="western"><surname>Gotoh</surname><given-names>T.</given-names></name><name name-style="western"><surname>Itoh</surname><given-names>T.</given-names></name></person-group> (<year>1997</year>). <article-title>Heterogeneity of mouse thymic macrophages: I. Immunohistochemical analysis</article-title>. <source>Arch Histol Cytol</source> <volume>60</volume>, <fpage>53</fpage>–<lpage>63</lpage>.</citation></ref><ref id="bibr118-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Speece</surname><given-names>A. J.</given-names></name></person-group> (<year>1964</year>). <article-title>Histochemical distribution of lysozyme activity in organs of normal mice and radiation chimeras</article-title>. <source>J Histochem Cytochem</source> <volume>12</volume>, <fpage>384</fpage>–<lpage>91</lpage>.</citation></ref><ref id="bibr119-0192623311430695"><citation citation-type="book" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Swerdlow</surname><given-names>S.</given-names></name><name name-style="western"><surname>Campo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Harris</surname><given-names>N.</given-names></name><name name-style="western"><surname>Jaffe</surname><given-names>E.</given-names></name><name name-style="western"><surname>Pileri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Stein</surname><given-names>H.</given-names></name><name name-style="western"><surname>Thiele</surname><given-names>J.</given-names></name><name name-style="western"><surname>Vardiman</surname><given-names>J.</given-names></name></person-group> (<year>2008</year>). <source>WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues</source>. <publisher-name>International Agency for Research on Cancer</publisher-name>, <publisher-loc>World Health Organization, Washington, DC</publisher-loc>.</citation></ref><ref id="bibr120-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Sykora</surname><given-names>K. W.</given-names></name><name name-style="western"><surname>Tomeczkowski</surname><given-names>J.</given-names></name><name name-style="western"><surname>Reiter</surname><given-names>A.</given-names></name></person-group> (<year>1997</year>). <article-title>C-kit receptors in childhood malignant lymphoblastic cells</article-title>. <source>Leuk Lymphoma</source> <volume>25</volume>, <fpage>201</fpage>–<lpage>16</lpage>.</citation></ref><ref id="bibr121-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Tacchini-Cottier</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zweifel</surname><given-names>C.</given-names></name><name name-style="western"><surname>Belkaid</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Mukankundiye</surname><given-names>C.</given-names></name><name name-style="western"><surname>Vasei</surname><given-names>M.</given-names></name><name name-style="western"><surname>Launois</surname><given-names>P.</given-names></name><name name-style="western"><surname>Milon</surname><given-names>G.</given-names></name><name name-style="western"><surname>Louis</surname><given-names>J. A.</given-names></name></person-group> (<year>2000</year>). <article-title>An immunomodulatory function for neutrophils during the induction of a CD4+ Th2 response in BALB/c mice infected with Leishmania major</article-title>. <source>J Immunol</source> <volume>165</volume>, <fpage>2628</fpage>–<lpage>36</lpage>.</citation></ref><ref id="bibr122-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Takahashi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Isobe</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ohtsuki</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sonobe</surname><given-names>H.</given-names></name><name name-style="western"><surname>Takeda</surname><given-names>I.</given-names></name><name name-style="western"><surname>Akagi</surname><given-names>T.</given-names></name></person-group> (<year>1984</year>). <article-title>Immunohistochemical localization and distribution of S-100 proteins in the human lymphoreticular system</article-title>. <source>Am J Pathol</source> <volume>116</volume>, <fpage>497</fpage>–<lpage>503</lpage>.</citation></ref><ref id="bibr123-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Taylor</surname><given-names>P. R.</given-names></name><name name-style="western"><surname>Martinez-Pomares</surname><given-names>L.</given-names></name><name name-style="western"><surname>Stacey</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>H. H.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>G. D.</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>S.</given-names></name></person-group> (<year>2005</year>). <article-title>Macrophage receptors and immune recognition</article-title>. <source>Annu Rev Immunol</source> <volume>23</volume>, <fpage>901</fpage>–<lpage>44</lpage>.</citation></ref><ref id="bibr124-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Thomas</surname><given-names>J.</given-names></name><name name-style="western"><surname>Haseman</surname><given-names>J. K.</given-names></name><name name-style="western"><surname>Goodman</surname><given-names>J. I.</given-names></name><name name-style="western"><surname>Ward</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Loughran</surname><given-names>T. P.</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Spencer</surname><given-names>P. J.</given-names></name></person-group> (<year>2007</year>). <article-title>A review of large granular lymphocytic leukemia in Fischer 344 rats as an initial step toward evaluating the implication of the endpoint to human cancer risk assessment</article-title>. <source>Toxicol Sci</source> <volume>99</volume>, <fpage>3</fpage>–<lpage>19</lpage>.</citation></ref><ref id="bibr125-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Tiacci</surname><given-names>E.</given-names></name><name name-style="western"><surname>Pileri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Orleth</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pacini</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tabarrini</surname><given-names>A.</given-names></name><name name-style="western"><surname>Frenguelli</surname><given-names>F.</given-names></name><name name-style="western"><surname>Liso</surname><given-names>A.</given-names></name><name name-style="western"><surname>Diverio</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lo-Coco</surname><given-names>F.</given-names></name><name name-style="western"><surname>Falini</surname><given-names>B.</given-names></name></person-group> (<year>2004</year>). <article-title>PAX5 expression in acute leukemias: Higher B-lineage specificity than CD79a and selective association with t(8;21)-acute myelogenous leukemia</article-title>. <source>Cancer Res</source> <volume>64</volume>, <fpage>7399</fpage>–<lpage>404</lpage>.</citation></ref><ref id="bibr126-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Torchia</surname><given-names>E. C.</given-names></name><name name-style="western"><surname>Boyd</surname><given-names>K.</given-names></name><name name-style="western"><surname>Rehg</surname><given-names>J. E.</given-names></name><name name-style="western"><surname>Qu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Baker</surname><given-names>S. J.</given-names></name></person-group> (<year>2007</year>). <article-title>EWS/FLI-1 induces rapid onset of myeloid/erythroid leukemia in mice</article-title>. <source>Mol Cell Biol</source> <volume>27</volume>, <fpage>7918</fpage>–<lpage>34</lpage>.</citation></ref><ref id="bibr127-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Torlakovic</surname><given-names>E.</given-names></name><name name-style="western"><surname>Slipicevic</surname><given-names>A.</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>C.</given-names></name><name name-style="western"><surname>DeCoteau</surname><given-names>J. F.</given-names></name><name name-style="western"><surname>Alfsen</surname><given-names>G. C.</given-names></name><name name-style="western"><surname>Vyberg</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chibbar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Florenes</surname><given-names>V. A.</given-names></name></person-group> (<year>2006</year>). <article-title>Pax-5 expression in nonhematopoietic tissues</article-title>. <source>Am J Clin Pathol</source> <volume>126</volume>, <fpage>798</fpage>–<lpage>804</lpage>.</citation></ref><ref id="bibr128-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Tung</surname><given-names>J. W.</given-names></name><name name-style="western"><surname>Mrazek</surname><given-names>M. D.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Herzenberg</surname><given-names>L. A.</given-names></name></person-group> (<year>2006</year>). <article-title>Phenotypically distinct B cell development pathways map to the three B cell lineages in the mouse</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>103</volume>, <fpage>6293</fpage>–<lpage>8</lpage>.</citation></ref><ref id="bibr129-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Vosshenrich</surname><given-names>C. A.</given-names></name><name name-style="western"><surname>Lesjean-Pottier</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hasan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Richard-Le Goff</surname><given-names>O.</given-names></name><name name-style="western"><surname>Corcuff</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mandelboim</surname><given-names>O.</given-names></name><name name-style="western"><surname>Di Santo</surname><given-names>J. P.</given-names></name></person-group> (<year>2007</year>). <article-title>CD11cloB220+ interferon-producing killer dendritic cells are activated natural killer cells</article-title>. <source>J Exp Med</source> <volume>204</volume>, <fpage>2569</fpage>–<lpage>78</lpage>.</citation></ref><ref id="bibr130-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Ward</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Erexson</surname><given-names>C. R.</given-names></name><name name-style="western"><surname>Faucette</surname><given-names>L. J.</given-names></name><name name-style="western"><surname>Foley</surname><given-names>J. F.</given-names></name><name name-style="western"><surname>Dijkstra</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cattoretti</surname><given-names>G.</given-names></name></person-group> (<year>2006</year>). <article-title>Immunohistochemical markers for the rodent immune system</article-title>. <source>Toxicol Pathol</source> <volume>34</volume>, <fpage>616</fpage>–<lpage>30</lpage>.</citation></ref><ref id="bibr131-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Ward</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Rehm</surname><given-names>S.</given-names></name></person-group> (<year>1990</year>). <article-title>Applications of immunohistochemistry in rodent tumor pathology</article-title>. <source>Exp Pathol</source> <volume>40</volume>, <fpage>301</fpage>–<lpage>12</lpage>.</citation></ref><ref id="bibr132-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Ward</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Sheldon</surname><given-names>W.</given-names></name></person-group> (<year>1993</year>). <article-title>Expression of mononuclear phagocyte antigens in histiocytic sarcoma of mice</article-title>. <source>Vet Pathol</source> <volume>30</volume>, <fpage>560</fpage>–<lpage>5</lpage>.</citation></ref><ref id="bibr133-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Ward</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>M.</given-names></name><name name-style="western"><surname>Anver</surname><given-names>M. R.</given-names></name><name name-style="western"><surname>Haines</surname><given-names>D. C.</given-names></name><name name-style="western"><surname>Kudo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gonzalez</surname><given-names>F. J.</given-names></name><name name-style="western"><surname>Kimura</surname><given-names>S.</given-names></name></person-group> (<year>2001</year>). <article-title>Hyalinosis and Ym1/Ym2 gene expression in the stomach and respiratory tract of 129S4/SvJae and wild-type and CYP1A2-null B6,129 mice</article-title>. <source>Am J Pathol</source> <volume>158</volume>, <fpage>323</fpage>–<lpage>32</lpage>.</citation></ref><ref id="bibr134-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Weerkamp</surname><given-names>F.</given-names></name><name name-style="western"><surname>Pike-Overzet</surname><given-names>K.</given-names></name><name name-style="western"><surname>Staal</surname><given-names>F. J.</given-names></name></person-group> (<year>2006</year>). <article-title>T-sing progenitors to commit</article-title>. <source>Trends Immunol</source> <volume>27</volume>, <fpage>125</fpage>–<lpage>31</lpage>.</citation></ref><ref id="bibr135-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Weiss</surname><given-names>L. M.</given-names></name><name name-style="western"><surname>Arber</surname><given-names>D.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>K. L.</given-names></name></person-group> (<year>1993</year>). <article-title>CD45: A review</article-title>. <source>Appl Immunohistochem</source> <volume>1</volume>, <fpage>166</fpage>–<lpage>81</lpage>.</citation></ref><ref id="bibr136-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Weiss</surname><given-names>L. M.</given-names></name><name name-style="western"><surname>Arber</surname><given-names>D.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>K.</given-names></name></person-group> (<year>1994</year>). <article-title>CD68: A review</article-title>. <source>Appl Immunohistochem</source> <volume>2</volume>, <fpage>2</fpage>–<lpage>8</lpage>.</citation></ref><ref id="bibr137-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Weiss</surname><given-names>L. M.</given-names></name><name name-style="western"><surname>Arber</surname><given-names>D. A.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>K. L.</given-names></name></person-group> (<year>1997</year>). <article-title>Clonality in lymphocyte predominance Hodgkin’s disease</article-title>. <source>Cancer Surv</source> <volume>30</volume>, <fpage>125</fpage>–<lpage>41</lpage>.</citation></ref><ref id="bibr138-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Welle</surname><given-names>M.</given-names></name></person-group> (<year>1997</year>). <article-title>Development, significance, and heterogeneity of mast cells with particular regard to the mast cell-specific proteases chymase and tryptase</article-title>. <source>J Leukoc Biol</source> <volume>61</volume>, <fpage>233</fpage>–<lpage>45</lpage>.</citation></ref><ref id="bibr139-0192623311430695"><citation citation-type="book" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Wick</surname><given-names>M.</given-names></name></person-group> (<year>2006</year>). <article-title>Immunohistology of melanocytic neoplasms</article-title>. In <source>Diagnostic Immunohistochemistry</source> (<person-group person-group-type="editor"><name name-style="western"><surname>Dabbs</surname><given-names>D.</given-names></name></person-group>, ed.), <comment>Chapter 6</comment>, pp. <fpage>162</fpage>–<lpage>79</lpage>. <publisher-name>Churchill Livingstone Elsevier</publisher-name>, <publisher-loc>Philadelphia, PA</publisher-loc>.</citation></ref><ref id="bibr140-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Willcox</surname><given-names>T. M.</given-names></name><name name-style="western"><surname>Speer</surname><given-names>R. W.</given-names></name><name name-style="western"><surname>Schlinkert</surname><given-names>R. T.</given-names></name><name name-style="western"><surname>Sarr</surname><given-names>M. G.</given-names></name></person-group> (<year>2000</year>). <article-title>Hemangioma of the spleen: Presentation, diagnosis, and management</article-title>. <source>J Gastrointest Surg</source> <volume>4</volume>, <fpage>611</fpage>–<lpage>3</lpage>.</citation></ref><ref id="bibr141-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Woloschalk</surname><given-names>G. E.</given-names></name><name name-style="western"><surname>Krco</surname><given-names>C. J.</given-names></name></person-group> (<year>1987</year>). <article-title>Regulation of kappa/lambda immunoglobulin light chain expression in normal murine lymphocytes</article-title>. <source>Mol Immunol</source> <volume>24</volume>, <fpage>751</fpage>–<lpage>7</lpage>.</citation></ref><ref id="bibr142-0192623311430695"><citation citation-type="journal" xlink:type="simple"><person-group person-group-type="author"><name name-style="western"><surname>Zon</surname><given-names>L. I.</given-names></name><name name-style="western"><surname>Gurish</surname><given-names>M. F.</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>R. L.</given-names></name><name name-style="western"><surname>Mather</surname><given-names>C.</given-names></name><name name-style="western"><surname>Reynolds</surname><given-names>D. S.</given-names></name><name name-style="western"><surname>Austen</surname><given-names>K. F.</given-names></name><name name-style="western"><surname>Orkin</surname><given-names>S. H.</given-names></name></person-group> (<year>1991</year>). <article-title>GATA-binding transcription factors in mast cells regulate the promoter of the mast cell carboxypeptidase A gene</article-title>. <source>J Biol Chem</source> <volume>266</volume>, <fpage>22948</fpage>–<lpage>53</lpage>.</citation></ref></ref-list></back></article>